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ABSTRACT
Inflammation provides broad immunological protection that is essential for our 
survival. This cellular response is characterised by a biphasic cycle consisting 
of an initial acute pro-inflammatory phase and a subsequent resolving anti-
inflammatory phase. Underlying each of these phases are changes in the 
expression of hundreds of immune genes, which encode for inflammatory 
mediators called cytokines. Importantly, the biphasic nature of inflammation 
requires cytokine expression to be highly regulated and coordinated to 
different timescales during each phase of inflammation. For the initial pro-
inflammatory response, cytokine expression needs to be rapid and robust to 
efficiently initiate host defence mechanisms and provide effective 
immunological protection. In contrast, the expression of anti-inflammatory 
cytokines is temporally delayed to ensure that anti-inflammation always 
follows pro-inflammation. In order to choreograph the expression of these 
cytokines during inflammation, numerous mechanisms within the cell serve to 
regulate and coordinate cytokine transcription.
Within the eukaryotic nucleus, multiple modes of transcriptional regulation 
function cooperatively to provide the regulatory capacity that is required for 
complex transcription patterns to emerge. These include the organisation of 
the genome, which confine cognate chromosomal contacts that are causal to 
transcription, and long-non coding RNAs (lncRNAs) that function to discretely 
fine tune transcriptional activity. Although many of the mechanisms that 
regulate transcription have been well described, their role in cytokine 
expression during inflammation remains largely unknown. In particular, the 
mechanisms that facilitate rapid and robust cytokine expression during pro-
inflammation and the regulatory networks that coordinate the biphasic 
regulation of inflammation are unresolved.
In this work, two novel lncRNAs were discovered to transcriptionally regulate 
these key features of cytokine expression during inflammation. The first, 
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UMLILO (Upstream Master LncRNA of the Inflammatory chemokine LOcus), 
was found to emanate from the ELR+ CXCL chemokine TAD and regulate the 
transcriptional activation of the pro-inflammatory ELR+ CXCL chemokines 
(IL-8, CXCL1, CXCL2 and CXCL3). By exploiting the pre-formed local 3D 
topology, UMLILO is able to epigenetically prime the chemokines for 
transcriptional activation. This involves the discrete deposition of H3K4me3 
onto the promoters of the chemokines, which allows for the pre-loading of 
transcriptional machinery prior to their signal-dependent activation. This 
reveals a fundamental mechanism for the epigenetic priming and rapid 
activation of pro-inflammatory cytokine genes. 
The second lncRNA, called AMANZI (A MAster Non-coding RNA antagoniZing 
Inflammation), was found to coordinate the transcription of two functionally 
opposed cytokines: the master pro-inflammatory IL-1β and the broad anti-
inflammatory IL-37. AMANZI is encoded in the promoter of IL-1β, which 
results in its concomitant expression when IL-1β is transcriptionally active. 
Functionally, AMANZI mediates the formation of a dynamic chromosomal 
contact between IL-1β and IL-37. This leads to the delayed transcriptional 
activation of IL-37 ensuring that the pro-inflammatory function of IL-1β 
precedes IL-37 mediated anti-inflammation. This revealed a novel biphasic 
circuit that coordinated the expression of IL-1β and IL-37, through the activity 
of AMANZI, to regulate the two functionally opposed states of inflammation. 
Clinical observations in healthy individuals revealed that a polymorphism 
occurring in AMANZI (rs16944) was able to augment the state of this genetic 
circuit and shift the relative levels of IL-1β and IL-37 to influence an 
individual’s inflammatory capacity. This affected the establishment of innate 
immunological memory, which is involved in the progression of many 
inflammatory conditions and the efficacy of certain vaccines. 
The work described here uncovers novel mechanisms that transcriptionally 
regulate key features of the inflammatory response. Importantly, this work 
implicates the role of two novel lncRNAs in inflammation, essentially 
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contributing to the functional annotation to the genome and providing novel 
targets for the modulation of pathogenic inflammation.
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Complexity within the human genome
The genome carries the instruction for all cellular functions in an elegant 
quaternary code. When correctly deciphered, this produces proteins that 
express the encoded information. Our ability to read the deoxyribonucleic acid 
(DNA) sequence comprising our genome marked the beginning of the 
genomics era. Perhaps the most revered effort in this field is the Human 
Genome Project (HGP), which produced the first draft of the human genome 
as well as the complete genome sequence of various other model organisms 
commonly studied in biology (Fleischmann et al., 1995, Blattner et al., 1997, 
Consortium, 1998, Adams et al., 2000, Arabidopsis Genome, 2000, Lander et 
al., 2001).
Because proteins are considered the functional outputs of gene expression, 
the number of protein-coding genes encoded within a genome intuitively 
represents the functional capacity and complexity of an organism. The current 
version of the human genome sequence comprises of approximately 3 billion 
nucleotide pairs and is estimated to encode for a collection of 20 000 protein-
coding genes (Venter et al., 2001, Willyard, 2018). Surprisingly, this accounts 
for only 2% of the human genome (Corces et al., 2018). Furthermore, 
organisms of seemingly lower complexity, such as worms and plants, are 
estimated to have an equivalent or richer gene content (Prasanth and 
Spector, 2007, Van Straalen and Roelofs, 2011). This revealed an unexpected 
disparity between gene content and the development of organismal 
complexity, giving rise to the G-value paradox (Hahn and Wray, 2002, 
Prasanth and Spector, 2007). How does such a relatively small repertoire of 
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protein-coding genes account for the wide range of cell phenotypes and 
specialised functions that define our species?
By definition, relative complexity is the minimum amount of information that is 
necessary for the operation of a system (Mattick, 2004). Increased protein-
coding capacity, while necessary, does not always lead to improved 
organismal complexity. This is because a system that only expands in its 
functional capabilities will eventually tend towards chaos without the proper 
regulation (Mattick, 2004). This underscores the need for the co-evolution of 
regulatory mechanisms as the genome gained function. It has been predicted 
that the acquisition of these regulatory mechanisms scale quadratically to the 
number of genes in the network, suggesting that the complexity of a system 
arises from its regulation (Mattick, 2004). 
The human genome is evolutionarily optimised to carry out all necessary 
functions using a library of approximately 20 000 proteins. Its complexity does 
not lie within this protein-coding potential, but rather the ability to regulate the 
expression of these genes in space and time. New paradigms in biology have 
indicated that organismal complexity arises from the expansion of the 
regulatory capacity within the non-coding regions of the genome (Mattick, 
2004). As a result, this posed the greatest challenge since the production of 
the first draft of the human genome: to functionally annotate and decrypt the 
regulatory functions and networks embedded in this portion of the code. 
In the last two decades, the protein-coding portion of the genome has been 
extensively studied. However, ascribing function to the non-coding genome 
has remained challenging and eluded biologists for a long time. It has become 
more apparent recently that this “dark matter” of the genome is replete with 
regulatory information that encodes for a large repertoire of mechanisms that 
cooperatively function to control gene expression. This ranges from higher 
order nuclear organisation of the genome to non-coding RNAs and the 
epigenetic regulation of transcription. Importantly, genome-wide association 
studies (GWAS) have revealed that the majority of single nucleotide 
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polymorphisms (SNPs) occur in the non-coding genome but are associated 
with changes in protein-coding gene expression (Maurano et al., 2012, 
Nishizaki and Boyle, 2017, van Arensbergen et al., 2019). This suggests that 
these SNPs are altering the regulatory functions found within these regions to 
generate divergent traits that are causal to health and disease. Despite the 
tremendous efforts in understanding the regulatory landscape of the genome, 
much of the function and regulation of the genome remains unknown. 
Therefore, modern day genomics continues to discover and characterise 
functional elements that regulate the expression of the genome in various 
biological processes. 
The innate immune response 
Amongst the many biological processes encoded within the genome, 
inflammation is a highly complex cellular response that is elicited by the innate 
immune system to provide broad immunological protection. Innate immunity is 
the first line of defence against microbial and viral infections and relies on 
regulatory programmes that dynamically choreograph changes in the 
expression of hundreds of immune genes (Rogatsky and Adelman, 2014).
A healthy inflammatory response is characterised by a biphasic cycle 
consisting initially of an acute pro-inflammatory phase, which serves to initiate 
host defence. This includes the remodelling of tissues, cell signalling for the 
recruitment of immune cells and the production of anti-microbial molecules, 
and the rewiring of cellular metabolism to redistribute energy and metabolite 
reserves to support pro-inflammation (Kornman, 2006). Together, these pro-
inflammatory activities induce immense physiological stress which can be 
deleterious to the cell, if left unresolved (Medzhitov, 2008). Thus, downstream 
of pro-inflammation is an anti-inflammatory phase, which antagonises pro-
inflammation, initiates tissue repair and restores basal cellular homeostasis 
(Figure 1.1) (Medzhitov, 2008, Rogatsky and Adelman, 2014). Each phase of 
inflammation is facilitated by a vast collection of immune genes which encode 
for inflammatory mediators called cytokines (Medzhitov, 2008, Rogatsky and 
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Adelman, 2014). Importantly, during the initial pro-inflammatory phase, pro-
inflammatory cytokine expression has to be rapid, robust and dynamically 
responsive to the burden of infection in order to be effective. During the 
subsequent anti-inflammatory phase, the temporally delayed expression of 
anti-inflammatory cytokines is paramount for the self-regulatory biphasic 
nature of inflammation. Therefore, cytokine expression during inflammation 
has to be coordinated to different timescales, suggesting that multiple layers 
of regulation facilitate the execution of such an intrinsically complex and 
important process.
Figure 1.1: The biphasic nature of inflammation
The progression of inflammation follows a balanced biphasic cycle. During the initial pro-
inflammatory phase, the transcription of pro-inflammatory cytokines is rapidly activated to 
effectively curb the progression of infection. This is subsequently resolved by the temporally 
delayed anti-inflammatory phase, which is characterised by the expression of anti-
inflammatory mediators such as IL-37 and IL-10. This phase serves to antagonise the pro-
inflammatory phase, initiate tissue repair and restore homeostasis. 
Numerous mechanisms operating at the level of transcription, mRNA 
maturation, mRNA turnover and protein translation are integrated into 
complex networks to effectively regulate inflammation (Rogatsky and 
Adelman, 2014). However, various studies have indicated that regulation at 
the transcriptional level is particularly important in shaping the inflammatory 
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response (Escoubet-Lozach et al., 2011, Rabani et al., 2011, Bhatt et al., 
2012). This is evident in the successive waves of coordinated immune gene 
activation and attenuation observed during inflammation (Amit et al., 2009). 
Furthermore, the dynamic range of innate immune gene transcription is 
extremely high (within 1000 fold) and is individually calibrated for each 
specific gene (Rogatsky and Adelman, 2014). This remarkable coordination 
and fine tuning of immune gene transcription indicates that highly 
sophisticated transcriptional programmes exist to regulate this process. 
Therefore, in order to understand the regulation of inflammation, it is important 
to understand how transcription is regulated in the human cell.
The basics of transcription
Transcription is the first step of gene expression and is thus fundamental to 
coordinating biological processes instructed by DNA. The products of this 
process are ribonucleic acid (RNA) molecules, which are functionally 
pervasive in biology, ranging from the transmission of genetic information from 
DNA to proteins (as messenger RNAs (mRNAs)) to the fine tuning of 
biological responses by a plethora of non-coding RNA species. The regulation 
of transcription is an essential control mechanism for orchestrating gene 
expression, ensuring that it is initiated in response to the correct 
developmental and environmental cues. As such, transcriptional regulation in 
multicellular higher-order organisms is complex and consists of numerous 
mechanisms of control.
Promoters
The most basic regulatory unit of transcription is the promoter (Johanson et 
al., 2019). This is a stretch of DNA that is proximally upstream of the 
transcriptional start site (TSS) and is embedded with transcription factor 
binding sites. This serves as a DNA docking platform for tissue-specific 
transcription factors that modulate the recruitment of RNA Polymerase II (Pol 
II). Pol II enzymatically drives transcription and undergoes the following 4 
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phases in a transcription cycle (Figure 1.2) (Hargreaves et al., 2009, Min et 
al., 2011, Rogatsky and Adelman, 2014):
1. Recruitment: The first step of the transcription cycle involves the 
assembly of the pre-initiation complex (PIC). This is facilitated by the 
loading of cognate transcription factors, transcriptional co-activators and 
Pol II to the promoter. In this complex, the C-terminal domain (CTD) of Pol 
II remains unphosphorylated. 
2. Initiation: Serine 5 (Ser5) of the Pol II CTD is then phosphorylated to 
initiate transcription that pauses proximal to the promoter. This produces 
short RNA transcripts of 25-60 nucleotides (nt) in length. Pol II pausing is 
i n d u c e d b y t h e p r e s e n c e o f t h e 5 , 6 - D i c h l o r o - 1 -β - d -
ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor (DSIF) and 
the negative elongation factor (NELF). In this state, Pol II is poised and 
ready for signal-dependent activation of transcription.
3. Pause-release: The recruitment of the positive-transcription elongation 
factor b (P-TEFb) phosphorylates DSIF, NELF, as well as Serine 2 (Ser2) 
of the Pol II CTD. This results in the dissociation of NELF from the protein 
complex, releasing Pol II from its suspended state. The recruitment of P-
TEFb to the paused promoter generally occurs in a signal-dependent 
manner and is mediated by transcription factors such as NF-κβ, the 
Mediator complex or Bromodomain and Extra-Terminal motif (BET) 
proteins. 
4. Elongation: The phosphorylation (Ser2/5) of the Pol II CTD allows for the 
binding of various RNA processing machinery and chromatin modifiers. 
These facilitate the elongation and maturation of a nascent RNA transcript 
during active transcription. Elongation will stop when Pol II traverses 
specific sequences that will terminate transcription and cause Pol II to 
dissociate from the DNA. 
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Figure 1.2: The phases of the transcription cycle
Transcription factors and Pol II are recruited to an accessible promoter region. Transcription is 
initiated with the phosphorylation of Ser2 on the Pol II CTD, leading to the production of a 
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short nascent transcript (25-60 nt). However, Pol II activity is paused by the presence of DSIF 
and NELF. The recruitment of P-TEFb by signal-dependent transcription factors results in the 
dissociation of NELF and the phosphorylation of DSIF and Pol II CTD Ser5, resulting in the 
pause-release of Pol II. With the help of chromatin modifiers and splicing machinery,  Pol II is 
able to traverse the gene body and produce a nascent RNA transcript. 
During a transcription cycle, the activity at a promoter can be regulated at two 
points: the recruitment of Pol II to the promoter and the pause-release of Pol II 
on the promoter. Primary response genes are rapidly induced in the absence 
of de novo protein synthesis (Fowler et al., 2011). These genes exist in a 
poised state whereby the PIC is assembled and Pol II activity is initiated prior 
to their transcriptional activation (Fowler et al., 2011). This allows for these 
genes to be regulated at the pause-release phase, resulting in fast 
transcriptional responses that resemble a digital kinetic profile (Fowler et al., 
2011). Many pro-inflammatory immune genes exist in this state, allowing for 
their quick transcriptional activation in response to pathogens (Fowler et al., 
2011, Rogatsky and Adelman, 2014). In contrast, secondary response genes 
are regulated at the level of Pol II recruitment and PIC assembly, introducing a 
temporal delay in the timeline of their activation (Fowler et al., 2011). Such 
responses may be more useful for the subsequent anti-inflammatory phase of 
inflammation. 
While promoters can be regulated by modulating the activity of Pol II, the 
propensity for transcription factors and Pol II to bind promoters imbues these 
proximal cis-regulatory elements with inherent transcriptional activity. 
However, not all DNA binding sites are occupied by their cognate transcription 
factors and it is well established that only certain subsets of genes are 
transcribed in different human cell types and under different cellular conditions 
(Natoli, 2016). This indicates that not all the promoters in the genome are 
simultaneously active. Instead, cells of specialised function or under different 
cellular conditions make use of specific sets of transcriptional programmes. 
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Chromatin accessibility
The assignment of these transcriptional programmes is dictated by the 
accessibility of the encoding DNA to transcription factors and transcriptional 
machinery. By controlling the accessibility of the genetic code, only certain 
subsets of genes that drive the relevant biological functions are read and 
expressed.
Genomic DNA (gDNA) is coiled around histone octamers, forming 
nucleoprotein complexes (called nucleosomes) which serve as the basic units 
of the chromatin fibre. These nucleosomes play a fundamental role in the 
compaction of the DNA fibre in the confined space of the nucleus, but also 
affect gene transcription by regulating DNA accessibility (Felsenfeld and 
Groudine, 2003). Super-resolution microscopy has revealed that the 
chromatin fibre exists in clusters to form structures that are reminiscent of 
“beads on a string”. The size of these clusters are associated with the state of 
the chromatin, with smaller clusters being active and larger clusters being 
inactive (Ricci et al., 2015). These two functional states of chromatin are 
termed eu- or heterochromatin, respectively. The former assumes an “open” 
configuration which is accessible for transcription, while the latter is 
condensed and impenetrable to most transcription factors and transcriptional 
machinery (Felsenfeld and Groudine, 2003). 
Techniques such as DNaseI hypersensitive site sequencing (DNase-Seq) 
(Boyle et al., 2008) or Assay for Transposase-Accessible Chromatin using 
Sequencing (ATAC-Seq) (Buenrostro et al., 2013) are able to map chromatin 
accessibility genome-wide and have revealed distinct chromatin accessibility 
profiles for different cell types and cellular functions (Buenrostro et al., 2015). 
Indeed, using a human cell line model for myeloid differentiation, overlaid 
ATAC-Seq and RNA Sequencing (RNA-Seq) showed that changes in the 
chromatin landscape were correlated to distinct gene expression profiles that 
were associated with the specialised function of distinct cell-types (Ramirez et 
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al., 2017). Thus, the modulation of promoter accessibility significantly 
contributes to transcriptional regulation (Buenrostro et al., 2015). 
The establishment of this regulatory landscape involves the local remodelling 
of chromatin in response to developmental and environmental cues. This can 
occur through the activity of chromatin remodelling complexes, such as SWI/
SNF, which can reposition nucleosomes or eject histones to create accessible 
nucleosome-free regions (Eberharter and Becker, 2004). Chromatin 
accessibility can also be directed by epigenetic histone modifications. Post-
translational modifications, such as acetylation and methylation to protruding 
histone tails, can alter their affinity to DNA. For example, the acetylation of 
lysine residues neutralises the positive charge of the histone tail, thus 
weakening the interaction with negatively charged DNA. This loosens the 
entire nucleosome complex providing improved accessibility to the DNA 
(Bannister and Kouzarides, 2011). It is therefore common to observe the 
acetylation of lysine 27 of histone 3 (H3K27Ac) at active promoter elements 
(Klemm et al., 2019). Active promoters are also decorated with tri-methylated 
lysine 4 of histone 3 (H3K4me3) (Soares et al., 2017). It is thought that 
H3K4me3 increases the local hydrophobicity of chromatin, allowing specific 
transcription factors to engage more favourably with DNA in the aqueous 
environment of the nucleus (Su et al., 2016). Indeed, H3K4me3 promoter 
occupancy is associated with the recruitment of histone acetyltransferases 
(HATs) (such as p300/CBP) as well as positive transcriptional regulators, 
which consolidate nucleosome accessibility and promote transcriptional 
activity, respectively (Crump et al., 2011, Lauberth et al., 2013, Soares et al., 
2017). Therefore, the composition and epigenetic histone modifications of 
nucleosomes affect the functional state of chromatin by regulating DNA 
accessibility to control transcription.
Enhancers
Despite promoters being regulated by chromatin accessibility and the 
availability of unique combinations of transcription factors, they are not 
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sufficiently complex to give rise to the intricate gene expression patterns 
observed in humans (Johanson et al., 2019). Promoters alone do not have the 
regulatory capacity to process the diverse signals underlying human cell 
function, suggesting that additional regulatory elements exist to increase the 
dimensionality of transcriptional regulation. 
In metazoans, additional regulatory elements called enhancers are distributed 
throughout the non-coding genome (Robson et al., 2019). These are distal 
cis-regulatory elements which recruit transcription factors and co-activators to 
aid the signal-dependent activation of transcription at cognate promoters 
(Figure 1.3) (Levine et al., 2014, Robson et al., 2019). Similar to promoters, 
the activity of an enhancer is dictated by changes in chromatin accessibility. 
Active enhancers are regions free of nucleosomes and enriched for H3K4me1 
and H3K27Ac occupancy (Calo and Wysocka, 2013, Pradeepa, 2017). These 
regions are typically identified by chromatin immunoprecipitation-sequencing 
(ChIP-Seq) signatures and functionally validated for enhancer activity by sub-
cloning the genomic region into reporter systems (Arnold et al., 2013) or 
through genetic perturbations that disrupt their regulatory activity (Canver et 
al., 2015, Diao et al., 2016). 
It is now apparent that enhancers far outnumber protein-coding genes and 
their promoters (Levine et al., 2014). In macrophages, the chromatin 
remodeller PU.1 has been found to shape the enhancer landscape of these 
cells and give rise to approximately 45 000 identified enhancer regions (Natoli 
et al., 2011). This large number of enhancers allows for redundant layers of 
regulation that ensure transcriptional robustness. Furthermore, many of these 
enhancers are activated by diverse stimuli to regulate a single promoter, 
increasing the signal diversity that a promoter can respond to (Figure 1.3). 
Conversely, multiple promoters can be regulated by a single enhancer, 
enabling multiplexed gene regulation. This suggests that through the complex 
combinatorial usage of enhancers, the regulatory capacity of the genome is 
significantly increased to allow for precise spatiotemporal and tissue-specific 
gene expression.
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Strikingly, unlike the proximal nature of promoters, the regulatory information 
encoded within enhancer regions are distal to the TSS (Robson et al., 2019). 
Genomic mapping of enhancers have revealed that they are found at vast 
distances from the genes that they regulate (Johanson et al., 2019). The most 
well studied promoter-enhancer interaction is the locus control region (LCR) 
that regulates the transcription of β-globin, which is positioned 50 kilobases 
(kb) away (Tolhuis et al., 2002). Through the formation of chromosomal loops, 
the distance between these two genomic regions is collapsed, allowing for the 
LCR to physically contact the β-globin promoter and activate transcription 
(Tolhuis et al., 2002). Forced looping of the LCR to the β-globin locus induced 
ectopic β-globin expression, confirming that chromatin contact was essential 
for transmitting regulatory information from distal enhancers to promoters 
(Deng et al., 2012). Similarly, live-cell imaging of enhancers, promoters and 
nascent transcription in Drosophila have also shown that transcriptional 
bursting corresponds to the proximity of these elements (Chen et al., 2018, 
Lim et al., 2018). Together, this highlights the importance of genome 
organisation in regulating active promoter-enhancer contacts for transcription. 
Figure 1.3: The interplay between proximal and distal cis-regulatory elements in 
transcription
Transcription is regulated by proximal (promoter) and distal (enhancer) cis-regulatory 
elements. The functional state of these regulatory elements is governed by the local 
accessibility of the chromatin to transcription factors and transcription machinery. Promoters 
primarily serve as docking platforms for transcription machinery at the TSS, while accessible 
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enhancers recruit transcription factors in a stimulus dependent manner to aid in the loading 
and activation of Pol II at promoters. Through combinatorial enhancer usage, the regulatory 
capacity of the genome is significantly increased to allow for transcription to occur in a tissue- 
and stimulus-specific manner. In the schematic above, this is illustrated as enhancer region 1 
and 2 being active (accessible), thus allowing for the activation of the cognate promoter by 
either stimulus 1 and 2. However, enhancer region 3 is inaccessible in this state, preventing 
the promoter from responding to stimulus 3. This highlights how transcription is shaped by the 
enhancer landscape.
In summary, the hallmark of transcriptional activation is the accessibility of the 
regulatory elements, which include proximal promoter elements as well as 
distal enhancer elements. Chromatin remodellers and epigenetic histone 
modifications are able to dynamically shape this landscape for different genes 
to be permissive for transcription. Furthermore, the combinatorial use of 
accessible enhancers and promoters provide the computational logic required 
for complex multicellular functions. The regulation of such promoter-enhancer 
permutations is coordinated by long-range chromosomal contacts, suggesting 
that genome organisation provides higher order modalities of transcriptional 
control.
Nuclear architecture 
The eukaryotic nucleus is a dense cellular compartment that houses the 
genome. In order to fit into this confined space, gDNA is highly condensed at 
different scales of length. At the smallest, the DNA helix is coiled around 
nucleosomes to form the chromatin fibre. This undergoes further volumetric 
compaction through the extensive formation of chromatin loops which 
constitute entire chromosomes. Over the last two decades, microscopy 
studies and chromosomal conformation capture (3C) technologies have 
provided many insights into the principles of genome organisation, including 
the non-random compaction and positioning of chromosomes and genes, the 
formation of functionally distinct homotypic chromatin compartments and 
spatially segregated intra-chromosomal domains. Importantly, it has become 
evident that these architectural features are imperative for providing higher-
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order regulation of gene expression by guiding long-range cognate promoter-
enhancer interactions. 
The first evidence of nuclear organisation came from microscopy studies 
which revealed that uncondensed interphase chromosomes occupied discrete 
nuclear volumes, known as chromosome territories (Figure 1.4) (Cremer and 
Cremer, 2001). The advent of unbiased genome-wide chromosomal contact 
maps, generated using Hi-C, showed that that these territories were further 
sub-divided into two large compartments (5-10 megabases (Mb)) that 
reflected the functional state of chromatin (Figure 1.4) (Lieberman-Aiden et 
al., 2009). The A (active) compartment consisted of euchromatin and actively 
transcribed regions near the nuclear interior, while the B (inactive) 
compartment was heterochromatised and transcriptionally inactive at the 
nuclear periphery (Gibcus and Dekker, 2013, Wijchers et al., 2016). Imaging 
approaches have confirmed that homotypic compartments interact and co-
localise in concordance with Hi-C maps (Boettiger et al., 2016). Importantly, 
spatial segregation according to chromatin state is linked to gene expression 
and can be dynamically modulated in response to various biological 
processes. For example, mapping of these compartments in human 
embryonic stem cells revealed substantial genome reorganisation and 
compartment switching during lineage specification (Dixon et al., 2015). 
At the sub-chromosome level, Hi-C maps revealed that the chromatin fibre is 
segmented into discrete regions enriched with self-associating chromosomal 
loops called topologically-associating domains (TADs) (Figure 1.4) (Dixon et 
al., 2012). The existence of these structures have been corroborated by direct 
visualisation of chromosome conformation using Oligopaint-labelled DNA 
fluorescent in situ hybridisation (FISH) and super-resolution microscopy 
(Szabo et al., 2018). With 90% of the genome configured as conserved TADs 
across different cell-types, these are considered to be ubiquitous 3D units of 
genome organisation (Finn et al., 2019, Johanson et al., 2019).
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Figure 1.4: The different scales of genome organisation
In the interphase nucleus, uncondensed chromosomes occupy distinct areas in the nucleus 
called chromosome territories. These territories are further sub-divided into two sub-
compartments according to the functional state of the chromatin: the active A compartment of 
the inactive B compartment. Homotypic compartments tend to cluster together and form 
chromosomal interactions. At the sub-chromosome level, genome-wide mapping of 
chromosomal contacts using Hi-C have revealed that the chromatin fibre is segregated into 
distinct regions enriched for chromosomal contacts, called topologically-associating domains 
(TADs). Through the formation of chromosomal loops, TADs bring distal regulatory elements 
and promoters into close spatial proximity. Within this confined space, these genetic elements 
can interact to engage in multi-gene complexes by forming phase-separated liquid 
condensates. This facilitates long-range cognate promoter-enhancer interactions which are 
causal to transcription. 
The formation of TADs is dependent on the extrusion and maintenance of 
chromosomal loops. This process is facilitated by architectural proteins such 
as CCCTC-binding factor (CTCF) and cohesin. It is thought that cohesin 
serves as the motor protein that traverses along the DNA and physically 
extrudes the DNA to form a loop, while convergent CTCF-bound sites serve to 
delimit the boundaries of the loops that constitute TADs (Sanborn et al., 2015, 
Ganji et al., 2018). In doing so, genes and regulatory elements that may be 
separated by large linear genomic distances are able to access each other in 
3D space to form multi-gene complexes that can be transcriptionally co-
regulated and coordinated (Lupianez et al., 2016). Conversely, this 
compartmentalised architecture can insulate transcriptional activity by serving 
as a physical barrier that segregates genes and regulatory elements 
(Lupianez et al., 2016, Gong et al., 2018). 
Numerous genome editing experiments have demonstrated the importance of 
this organisation, with the loss of TAD boundaries and chromosomal loops 
resulting in the re-wiring of promoter-enhancer contacts and the ectopic 
expression of genes. For example, the deletion of a CTCF demarcated 
boundary at the X chromosome inactivation centre (XIC) resulted in the partial 
fusion of adjacent TADs and aberrant gene activation (Nora et al., 2012). 
Large scale genomic rearrangements, such as inversions and duplications, 
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across TAD boundaries of a region encoding developmental genes, resulted 
in the disruption of TAD structures and the development of severe limb 
malformations in mice (Lupianez et al., 2015). CTCF binding sites are also 
sensitive to DNA methylation, which can compromise CTCF occupancy and 
loop demarcation. Indeed, targeted CTCF motif methylation using deactivated 
Cas9 (dCas9) fused to the DNMT3a DNA methyltransferase, disrupted loop 
configurations that insulated transcriptional activity (Liu et al., 2016). The loss 
of this insulation capacity has been shown to be causal to many diseases, 
including gliomas, where gain-of-function mutations that result in the hyper-
methylation of DNA, such as at CTCF sites, drive insulator dysfunction and 
oncogene activation (Flavahan et al., 2016). These examples show that the 
3D genomic organisation is imperative for the regulation of transcription by 
facilitating or limiting genome-wide promoter-enhancer contacts through 
chromosomal looping and TAD demarcation.
While the formation of TADs facilitate cognate promoter-enhancer contacts, 
recent evidence has indicated that the physical interaction is coordinated by 
liquid-liquid phase separation (LLPS) (Figure 1.4). Multivalent proteins or 
proteins with intrinsically disordered domains can form phase-separated liquid 
condensates when locally concentrated in the cell. Strikingly, various nuclear-
resident proteins, such as transcription factors, proteins from the Mediator 
complex and Pol II have been observed to form such condensates (Strom et 
al., 2017, Boija et al., 2018, Cho et al., 2018, Chong et al., 2018, Sabari et al., 
2018). Importantly, homotypic condensates are able to interact and mix while 
excluding other biochemically incompatible biomolecules. This suggests that 
genomic loci bound by proteins of homotypic biochemistry are able to interact 
with complementary condensates and create compartments that facilitate 
specific chromosomal interactions within TADs. In support of this, the 
assembly of artificial condensates on specific loci resulted in their physical 
interaction, demonstrating that the mixing of phase-separated liquid 
condensates can generate mechanical forces that are sufficient to shape 
chromosomal interactions (Shin et al., 2018). 
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LLPS and the formation of “transcriptional condensates” provides a more 
granular understanding of promoter-enhancer contacts. Enhancers 
(specifically large stretches of enhancers known as super-enhancers) and 
promoters can serve as nucleation sites for LLPS by recruiting and 
concentrating various transcription factors and co-activators on chromatin 
(Robson et al., 2019). Transcription can then be induced when promoter 
condensates mix with compatible enhancer condensates to form a 
transcriptional hub that specifies cognate promoter-enhancer interactions 
(Robson et al., 2019). This would provide highly precise control for the 
establishment of chromosomal contacts that are causal to transcription within 
TADs. 
It has become clear that the organisation of the genome is non-random, but 
rather intricately arranged to provide high-order regulation of transcription. 
Through different scales of organisation, specific promoter-enhancer contacts 
are facilitated by the formation of increasingly smaller compartments for the 
sequential minimisation of their genomic search space (Figure 1.4). 
Numerous immune genes have been found to occupy the same TADs, 
suggesting that their regulation is coordinated through compartmentalised 
chromosomal looping events (Jin et al., 2013).
While there are numerous single case studies supporting this model of 
genomic confinement and function, a recent study done in Drosophila 
challenged this paradigm (Ghavi-Helm et al., 2019). Using heterozygous 
mutants that carried a wild-type set of chromosomes as well as a mutant set 
containing extensive genomic rearrangements, the investigators were able to 
map and compare the topology and gene expression patterns in an allele-
specific manner genome-wide. Remarkably, they found that widespread 
topological variations only affected a small fraction of nearby gene 
expression. This suggested that genome topology was uncoupled from gene 
expression. While this study does not debase the enormous body of work that 
supports the role of genome organisation in the regulation of gene expression, 
it does highlight our incomplete understanding of how the genome is 
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regulated and suggests that there may be other collaborative mechanisms 
that facilitate the complexity of transcription and gene expression (Finn and 
Misteli, 2019, Ghavi-Helm et al., 2019). 
Long non-coding RNAs (lncRNAs)
Deep sequencing of the transcriptome has revealed that the human genome 
is pervasively transcribed. However, less than 2% of these transcripts encode 
for proteins, while the remaining fraction of non-coding transcripts mostly 
emanates from the “dark” regions of the genome and is largely 
uncharacterised (Lander et al., 2001, Bertone et al., 2004, Kapranov et al., 
2007, Quinn and Chang, 2016). As a result, it was thought that many of these 
non-coding transcripts were biologically functionless and the result of 
transcriptional noise. However, through extensive characterisation of the 
transcriptome over the last two decades, it has emerged that non-coding 
RNAs play important roles in almost every biological process (Quinn and 
Chang, 2016).
Small non-coding RNAs (such as transfer RNAs, Piwi-associated RNAs and 
microRNAs (miRNAs)) are highly conserved and their biological roles have 
been appreciated for a long time (Kung et al., 2013). In contrast to this, the 
function of long non-coding RNAs (lncRNAs) have remained elusive and 
controversial because of their low abundance and poor conservation (Mercer 
et al., 2011, Kung et al., 2013). Furthermore, they are not easily amenable to 
study by classical methods developed for mRNAs, thus requiring the 
development of more specialised tools (Fok et al., 2017). Despite this, there 
are now numerous examples of well characterised lncRNAs that clearly show 
their participation in the regulation and fine tuning of gene expression (Wang 
and Chang, 2011, Quinn and Chang, 2016).
LncRNAs are generally transcribed by Pol II and can arise from promoters 
and enhancers as well as regions intervening or from within protein-coding 
genes (Quinn and Chang, 2016). These transcripts often undergo post-
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transcriptional modifications including 5 ʹ capping, splicing and 3 ʹ 
polyadenylation (Quinn and Chang, 2016). Mature lncRNAs assume specific 
secondary and higher-order conformations which often imbue these 
transcripts with their functionality. By providing binding sequences and 
structural domains for interaction with other biomolecules, lncRNAs can 
essentially serve as the interface between DNA, RNA and proteins (Mercer 
and Mattick, 2013). With the current catalogue, lncRNAs are curated into four 
different classes according to their mode of function (Figure 1.5):
Decoys
LncRNAs can function as molecular decoys that competitively sequester 
transcription factors and miRNAs to regulate gene expression. For example, 
Lethe is a pseudogene lncRNA that negatively regulates NF-κβ signalling. 
Lethe is able to interact with and titrate away RelA, a subunit of NF-κβ, 
preventing the binding and activation of NF-κβ regulated genes (Rapicavoli et 
al., 2013). Similarly, the pseudogene PTEN1 was found to bind regulatory 
miRNAs that target the tumour suppressor gene PTEN. In doing so, it 
sequesters silencing miRNAs away from PTEN mRNA, allowing for the 
expression of PTEN to proceed unencumbered (Poliseno et al., 2010).
Scaffolds
LncRNAs can also serve as platforms for the assembly of multi-component 
biomolecular structures, thereby coordinating diverse functions in space and 
time. These lncRNAs are able to bind multiple effector partners which can be 
transcriptionally activating or repressive. In embryonic stem cells, many genes 
exist in a state of “quantum superposition" by having functionally ambivalent 
histone marks, such as methylated H3K4 (active) as well as methylated 
H3K27 (inactive). This state needs to be collapsed during differentiation, so 
that the chromatin either assumes the active or inactive histone methylation 
form (Tsai et al., 2010). The lncRNA HOTAIR is able to resolve this ambivalent 
chromatin state at the HOXD locus, by recruiting both the polycomb 
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repressive complex 2 (PRC2) as well as LSD1 (Rinn et al., 2007, Tsai et al., 
2010). Functionally, this allows for the multiplexing of two distinct histone 
modifications, as PRC2 methylates H3K27 and the LDS1/CoREST/REST 
complex demethylates H3K4. Overall, this results in the onset of an inactive 
chromatin state that represses transcription (Tsai et al., 2010). Thus, HOTAIR 
functions as a scaffold to recruit two different histone modification complexes 
to provide combinatorial epigenetic histone alterations that together, suppress 
gene expression at the HOXD locus.
Guides
A subset of lncRNAs can spatially direct their activity to specific loci in the 
genome, in cis or trans. This provides highly specific, spatially regulated 
control of gene expression. LncRNA activity can be constrained to their site of 
transcription by Pol II tethering or traverse long-range distances to function at 
distal sites defined by sequence, structural or biochemical interfaces that 
confer some kind of specificity (Wang and Chang, 2011). HOTTIP is 
expressed from the HOXA gene cluster and serves to regulate homeotic gene 
expression in cis during development. It recruits the WD repeat-containing 
protein 5/Mixed Lineage Leukemia (WDR5/MLL) protein complex to deposit 
local histone methylation marks, which maintain an active chromatin state 
across its target genes (Wang et al., 2011). Conversely, HOTAIR is 
transcribed from the HOXC locus on chromosome 12, but transcriptionally 
silences genes at the HOXD locus on chromosome 2 by targeted locus-
specific recruitment fo the PRC2 silencing complex (Rinn et al., 2007). 
Enhancer RNAs (eRNAs)
Owing to the advances in sequencing technologies, such as the development 
of Cap Analysis of Gene Expression (CAGE), it was found that enhancer 
regions are actively transcribed (Andersson et al., 2014). Transcription of 
enhancers occurs bi-directionally to generally produce unspliced and non-
polyadenylated transcripts of approximately 300-400 nt in length, termed 
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eRNAs (Andersson et al., 2014). Early experiments showed that the depletion 
of eRNAs led to the loss of transcription of nearby genes, while the tethering 
of eRNAs to reporter genes led to enhanced transcription. These studies 
provided the first evidence that eRNAs were functional as transcriptional 
activators (Lai et al., 2013, Lam et al., 2013, Li et al., 2013, Melo et al., 2013). 
eRNAs are now known to interact with the Mediator complex and facilitate 
chromosomal looping of enhancers to cognate promoters to activate 
transcription (Lai et al., 2013). Importantly, the transcription of different eRNAs 
was found to be cell-type specific and responsive to a variety of 
developmental and cellular contexts, allowing for them to aid in the precise 
spatiotemporal and tissue-specific regulation of gene expression (Lai et al., 
2013, Andersson et al., 2014). 
Figure 1.5: The different molecular mechanisms of lncRNA function in the regulation of 
transcription
LncRNAs emanating from enhancer regions (eRNAs) interact with the Mediator complex to 
facilitate chromosomal looping of enhancers to their cognate promoters for transcriptional 
activation. LncRNAs can also serve as scaffolds for multiple protein complexes, allowing them 
to exhibit multi-function capabilities in regulating transcription. They can also function as 
guides that target transcriptional regulators to particular loci or act as decoys that titrate 
proteins and RNAs (such as miRNAs) away to modulate transcription. 
Currently, lncRNAs constitute 70% of the transcriptome, but only a small 
fraction of these have been well studied. As technologies continue to 
advance, the catalogue of lncRNAs will only grow, widening the gap in our 
knowledge. By developing our understanding of the role of these diverse 
molecules in various biological processes, they might emerge as novel drug 
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targets for the next generation of therapeutics. Such therapeutic modalities 
will function at the transcriptional level and may prove to be more efficacious 
than the current post-translational modulators, which often rely on a 
mechanism of protein titration. 
Aims
While inflammation provides essential immunological protection, its 
dysregulation is also a major contributor to many diseases, including diabetes, 
atherosclerosis, gout and rheumatoid arthritis (Netea et al., 2017). In order to 
develop novel therapies that can modulate pathogenic inflammation more 
effectively, it is paramount that a clear understanding of the mechanisms that 
regulate inflammation is established. For example, novel insights into the role 
of tumour-associated macrophages have revealed that these immune cells 
are reprogrammed by the tumour microenvironment to become 
immunosuppressive of the T-cell mediated anti-tumour response. As a result, 
this allows for the tumour to evade immune surveillance and continue its 
progression uninhibited (Aras and Zaidi, 2017). Therapeutics that can reverse 
the immunosuppressive state of the macrophages have been shown to be 
beneficial in delaying tumour growth (Tian et al., 2013, Liu et al., 2015). Other 
methods involve the inhibition of this negative immune regulation by disrupting 
receptor-ligand interactions that are causal to T-cell dysfunction (Seidel et al., 
2018). By reactivating and exploiting the immune response, these 
immunotherapies have proven to be a highly effective form of treatment for 
certain cancers and driven the tremendous growth in the industry seen in 
recent years. In contrast, sepsis is caused by the severe dysregulation of the 
inflammatory response and is the leading cause of hospital-related deaths 
worldwide. Despite this, treatment options have remained severely limited and 
archaic (Hotchkiss et al., 2009, Waterhouse et al., 2018). This is because no 
new treatments for sepsis have successfully been introduced in the last 25 
years due to the poor understanding of the pathogenic mechanisms 
underlying sepsis (Hotchkiss et al., 2009, Waterhouse et al., 2018).
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These examples highlight the pervasive role of innate immunity in maintaining 
health and driving disease. They also underscore the need to gain deeper 
insights into the fundamental processes that regulate the inflammatory 
response, in order effectively modulate its function. Transcription has been 
implicated as a key regulator of the inflammatory response (Escoubet-Lozach 
et al., 2011, Rabani et al., 2011, Bhatt et al., 2012). It is clear that the 
eukaryotic cell is replete with regulatory mechanisms that cooperatively 
function to govern the precise transcription of the genomic code. These 
include the organisation of the genome to coordinate specific promoter-
enhancer contacts and the role of lncRNAs to fine tune locus-specific 
transcription. While there is a good working model that describes the many 
facets of transcriptional regulation in the nucleus, many of the molecular 
mechanisms and networks that regulate transcription specifically during the 
inflammatory response remain poorly understood. Therefore, the broad aim of 
this work was to dissect the molecular mechanisms and genetic circuitry that 
regulate some of the fundamental aspects of inflammation:
1. The rapid and robust transcriptional activation of the innate immune genes
2. The coordination of pro- and anti-inflammatory cytokine transcription for 
the biphasic regulation of inflammation
3. The role of these molecular mechanisms in regulating innate 
immunological memory (trained immunity)
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Chapter 2
A LONG NON-CODING RNA PRIMES IMMUNE 
GENE EXPRESSION IN THE ELR+ CXCL 
CHEMOKINE TAD
Introduction
The initial phase of inflammation is characterised by the transcriptional 
activation of various pro-inflammatory cytokines and chemokines, which are 
involved in cellular signalling and chemotaxis, respectively (Rogatsky and 
Adelman, 2014). Importantly, the rapid and robust transcriptional activation of 
these immune genes is fundamental to the success of this pro-inflammatory 
phase. In order to meet the fast transcriptional kinetics required, the 
promoters of many pro-inflammatory immune genes exist in a primed state 
(Fowler et al., 2011, Bhatt et al., 2012). This allows for their rapid activation by 
signal-dependent transcription factors (Bhatt et al., 2012). 
Tumour necrosis factor (TNF) can induce the pro-inflammatory response 
through the rapid transcriptional induction of immune genes (Paulsen et al., 
2013). Hi-C studies have shown that numerous TNF-responsive genes co-
occupy TADs, suggesting their potential co-regulation (Jin et al., 2013). 
Remarkably, mapping of these chromosomal contacts revealed that TNF-
responsive promoter-enhancer contacts were pre-formed in the unstimulated 
state (Jin et al., 2013). Intuitively, pre-formed chromosomal loops reduce the 
stochasticity of transcription by creating insulated compartments from which 
co-regulated genes can be primed and robustly transcribed. In contrast, the 
slower transcriptional kinetics associated with the dynamic formation of 
promoter-enhancer contacts may subvert the effectiveness of pro-
inflammatory immune gene transcription. Thus, the 3D organisation of innate 
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immune genes may play an important role in aiding the rapid and robust 
transcription of pro-inflammatory genes. 
Within the TNF-responsive immune gene TADs, TNF induction of transcription 
was shown to be independent of SWI/SNF chromatin remodelling (Ramirez-
Carrozzi et al., 2009). This suggests that the chromatin of rapidly responsive 
immune genes is accessible prior to stimulation. In contrast, interferon-β (IFN-
β)-induced transcription is dependent on SWI/SNF activity, and as a result 
has slower activation kinetics (Ramirez-Carrozzi et al., 2009). The accessible 
state of TNF-responsive genes allows for their regulation at the level of Pol II 
pause-release (Adelman et al., 2009). This means that the promoters of these 
immune genes exist in a poised state, where the PIC is pre-assembled and 
Pol II activity has been paused on the promoter (Figure 1.2). This allows for 
these promoters to be rapidly activated by signal-dependent transcription 
factors which recruit P-TEFb to release Pol II from its suspended state upon 
stimulation (Hargreaves et al., 2009). 
At the promoters of these rapidly inducible genes, dense CpG islands and 
epigenetic histone modifications, such H3 and H4 acetylation and H3K4me3, 
maintain the euchromatin state and instruct the pre-loading of transcriptional 
machinery, respectively (Ramirez-Carrozzi et al., 2009, Fenouil et al., 2012, 
Rogatsky and Adelman, 2014). In particular, H3K4me3 is a prominent histone 
mark that has been shown to epigenetically prime promoters and direct the 
assembly of the PIC (Lauberth et al., 2013). The loading of Pol II during PIC 
assembly is mediated by the general transcription factor II D (TFIID), which is 
responsible for core promoter recognition and binding (Thomas and Chiang, 
2006, Juven-Gershon et al., 2008). In two seminal studies, TFIID was found to 
selectively bind H3K4me3 via the TATA box-binding protein 3 (TAF3) subunit, 
thus allowing for the selective assembly of the PIC at H3K4me3 marked 
genes (Vermeulen et al., 2007, Lauberth et al., 2013). In support of this, it is 
thought that H3K4me3 increases the local hydrophobicity of chromatin and 
assists with the cooperative binding of transcription factors to DNA in the 
aqueous nucleoplasm (Su et al., 2016). Further functional studies have 
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demonstrated that H3K4me3 is causal to transcription (Cano-Rodriguez et al., 
2016). Using the histone methyltransferase PRDM9 fused to dCas9, targeted 
local H3K4me3 deposition at promoter regions induced the expression of 
transcriptionally silenced genes (Cano-Rodriguez et al., 2016). Therefore, 
H3K4me3 is instructive of transcription and is predictive of the transcriptional 
responsiveness and strength of a promoter (Lauberth et al., 2013, Saeed et 
al., 2014). While it is clear that this epigenetic histone modification is essential 
for establishing the primed state of rapidly responsive genes, such as the pro-
inflammatory genes, the preceding molecular mechanisms that spatially direct 
the discrete deposition of H3K4me3 at these specific promoters have 
remained unknown.
In a recent study, our laboratory described the discovery and function of a 
novel family of lncRNAs, called Immune-gene Priming LncRNAs (IPLs) 
(Fanucchi et al., 2019). These were found to epigenetically prime the 
transcriptional response of innate immune genes. Using a bespoke 
bioinformatic pipeline that integrated chromosomal contact (from Hi-C and 
Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET)), 
CAGE and ChIP-Seq datasets, it was revealed that an IPL emanated from 
within each of the TADs containing primed TNF-responsive genes. 
Classification of these TADs revealed sub-classes where (1) an IPL made 
chromosomal contact with a single primed TNF-responsive gene or (2) an IPL 
made chromosomal contacts with multiple primed TNF-responsive genes. In 
depth mechanistic studies demonstrated that the IPLs interacted with the 
WDR5/MLL1 complex to direct local H3K4me3 accumulation. By exploiting 
the 3D genome architecture, the IPLs were able to spatially direct H3K4me3 
deposition on the promoters of TNF-responsive immune genes and prime 
their transcriptional activity.
One candidate IPL, called UMLILO (Upstream Master LncRNA of the 
Inflammatory chemokine LOcus), was found to emanate from the glutamic 
acid-leucine-arginine positive (ELR+) CXCL chemokine TAD and made 
chromosomal contacts with interleukin-8 (IL-8), (C-X-C motif chemokine 
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ligand 1) CXCL1, CXCL2 and CXCL3 (Fanucchi et al., 2019). The expression 
of these chemokines are responsible for the induction of neutrophil 
chemotaxis, which is essential for amplifying the pro-inflammatory response 
and initiating offensive measures, such as phagocytosis, the release of anti-
microbials and the production of neutrophil extracellular traps (Kobayashi, 
2008, Amulic et al., 2012). It was hypothesised that this lncRNA functioned as 
a typical IPL to regulate the transcriptional priming and activity of these 
chemokines. 
In this chapter UMLILO was functionally validated for IPL activity. This 
included the depletion of UMLILO and measuring the effect on the 
transcription, chromosomal contacts and H3K4me3 accumulation on 
neighbouring chemokine genes. The results presented here demonstrate that 
UMLILO exploits the local 3D topology to access neighbouring chemokine 
genes and regulate their transcription through the discrete deposition of 




Previously unpublished Hi-C data was analysed and the interaction heat map 
was generated by Maxim Imakaev as previously described (Imakaev et al., 
2012). ChIA-PET data from TNF treated primary human umbilical vein 
endothelial cells (HUVECS) enriched for Pol II (Ser2/5) mediated 
chromosomal contacts was obtained from the National Centre for 
Biotechnology Information (accession number: GSE41553) (Papantonis et al., 
2012). Recovered PETs were processed and analysed by Maxim Imakaev as 
described by Fanucchi et al., 2019. ChIP-Seq data made use of the 
Encyclopaedia of DNA Elements (ENCODE) database and was visualised 
using the UCSC Genome Browser (https://genome.ucsc.edu). CAGE data 
was from the Functional Annotation of the Mammalian Genome 5 (FANTOM 
5) database and visual ised using the Zenbu Browser (http:/ /
fantom.gsc.riken.jp/zenbu). 
Cell culture
HUVECs (Lonza) were grown using the Endothelial Cell Growth Medium-2 
(EGM-2) Bullet Kit (Lonza) containing Endothelial Basal Medium, vascular 
endothelial growth factor (concentration not specified by EGM-2 kit) and 2% 
foetal bovine serum (FBS). Cells were cultured in T25 flasks in a humidified 
incubator with 5% CO2 at 37˚C until 80% confluent (as determined by 
inspection using a light microscope) before sub-culturing. To dissociate the 
cells, the cell culture medium was discarded, the cells were washed with 1X 
phosphate buffered saline (PBS) (Thermo Fisher Scientific) and treated with 1 
ml TrypLE Express (Thermo Fisher Scientific). After 2-3 minutes of incubation 
at 37˚C, 1 ml of complete cell culture medium was added to neutralise the 
TrypLE. Repeat pipetting was performed to dissociate the cells into a single-
cell suspension, after which 80% of the cell suspension was discarded. 
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Complete cell culture medium was then added to make up a final volume of 5 
ml. 
HeLa cells (Sigma-Aldrich) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Thermo Fisher Scientific) containing 1% GlutaMAX 
(Thermo Fisher Scientific) and 10% FBS (Thermo Fisher Scientific). HeLa 
cells were sub-cultured in the same way as described for HUVECs.
HUVEC stimulation with TNF and reverse transcription quantitative PCR 
(RT-qPCR)
2x105 HUVECs were seeded into a 24-well plate and serum starved (HUVEC 
medium with 0.5% FBS) for 24 hours. The cells were then treated with 10 ng/
ml of TNF (Sigma-Aldrich) for 30 minutes. RNA was extracted from these cells 
according to the instructions of the Direct-zol RNA Miniprep Kit (Zymo) 
(Appendix A2.1). 1 μg of this RNA was then converted to cDNA using the 
SuperScript IV First-Strand Synthesis System according to the manufacturer’s 
instructions (Appendix A2.2) (Thermo Fisher Scientific). qPCR was performed 
using the CFX Real-Time PCR Detection System (Bio-Rad) and the following 
reaction was set up as technical duplicates: 1 μl of the cDNA library, 0.25 μM 
forward primer, 0.25 μM reverse primer, 5 μl of the Sso Advanced Universal 
SYBR Green Supermix (Bio-Rad) and made up to a final volume of 10 μl with 
water. Reactions were subject to the following cycle conditions: initial 
denaturation of 95˚C for 3 mins, and 45 cycles of denaturation at 95˚C for 10 
seconds, primer annealing at 55˚C for 10 seconds, extension at 72˚C for 20 
seconds. Amplicons were verified by melt curve analysis (ramp up from 
65-95˚C at 0.5˚C increments). Relative expression levels were calculated 
according to the delta delta Ct method using HPRT as the house-keeping 
gene. Relative fold changes were then calculated by normalising relative 
expression values to the control condition of each experiment. Primer 
sequences are provided in Table 1.1. 
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Table 1.1: List of primers used for RT-qPCR
siRNA depletion of UMLILO
A siRNA pool targeting UMLILO (Table 1.2) (Dharmacon) was delivered into 
HUVECs by electroporation using the Neon Transfection System (Thermo 
Fisher Scientific). 1.5x105 HUVECs were prepared according to the 
instructions provided by the Neon Transfection System (Appendix A2.3) and 
were electroporated with 20 nM of the siRNA pool in a 10 μl tip according to 
the following parameters: 1 pulse of 1 350 V for 30 ms.  The electroporated 
cells were immediately seeded in a 24-well plate with 0.5 ml of complete 
HUVEC medium per well for the cells to recover. After 24 hours, the medium 
was replaced with HUVEC medium containing 0.5% FBS to serum starve the 
cells for 24 hours. 48 hours post-electroporation, the cells were then 
stimulated with 10 ng/ml TNF for 30 minutes prior to RNA extraction, cDNA 
synthesis and qPCR (as described above).
















Table 1.2: List of siRNA sequences used to target UMLILO
3C
3C was performed following the protocol described by Hagege et al., with 
minor modifications (Hagege et al., 2007). Briefly, 8x106 singlet HeLa cells 
were resuspended in 10% (v/v) FBS/PBS and crosslinked with 1% 
formaldehyde for 10 minutes at room temperature. The formaldehyde was 
quenched with 0.125 M cold glycine and incubated for 5 minutes on ice. The 
fixed cells were harvested by centrifugation at 225 g for 8 minutes at 4°C and 
lysed in 3C lysis buffer (Appendix A3.1) for 30 minutes. To aid this lysis, the 
cell suspension was dounce homogenized with pestle B. The nuclei were then 
collected by centrifugation at 400 g for 5 minutes at 4°C. The pellet was 
resuspended in 1.2X Buffer R (Thermo Fisher Scientific) with 0.3% SDS. This 
was incubated at 37°C for 1 hour with gentle shaking. 2% Triton X-100 was 
added and incubated at 37°C for 1 hour to sequester the SDS. 550 units of 
HindIII (Thermo Fisher Scientific) was incubated with the mixture at 37°C 
overnight and gentle shaking. The following day, 1.3% of SDS was added and 
incubated at 65°C for 20 minutes to stop the digestion. 6.125 ml of 1.15X T4 
ligation buffer (Thermo Fisher Scientific) and 20% Triton X-100 was then 
added and incubated for 1 hour at 37°C with gentle shaking. 100 U of T4 
ligase (Thermo Fisher Scientific) was added to the reaction and incubated at 
16°C for 4 hours with gentle shaking, followed by 30 minutes at room 
temperature. 300 μg of Proteinase K (Thermo Fisher Scientific) was added to 
reverse the crosslinks. This was incubated at 65°C overnight. RNA was then 
digested with 300 μg of RNAse A and incubated at 37°C for 30 minutes. The 
remaining genomic DNA was then purified by phenol/chloroform extraction 
siRNA Sequence (5ʹ - 3ʹ)
AUC UUA AAU UAG AGG CGA AUU
CAU ACA AAU UCU CGC AGC AUU
AAG AGU UGG UAC ACG GUG AUU
GCA UAU UAA CCC UAC AAG UUU
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and precipitated using isopropanol. 3C reactions were mixed with an equal 
volume of phenol-chloroform and mixed vigorously. These were decanted into 
a Maxtract tube (Qiagen) and centrifuged at 1 800 g for 10 minutes at room 
temperature. The DNA in the recovered supernatant was then precipitated by 
adding an equal volume of isopropanol, 10% (of original volume) 3M sodium 
acetate and 5 μl Glycoblue. The mixture was vortexed and  then incubated at 
-80˚C for 1 hour. Precipitated DNA was recovered by centrifugation at 3 000 g 
for 30 minutes at 4˚C. DNA pellets were washed twice with 500 μl of ice cold 
70% ethanol. Recovered 3C libraries were resuspended in 50 μl TE buffer 
(Appendix A3.2). 
Proximity ligated DNA products were detected using unidirectional primers 
(Table 1.3) and qPCR. These primers were designed by mapping all HindIII 
sites within this region and simulating proximity ligation products in Snapgene. 
Using these chimeric products as templates, Primer Blast (https://
www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to identify primers that 
had a uniform annealing temperature and were specific to the 3C ligation 
product. The function of each primer was tested in combination with the 
universal anchor primer by PCR. Resultant amplicons were visualised by 
agarose gel electrophoresis (Appendix A1.1). Primer amplification efficiency 
was determined by performing qPCR on a dilution series of a control 3C 
library (Appendix A1.1). Primers that were efficient and specific when 
annealed at 58˚C were chosen for the assay.
qPCR to measure interaction frequencies was performed on the CFX Real-
Time PCR Detection System (Bio-Rad) and the following reaction was set up 
as technical triplicates: 1 μl 3C library, 0.25 μM anchor primer, 0.25 μM test 
primer, 5 μl Sso Advanced Universal SYBR Green Supermix (Bio-Rad) and 
made up to a final volume of 10 μl with water. qPCR reactions were carried 
out with an initial denaturation of 95˚C for 3 mins, and 35 cycles of 
denaturation at 95˚C for 10 seconds, primer annealing at 58˚C for 10 
seconds, extension at 72˚C for 20 seconds. Amplicons were verified by melt 
curve analysis (ramp up from 65-95˚C at 0.5˚C increments). A putative 
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interacting genomic region (GAPDH) was used to normalise for variation 
between 3C library preparations. Interaction frequencies were further 
normalised to random interaction frequencies as determined by a 3C library 
prepared from a bacterial artificial chromosome (RP11-68O13, Empire 
Genomics) containing the genomic region of interest.
In order to deplete UMLILO prior to assaying chromosomal contacts by 3C, 
siRNAs (20 nM) were delivered by RNAiMax (Thermo Fisher Scientific) 
transfection, according to the manufacturer’s protocol (Appendix A2.4), into 
the HeLa cells 48 hours before harvesting their cell nuclei.  
Table 1.3 List of primers used for 3C-qPCR





















1x106  HUVECs were fixed with 3.7% formaldehyde for 10 minutes at room 
temperature. The cells were washed with cold PBS three times, after which 
0.125 mM of cold glycine was added and incubated for 5 minutes at room 
temperature with gentle shaking. The cells were then washed twice with 10 ml 
cold PBS, resuspended in 5 ml of PBS and centrifuged at 1000 g for 5 
minutes. The pellet was resuspended in FA lysis buffer (Appendix A3.3) and 
sonicated using the Covaris S220 Sonicator to generate DNA fragments 
between 500 - 1000 bp in size. The sonicated material was collected by 
centrifugation at 8 000 g for 30 seconds at 4°C. 50 μl of each sample was 
reserved to serve as an input control to normalise for DNA concentration. 
Each immunoprecipitation reaction contained 25 μg of protein, 1:10 RIPA 
buffer (Appendix A3.4) and 1 μg of the appropriate ChIP-grade antibody (anti-
H3K4me3 (ab8580; Abcam), MED12 (A300–774A; Bethyl Laboratories), anti-
RNA Pol II (Ser5) (ab5131; Abcam), anti-WDR5 (ab56919; Abcam). A mixture 
of protein A and G magnetic beads (Resyn Biosciences) was prepared by pre-
absorbing with sonicated single-stranded salmon sperm DNA (1.5 μg per 20 
μl beads) and incubated with the reactions at 4°C overnight with rotation. 
Magnetically capture beads were washed three times with 1 ml wash buffer 









GAPDH control F1 TGCCAATCTCCTTGTTTTCTAATG
GAPDH control F2 TATTCCCCCAGGTTTACATGTTC
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captured DNA was eluted from the beads by adding 120 μl elution buffer 
(Appendix A3.7) and incubating at 37°C for 15 minutes with rotation. The DNA 
was then purified using phenol/chloroform extraction and precipitated as 
previously described. Pelleted DNA libraries were resuspended in 50 μl TE 
buffer (Appendix A3.2). qPCR primer sequences are provided in Table 1.4. 
qPCR was performed as previously described for 3C. Percentage of input was 
calculated using the following: 2-(experiment ct - input ct)
Table 1.4: List of primers for ChIP-qPCR













UMLILO emanates from the ELR+ CXCL chemokine TAD
The 3D organisation of the genome is essential for mediating specific 
chromosomal contacts which are causal to transcription (Deng et al., 2012, 
Fanucchi et al., 2013, Morgan et al., 2017). Genome-wide chromosomal 
contact maps, such as those generated by Hi-C or ChIA-PET can help identify 
target genes that are regulated by specific distal elements. Analysis of 
previously unpublished Hi-C data indicated that the ELR+ CXCL chemokine 
genes (IL-8, CXCL1, CXCL2 and CXCL3) co-occupy the same TAD on 
chromosome 4 (Figure 2.1A). UMLILO, a previously uncharacterised multi-
exonic lncRNA that is 575 nt in length, emanated from this TAD. 
In order to gain better resolution of specific chromosomal contacts within this 
region, publicly available ChIA-PET data generated from HUVECs was 
examined (Papantonis et al., 2012). PETs recovered by this method are 
enriched by immunoprecipitation of a particular chromatin-interacting protein 
of interest, thus retrieving very specific contacts (Fullwood et al., 2009). We 
examined the dynamics of chromosomal contacts within the ELR+ CXCL 
chemokine TAD that were mediated by actively transcribing Pol II Ser2/5 in 
response to TNF stimulation. Prior to TNF exposure, very few Pol II-mediated 
contacts were observed within the TAD, as the genes were transcriptionally 
inactive in this unstimulated state. Numerous Pol II-mediated contacts 
emerged after 30 minutes of TNF stimulation (Figure 2.1 B). Importantly, there 
was an enrichment of these contacts specifically between UMLILO and the 
ELR+ CXCL chemokine genes, suggesting the formation of a multi-gene 
complex by chromosomal looping during active transcription. 
Next, ChIP-Seq data from ENCODE was analysed to determine the chromatin 
state of the genes in unstimulated primary HUVECs and HeLa cells. The 
chemokine genes in contact with UMLILO were enriched for active epigenetic 
histone marks (H3K4me1, H3K4me2, H3K4me3 and H3K27Ac) (Figure 2.1C). 
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Specifically, the enrichment of H3K27Ac indicated that each of these genes 
were accessible prior to stimulation. The lack of H3K36me3 (a mark of active 
transcription) and the enrichment of H3K4me3 confirmed that these genes 
were not being actively transcribed in the unstimulated state, but rather 
primed for transcriptional activation (Sims and Reinberg, 2009). This 
appeared to be true for all the chemokine genes in this TAD, with the 
exception of CXCL1 in the HeLa dataset.
CAGE is a highly sensitive genome-wide method for detecting the 5ʹ end of 
transcripts and the mapping of TSSs (Shiraki et al., 2003). CAGE data 
available from the FANTOM consortium corroborated previous RNA-Seq 
annotations of UMLILO. It confirmed that UMLILO was transcribed in the 
sense (forward) direction and expressed in multiple cells types, including 
professional immune cells such as macrophages and neutrophils, as well as 
non-immune cells such HUVECs and HeLa (Figure 2.1D). Importantly, 
UMLILO was detected in immune challenged and unchallenged cells, albeit at 
significantly lower levels in the resting cells. This indicated that UMLILO was 
transcribed at a basal level in unstimulated cells.  
Taken together, UMLILO emerges from the ELR+ CXCL chemokine TAD 
containing IL-8, CXCL1, CXCL2 and CXCL3. These genes are epigenetically 
primed prior to their activation and specifically engage in chromosomal 
contacts with UMLILO during active transcription. This suggests that these 







Figure 2.1: UMLILO emanates from the ELR+ CXCL chemokine TAD and engages in 
specific chromosomal contacts with the chemokine genes
(A) Hi-C analysis showed that UMLILO emanates from a TAD containing TNF-responsive 
ELR+ CXCL chemokine genes.
(B) ChIA-PET interactions showing the dynamics of Pol II-mediated (ser2/5) chromosomal 
contacts in HUVECs, before and after TNF stimulation. Prior to TNF treatment, very few 
active Pol II-mediated contacts were recovered as the genes were transcriptionally 
inactive. Upon stimulation, a large number of Pol II-mediated contacts emerged, 
specifically between UMLILO, IL-8, CXCL1, CXCL2 and CXCL3, to form a multi-gene 
complex. 
(C) ChIP-Seq analysis in unstimulated HUVECs and HeLa cells from the ENCODE database. 
All the chemokines that UMLILO interacted with were enriched for active chromatin marks 
(H3K4me1, H3K4me2, H3K4me3 and H3K27Ac). The lack of H3K36me3 (active 
transcription) and the enrichment of H3K4me3 indicated that these genes were not 
actively transcribed prior to stimulation, but were primed for transcriptional activation, 
respectively. 
(D) CAGE data from the FANTOM 5 database showed that UMLILO was transcribed in 
profession immune cells as well as non-immune cells. UMLILO levels were highest in 
immune challenged cells, but basal levels of UMLILO were detected in unstimulated cells 
too.
UMLILO is required for chemokine transcription
In order to determine the transcriptional response of UMLILO and its 
associated chemokines, HUVECs were stimulated for 30 minutes with TNF 
and gene expression was quantified using RT-qPCR. Chemokine transcription 
was strongly induced by TNF (ranging from 15-20 fold increase) and this was 
accompanied by a 2.5 fold increase in UMLILO expression from basal levels 
(Figure 2.2A). The expression of ANKRD17 was used as a negative control, 
as it is non-responsive to TNF and occupies a neighbouring TAD. To 
determine whether UMLILO was required for this transcriptional activation, 
RNA interference (RNAi) was used to deplete UMLILO in HUVECs. A pool of 
small interfering RNAs (siRNAs) were targeted to UMLILO and observed to 
efficiently knockdown UMLILO by approximately 80% (Figure 2.2B). siRNAs 
targeting the green fluorescent protein (GFP) was used as a negative control 
(siGFP). Strikingly, depletion of UMLILO 48 hours prior to TNF stimulation 
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significantly abrogated the transcriptional activation of the chemokines 
compared to the negative control (Figure 2.2B). Importantly, the effect of 
UMLILO silencing was confined to the chemokines within this TAD, as 
ANKRD17 remained unaffected. These data demonstrated that UMLILO is a 
bonafide functional lncRNA that is essential for the co-regulated transcription 
of IL-8, CXCL1, CXCL2 and CXCL3 in response to TNF stimulation.
 
Figure 2.2: UMLILO is essential for co-regulated chemokine transcription
(A) RT-qPCR measurements showed that TNF stimulation induced the transcription of 
UMLILO and its associated chemokines in HUVECs. ANKRD17, a gene in a neighbouring 
TAD, was unaffected by TNF treatment. (n=3)
(B) Knockdown of UMLILO using siRNAs in HUVECs significantly abrogated chemokine 
transcription in response to TNF compared to the siGFP control. ANKRD17 expression 
remained unaffected by the loss of UMLILO. (n=3)
Data are represented as mean±SEM. n=number of independent experiments. p values were 




Chromosomal contacts with UMLILO are pre-formed
From Hi-C contact maps, it is clear that UMLILO and the ELR+ CXCL 
chemokines occupy the same TAD (Figure 2.1A) and are likely to participate 
in chromosomal contacts. The ChIA-PET data supports this by showing that 
UMLILO was in contact with these genes during active transcription via Pol II-
mediated interactions (Figure 2.1B). However, with the limited resolution of Hi-
C and the selection bias of ChIA-PET for Pol II-mediated contacts, it remained 
unclear whether UMLILO specifically engages with the chemokine genes in 
the unstimulated state.
In order to study the dynamics of the chromosomal contacts between UMLILO 
and the ELR+ CXCL chemokine genes, 3C was performed on HeLas to 
generate a high resolution interaction map across this TAD, before and after 
TNF stimulation (Figure 2.3 A). IL-8 was used as an anchor point and primers 
were designed across the TAD to test for chromosomal interactions. Primers 
targeting regions outside of the TAD were used as negative controls. In the 
unstimulated state, it was observed that UMLILO engaged in chromosomal 
contacts with all the chemokine genes, corresponding to the PETs recovered 
from Pol II Ser2/5 ChIA-PET. After 30 minutes of TNF activation, the 
frequency of these contacts largely remained unchanged. This suggested that 
UMLILO and the chemokine genes existed in a pre-formed multi-gene 
complex, which may be significant for the priming of the chemokine promoters 
prior to their activation and their co-regulated expression. 
UMLILO does not mediate the chromosomal contacts in the ELR+ CXCL 
chemokine TAD
Through the recruitment of the Mediator complex, eRNAs are able to facilitate 
precise chromosomal contacts that are causal to transcription (see section 
entitled Enhancer RNAs). From the previous results, the transcription of the 
chemokine genes was dependent on UMLILO and engaged in chromosomal 
contacts (Figure 2.2B and Figure2.3A). In order to determine whether 
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UMLILO played a role in the formation and maintenance of these contacts, 
which are likely to be causal to the co-regulated transcription pattern of the 
chemokines, the basal levels of UMLILO were depleted by siRNA prior to 
performing 3C on the locus. Previously validated siRNAs were delivered into 
HeLa cells and 3C was carried out on unstimulated cells 48 hours later using 
the same primer sets as before. Knockdown of UMLILO did not affect the 
earlier described pre-formed contacts compared to the negative control 
siGFP (Figure 2.3B). This indicated that the formation of the multi-gene 
complex was not dependent on UMLILO, suggesting that this lncRNA did not 
function like an eRNA to coordinate chromosomal loops and mediate the 
transcription of the chemokine genes. 
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Figure 2.3: UMLILO does not mediate the pre-formation of chromosomal contacts
(A) 3C across the chemokine TAD in HeLas revealed that there were no significant changes 
in chromosomal contacts between UMLILO and the chemokine genes before and after 
TNF stimulation. This suggests that these contacts are pre-formed prior to stimulation 
(inset). IL-8 was used as an anchor point and a primer set designed to target a region 




(B) Depletion of baseline UMLILO levels using siRNAs (siUMLILO) in HeLas did not alter the 
chromosomal contacts (as measured by 3C) in this region compared to the siRNA 
targeting the GFP sequence (siGFP) control. This indicated that UMLILO does not 
mediate the formation and maintenance of this pre-formed architecture (inset). (n=3)
Data are represented as mean±SEM. n=number of independent experiments.
UMLILO is required for H3K4me3 and Pol II occupancy at the chemokine 
promoters
H3K4me3 is causal to transcription by facilitating transcription factor binding 
and the assembly of the PIC (Vermeulen et al., 2007, Lauberth et al., 2013, 
Cano-Rodriguez et al., 2016). H3K4me3 deposition is carried out by the MLL 
family of histone methyltransferases (Wang et al., 2012). Importantly, it 
associates with WDR5, which functions as an adaptor protein which can bind 
RNA (Yang et al., 2014). It has been found that the WDR5/MLL1 complex can 
associate with lncRNAs such as NeST and HOTTIP, to spatially direct the 
deposition of H3K4me3 at their target genes (Wang et al., 2011, Gomez et al., 
2013). 
As previously observed, UMLILO engages in chromosomal contacts with the 
ELR+ CXCL chemokine genes, which are H3K4me3 primed prior to TNF 
activation. In order to test whether UMLILO was regulating H3K4me3 
deposition at the promoters of these chemokine genes, UMLILO was knocked 
down and ChIP-qPCR was performed. Using the same siRNAs as before, 
UMLILO was efficiently depleted (Figure 2.2B) 48 hours prior to TNF 
stimulation in HUVECs. siGFP was used as a comparative control. The 
promoter DNA of IL-8, CXCL1, CXCL2 and CXCL3 were pulled down using an 
anti-H3K4me3 antibody and quantified using qPCR. Compared to the siGFP 
control, the loss of UMLILO resulted in the significant loss of H3K4me3 
occupancy across all the chemokine promoters (Figure 2.4A). This 
demonstrated that UMLILO was essential for H3K4me3 deposition at the 
promoters of these chemokines. Accompanying the loss of H3K4me3 was the 
significant loss of Pol II occupancy (Figure 2.4B). qPCR on libraries prepared 
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using an anti-WDR5 antibody also showed significant loss in WDR5 
occupancy at the chemokine promoters (Figure 2.4C), suggesting that 
UMLILO was recruiting MLL1 to this multi-gene complex via WDR5. All these 
effects of UMLILO knockdown were not observed on the control gene, 
ANKRD17. Furthermore, all ChIP-qPCR experiments were accompanied by a 
control library prepared using an IgG antibody in order to determined 
background DNA pull down. 
Taken together, these results revealed the UMLILO was required for the 
deposition of H3K4me3 at the chemokine genes within this TAD. As a result, 
UMLILO indirectly facilitated Pol II loading, which is essential for transcription. 
Furthermore, UMLILO was able to do this via the recruitment of WDR5, which 
interacts with MLL1 to catalyse the deposition of H3K4me3 at the promoters 
of this chemokine multi-gene complex.
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Figure 2.4: UMLILO mediates H3K4me3 and Pol II occupancy at the chemokine 
promoters by recruiting WDR5
(A) ChIP-qPCR showed that the depletion of UMLILO using siRNAs in HUVECs, prior to TNF 
stimulation, resulted in the loss of H3K4me3 at the chemokine promoters (siUMLILO vs 
siGFP control). (n=3)
(B) Accompanying the loss of H3K4me3 was the loss of Pol II occupancy at the chemokine 
promoters. (n=3)
(C) UMLILO knockdown modulated the locus-specific recruitment of WDR5, which interacts 
with the MLL1 histone methyltransferase responsible for the catalysis of H3K4me3 
deposition. (n=3)
Data are represented as mean±SEM. n=number of independent experiments. p values were 






Rapid and robust transcriptional activation of pro-inflammatory immune genes 
is essential for providing effective immunological protection. Therefore, many 
of these immune genes exist in a primed state (Fowler et al., 2011, Bhatt et 
al., 2012). H3K4me3 occupancy is central for establishing this primed state, 
as it marks the genes for the pre-loading of transcriptional machinery onto 
their promoters (Lauberth et al., 2013). This allows for these genes to be 
regulated by signal-dependent transcription factors which release paused Pol 
II for active transcription (Fowler et al., 2011, Bhatt et al., 2012).
In this chapter, the data presented shows that a previously uncharacterised 
lncRNA, UMLILO, was essential for the H3K4me3 priming of the ELR+ CXCL 
chemokines. Indeed, the loss of UMLILO resulted in the loss of H3K4me3 and 
Pol II occupancy at the promoters of these genes. This corresponded with the 
well known role of H3K4me3 for Pol II loading at promoters (Lauberth et al., 
2013). Furthermore, this revealed the causal mechanism underlying the loss 
of chemokine transcription when UMLILO was depleted. Chromatin interaction 
mapping by 3C revealed that UMLILO and the chemokine genes were 
engaged in a pre-formed multi-gene complex. UMLILO did not play a role in 
the establishment or maintenance of these chromosomal contacts, suggesting 
that UMLILO does not have architectural abilities like eRNAs. Taken together, 
it appears that UMLILO rather exploits the 3D topology and is able to recruit 
the WDR5/MLL1 complex to the promoters of the chemokines and direct 
discrete local H3K4me3 deposition prior to immune activation (Figure 2.5).  
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Figure 2.5: A schematic showing the functional mechanism of UMLILO
(A) UMLILO engages in specific chromosomal contacts with the ELR+ CXCL chemokine 
genes to form a multi-gene complex. Within this compartment, UMLILO recruits WDR5 





deposition of H3K4me3 on the promoters of the chemokine genes, priming them for 
transcriptional activation. 
(B) H3K4me3 priming facilitates the assembly of the PIC and the pre-loading of paused Pol II.
(C) Upon TNF activation, signal-dependent transcription factors recruit P-TEFb to release the 
paused Pol II from its suspended state. This results in the active co-transcription of the 
chemokine genes, in a rapid and robust manner.
By establishing a pre-formed multi-gene complex, the stochasticity associated 
with transcriptional activation is significantly reduced, allowing for the robust 
and coordinated co-transcription of the chemokine genes (Cavalli and Misteli, 
2013). Within this multi-gene complex, the H3K4me3 epigenetic priming by 
UMLILO changes the ground state of these genes into a poised state, 
allowing for the fast kinetic responses required. Therefore, the 
superimposition of these two layers of regulation (structural and epigenetic) 
underly the rapid and robust transcriptional responses required by pro-
inflammatory genes. 
Chromosomal contacts observed by Hi-C and 3C, however, represent static 
snapshots derived by averaging contact frequencies across an entire cell 
population. Using imaging-based single cell analysis and polymer modelling, 
the collective data from Hi-C experiments can be deconvolved to reveal a 
repertoire of genomic configurations, highlighting the probabilistic nature of 
genome organisation (Giorgetti et al., 2014). Furthermore, single cell Hi-C 
experiments and FISH-based imaging have demonstrated extensive 
heterogeneity in chromosomal contacts across a cell population (Flyamer et 
al., 2017, Fudenberg and Imakaev, 2017, Finn et al., 2019). Contributing to 
this inter-cellular variation, recent studies have suggested that TADs and 
chromosomal loops are dynamic structures (Hansen et al., 2018). Such 
variation may subvert the effectiveness of UMLILO to prime the chemokine 
genes and lead to variegated gene expression across the cell population 
(Noordermeer et al., 2011). This may undermine the ability of a cell to mount a 
sufficiently powerful pro-inflammatory response to effectively combat a 
pathogen. The emergence of rare “jackpot” cells, which happen to be in a 
configuration that supports the transcription of specific genes and display 
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increased levels of expression, may be able to compensate for the silent 
neighbouring cells. However, using intronic RNA single molecule FISH 
(smFISH), the ELR+ CXCL chemokine genes were observed to be robustly 
transcribed in the majority of TNF stimulated cells, refuting the role of rare 
“jackpot” cells in directing the inflammatory response (Fanucchi et al., 2019). 
Recent studies have demonstrated that the turnover of TADs and 
chromosomal loops is highly dynamic and are lost and re-formed within 
minutes (Hansen et al., 2018). This could reconcile the disparity between the 
fluid nature of TADs and the ability for robust transcription. Due to the high 
frequency of chromosomal loop assembly and disassembly, UMLILO could 
function cyclically on its cognate chemokine genes during the assembled 
phase of the multi-gene complex. In doing so, even when the complex is 
temporarily dissolved, the chemokine genes will be in a primed state and 
ready for transcriptional activation. This would explain the robust transcription 
patterns of these chemokines observed in single cells, despite the extensive 
inter-cellular variation in genome organisation (Fanucchi et al., 2019, Finn et 
al., 2019).
In order for UMLILO to prime the chemokine genes, its activity must occur in 
resting cells, prior to immune activation. Although it is transcriptionally 
responsive to TNF treatment, CAGE data and our own have indicated that 
there are basal levels of UMLILO in unstimulated cells. This means that 
UMLILO is able to prime the chemokine genes during homeostatic conditions, 
suggesting that basal UMLILO transcription is independent of TNF activation. 
Furthermore, RNA smFISH experiments have shown that UMLILO transcripts 
are not distributed widely across the nucleus, but rather remain localised near 
the chemokine genes (Fanucchi et al., 2019). RNA-Seq experiments have 
also demonstrated that the function of UMLILO is restricted to the ELR+ 
CXCL chemokine TAD (Fanucchi et al., 2019). These findings suggest that 
there are mechanisms that retain UMLILO within the multi-gene complex after 
its transcription. Such mechanisms are currently unknown, but we can 
speculate that UMLILO is able to recruit WDR5/MLL1 while being transcribed 
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and tethered by Pol II, form DNA-RNA R-loops or recruit other proteins that 
keep UMLILO localised to its site of transcription (Long et al., 2017). 
While it is clear that UMLILO interacts with the WDR5/MLL1 complex to 
execute its function (Fanucchi et al., 2019), some aspects describing the 
protein complex associated with UMLILO may also be incomplete. It is 
possible that UMLILO function may not be l imited to histone 
methyltransferase activity, but rather serve as a scaffold for expanded 
functional capabilities. There are numerous examples of histone modifiers in 
complex with metabolic enzymes (Kera et al., 2013, Matsuda et al., 2016). 
This is because cellular metabolism is closely linked to histone modifications, 
as it provides the substrates for the deposition of these epigenetic marks (Fok 
et al., 2018). For example, methionine adenosyltransferase, which is 
responsible for the synthesis of the methyl donor, S-adenosylmethionine, 
exists in a complex with the H3K9 methyltransferase, SETDB1 (Kera et al., 
2013). Together, this complex epigenetically regulates COX2 gene expression 
through the local production of the methyl donor, which is essential for the 
deposition of the repressive H3K9me3 mark (Kera et al., 2013). It is possible 
that UMLILO can recruit metabolic enzymes to locally produce the metabolites 
required for H3K4me3 deposition. By doing so, stricter spatial limitations are 
imposed for the highly specific and discrete priming of genes. Thus, it might 
be worthwhile in future studies to characterise the ribonucleoprotein complex 
more fully to elucidate any other potential functions.  
In summary, the discovery and characterisation of UMLILO and the IPLs 
illuminate a novel mode of transcriptional regulation of the innate immune 
genes during inflammation (Fanucchi et al., 2019). This provides a novel class 
of drug target candidates that can be modulated to attenuate inflammatory 
responses, highlighting the importance of this work, as many diseases are 
caused by excessive inflammation (Netea et al., 2017). Furthermore, 
numerous other genes within the genome respond in a similarly rapid and 
robust signal-dependent manner, suggesting that other “IPL-like” lncRNAs 
exist to direct the H3K4me3 priming of these genes. By applying the 
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bioinformatic pipeline described by Fanucchi et al., it is possible to discover 
these lncRNAs, which may function pervasively in human biology and provide 
novel ways for manipulating biological processes. 
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Chapter 3
A CHROMATIN-REGULATED BIPHASIC CIRCUIT 
C O O R D I N A T E S I L - 1 β A N D I L - 3 7 
TRANSCRIPTION DURING INFLAMMATION
Introduction
Inflammation is characterised by a biphasic cycle consisting initially of an 
acute pro-inflammatory phase, which is subsequently resolved by anti-
inflammatory processes (Medzhitov, 2008, Rogatsky and Adelman, 2014). 
During the first stage, the induction of the pro-inflammatory immune genes 
needs to occur rapidly in order to initiate host defences and curb the 
progression of infection. The subsequent activation of the anti-inflammatory 
phase is temporally delayed and serves to attenuate pro-inflammation, initiate 
tissue repair and restore the basal cellular state (Medzhitov, 2008, Rogatsky 
and Adelman, 2014).  The dysregulation of this response generally manifests 
as a state of hyper-inflammation or immunosuppression, both of which are 
major contributors to the pathogenesis of many diseases, including sepsis, 
atherosclerosis and cancer (Hotchkiss et al., 2009, Grivennikov et al., 2010, 
Back and Hansson, 2015). Therefore, inflammation is a careful balancing act 
between pro- and anti-inflammation, with shifts that tilt this balance being 
deleterious to human health. Each phase of the inflammatory response is 
directed by the coordinated transcription of key cytokines, suggesting that 
their regulation is intimately linked. However, the molecular mechanisms that 
orchestrate this coordinated gene expression remain poorly understood.
The interleukin-1 (IL-1) family of cytokines and receptors constitute one of the 
main signalling routes of inflammation and have long been implicated in 
modulating this host response (Dinarello, 2013, Mantovani et al., 2019). The 
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IL-1 family is functionally diverse and consists of seven pro-inflammatory 
agonists (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36βɣ and IL-36ɣ), one anti-
inflammatory cytokine (IL-37) and three receptor antagonists (IL-1Ra, IL-36Ra 
and IL-38) (Mantovani et al., 2019). Phylogenetic analysis of the IL-1 family 
revealed that pro-inflammatory function co-evolved with anti-inflammatory 
capabilities 420 million years ago, highlighting the evolutionary significance for 
developing a balanced inflammatory response (Rivers-Auty et al., 2018). By 
encompassing both pro- and anti-inflammatory function, the coordinated 
induction of the IL-1 family can contribute to the different stages of an 
inflammatory cycle.
Interleukin-1 beta (IL-1β) is a master cytokine positioned at the apex of 
inflammation (Kornman, 2006). It is one of the first genes to be 
transcriptionally activated in the face of immune challenge and is 
predominantly expressed in monocytes, macrophages and dendritic cells 
(Kornman, 2006, Moorlag et al., 2018). The expression of IL-1β induces 
powerful pro-inflammatory functions, including the induction of other pro-
inflammatory cytokines, such as IL-6 and TNF-α, and the consolidation of 
glycolytic metabolism (Jung et al., 2003, Cheng et al., 2014). Overproduction 
of IL-1β is detrimental and contributes to many hyper-inflammatory diseases, 
such as rheumatoid arthritis, gout, atherosclerosis and other auto-
inflammatory syndromes (Dinarello, 2011). Blocking of IL-1β has proven to be 
a highly effective way to attenuate pro-inflammation and control these 
diseases, highlighting the critical and hierarchical role of IL-1β in the 
inflammatory response (Dinarello, 2011).
Due to the powerful upstream pleiotropic function of IL-1β, its expression is 
tightly regulated by a two-factor activation mechanism. The first step occurs at 
the level of IL-1β transcription, which produces a mRNA sequence that 
encodes for the inactive pro-IL-1β protein. The second level of regulation 
involves the conversion of pro-IL-1β into its active form by intracellular 
inflammasome-associated proteases, such as caspase-1, or extracellular 
inflammatory proteases (Moorlag et al., 2018). Despite this regulation, human 
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blood monocytes constitutively express activated caspase-1, essentially 
removing the post-translational regulation of IL-1β (Netea et al., 2009). This 
suggests that in these cells, which are a major source of IL-1β, the 
transcriptional regulation of IL-1β is particularly important in shaping a 
calibrated inflammatory response.
Genome wide association studies (GWAS) have revealed that the non-coding 
genome is replete with polymorphisms that affect coding gene function 
(Nishizaki and Boyle, 2017). As such, polymorphisms in the promoter region 
of IL-1β have been shown to regulate inflammatory responses by altering 
IL-1β transcription (Wen et al., 2006). In particular, the rs16944 polymorphism 
(G>A) influences susceptibility to multiple immune-related diseases and is 
highly prevalent worldwide, with approximately a third of the global population 
being homozygous for this variation (Genomes Project et al., 2015) (Figure 
3.1A). Importantly, strong associations have been made between this 
pervasive polymorphism and many inflammatory disease states, including 
periodontitis (Wu et al., 2015), systemic sclerosis (Huang et al., 2016), 
pancreatitis (Li et al., 2015a) and lethal sepsis (Jimenez-Sousa et al., 2017). 
Furthermore, the rs16944 polymorphism is also associated with enhanced risk 
and severity of infectious diseases, such as those caused by Mycobacterium 
tuberculosis (Awomoyi et al., 2005), hepatitis B virus (Fan et al., 2017) and 
fungal infections (Wojtowicz et al., 2015) (Figure 3.1B). Although the precise 
mechanism by which this SNP affects IL-1β transcription remains unknown, 
its influence in multiple inflammatory conditions provides strong correlative 
evidence that the correct transcriptional regulation of IL-1β is imperative for a 
successful immune response. 
56
Figure 3.1: The global distribution of the rs16944 SNP genotypes and the associated 
phenotypes
(A) The rs16944 SNP occurs in the promoter region of IL-1β (G>A) and has approximately 
50/50 allelic distribution worldwide. This means that a third of the global population is 
either homozygous AA or homozygous GG.
(B) The rs16944 SNP has been extensively studied and homozygous phenotypes are 
strongly correlated with highly divergent inflammatory responses. rs16944 GG individuals 
display improved protection from vaccination but are predisposed to hyper-inflammatory 
conditions. Conversely, rs16944 AA individuals are at risk for infection and have and 
increased likelihood for developing immunosuppressive disorders. 
While it is clear that IL-1β plays an important role in driving the pro-
inflammatory component of inflammation, the compensatory role of IL-37 as a 
powerful and broad anti-inflammatory cytokine has only recently emerged 
(Nold et al., 2010, Li et al., 2015b, Li et al., 2019). More specifically, functional 
studies have shown that IL-37 can inhibit innate immunity by effectively 
modulating IL-1β production (Nold et al., 2010). Furthermore, although no 
murine homolog of IL-37 exists, several studies using IL-37 expressing 




mouse, and have revealed that IL-37 plays a protective role in the 
suppression of pathogenic inflammation (Nold et al., 2010). 
Mechanistically, IL-37 can function intracellularly to down regulate the 
transcription of pro-inflammatory cytokines or extracellularly through IL-1R8 
and IL-18R signalling to induce inhibitory signals (Sharma et al., 2008, Nold et 
al., 2013, Nold-Petry et al., 2015). The latter is associated with the inhibition of 
the inflammasome, which is important for IL-1β maturation (Moretti et al., 
2014). IL-37 can also activate AMP-activated protein kinase (AMPK), which 
serves as a key metabolic sensor that regulates energy homeostasis (Hardie 
et al., 2012, Cavalli et al., 2017). By doing so, IL-37 reverses the glycolytic 
state of the cell during pro-inflammation and restores the normative oxidative 
phosphorylation (Cavalli and Dinarello, 2018). These functions of IL-37 
diametrically oppose key activities of IL-1β, suggesting that IL-37 is a strong 
candidate able to modulate IL-1β-mediated responses (Figure 3.2A and B). 
Figure 3.2: A schematic summarising the diametrically opposed functions of IL-1β and 
IL-37
(A) IL-1β is one of the first cytokines to be transcriptionally activated in a cell under immune 
challenge (macrophage depicted here). The maturation of IL-1β usually requires the 
caspase-1 activity associated with the inflammasome. In human circulating monocytes, 
activated caspase-1 is constitutively expressed, negating the regulatory role of this post-
translational regulation and emphasising the regulatory role of transcription. Mature IL-1β 
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A B
can signal in an autocrine and paracrine manner to induce the expression of other pro-
inflammatory cytokines as well as shift the cellular metabolism of the cell towards 
glycolysis. 
(B) IL-37 diametrically opposes the functions of IL-1β and serves as a broad inhibitor of pro-
inflammation. IL-37 can also function in an autocrine or paracrine manner, in order to 
inhibit pro-inflammatory gene expression and inflammasome function, as well as reverse 
glycolytic metabolism by restoring oxidative phosphorylation. Importantly, the expression 
of IL-37 is delayed and occurs downstream of IL-1β. 
Many diseases with an inflammatory basis are accompanied by the 
dysregulation of IL-37 (Xu et al., 2015). Polymorphisms in IL-37 have been 
shown to be expressed quantitative trait loci (eQTLs) for IL-1β (Offenbacher 
et al., 2018). This suggests that the transcriptional regulation of IL-1β and 
IL-37 are linked, and potentially participate in balancing the functionally 
opposed biphasic nature of inflammation. However, the mechanism describing 
how IL-1β and IL-37 may be transcriptionally coordinated remains unknown.
Within the eukaryotic nucleus, multiple layers of transcriptional regulation, 
such as chromosomal loops and lncRNAs, work cooperatively to coordinate 
and control transcription (see Chapter 1). Such mechanisms are essential for 
the regulation of immune gene expression during inflammation (see Chapter 
2). Interestingly, the functionally opposed IL-1β and IL-37 are located within 
the same TAD. However, the significance of this architecture and the role of 
lncRNAs in the regulation and coordination of their transcription, during 
inflammation, currently remains unclear.
In this chapter, the genetic circuitry and molecular mechanisms that 
coordinate the transcription of the functionally opposed IL-1β and IL-37 were 
dissected. Assessment of the region surrounding the rs16944 SNP uncovered 
a novel lncRNA that was transcribed from the IL-1β promoter. Functional 
experiments implicated this lncRNA in the transcriptional activation of IL-37 
through the formation of dynamic chromosomal contacts. Importantly, IL-37 is 
a negative regulator of IL-1β, revealing a chromatin-regulated feedback circuit 
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that coordinated IL-1β and IL-37 transcription to follow the biphasic 




Hi-C sequencing data generated by (Rao et al., 2014) was visualised using an 
online Hi-C browser (http://promoter.bx.psu.edu/hi-c/view.php). Capture Hi-C 
from (Javierre et al., 2016) was visualised using the online Capture Hi-C 
Plotter (https://www.chicp.org). Publicly available ChIP-Seq datasets were 
examined using the UCSC Genome Browser. The traces shown here are from 
the BLUEPRINT project and the ENCODE consortium. CAGE data was from 
the FANTOM 5 database and visualised using the Zenbu browser. 
Cell culture
The THP-1 cell line was kindly donated by Susan Malfeld from the National 
Institute of Communicable Diseases. These cells were grown in RPMI 1640 
medium (Thermo Fisher Scientific) supplemented with 10% FBS (Thermo 
Fisher Scientific), 1% GlutaMAX (Thermo Fisher Scientific) and 50 nM 2-
mercaptoethanol (Thermo Fisher Scientific). When the cells reached a density 
of approximately 1x106 cells/ml, 70% of the cell culture was discarded and the 
volume was replaced with fresh complete culture medium. THP-1 monocytes 
were differentiated using 100 ng/ml 12-myristate 13-acetate (PMA) for 24 
hours. PMA-differentiated THP-1 macrophages were then allowed to rest for 
another 24 hours in PMA-free medium prior to being used. HEK293T cells 
(Sigma-Aldrich) were cultured in DMEM (Thermo Fisher Scientific) containing 
1% GlutaMAX (Thermo Fisher Scientific) and 10% FBS (Thermo Fisher 
Scientific). HEK293T cells were sub-cultured in the same way as described in 
the Cell Culture section of Chapter 2. The retinal pigment epithelial 1 (RPE1) 
cell line (ATCC) was cultured in DMEM/F12 (Thermo Fisher Scientific) 
containing 1% GlutaMAX (Thermo Fisher Scientific) and 10% FBS (Thermo 
Fisher Scientific). RPE1 cells were sub-cultured in the same way as described 
in the Cell Culture section of Chapter 2. HeLa cells were grown as previously 
described in the Cell Culture section of Chapter 2.
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THP-1 stimulation with LPS and RT-qPCR
To isolate primer sets that could detect AMANZI transcription, qPCR primers 
were designed to overlap and tile the entire putatively transcribed AMANZI 
region  (primer sequences provided in Table 2.1). 2.5x105 THP-1 monocytes 
were seeded per well in a 24-well plate and treated with 10 ng/ml 
lipopolysaccharide (LPS) (Sigma-Aldrich) for 60 minutes, after which RNA 
was extracted, cDNA was synthesised and qPCR was carried out as 
described in HUVEC stimulation with TNF and RT-qPCR in Chapter 2.
To compare the transcription pattern of IL-1β and AMANZI in response to LPS 
stimulation, THP-1 monocytes, THP-1 macrophages and RPE1 cells were 
stimulated with 10 ng/ml LPS for 24 hours. THP-1 monocytes were stimulated 
as described above. For THP-1 macrophages, 2.5x105 THP-1 monocytes 
were PMA-differentiated prior to stimulation with 10 ng/ml LPS. For the RPE1 
cells, 7.5x104 were seeded and allowed to adhere for 24 hours before LPS 
(10 ng/ml) stimulation. After LPS stimulation, RNA was extracted, cDNA was 
synthesised and qPCR was carried out (using Primer set 6 from Table 2.1) as 
described in HUVEC stimulation with TNF and RT-qPCR in Chapter 2.
Table 2.1: List of overlapping primers tiling AMANZI
Primer Name Sequence (5ʹ - 3ʹ)
Primer set 1 F TGCCAGTTTCTCCCTCGCTG
Primer set 1 R ATTAGTCCCCTCCCCTAAGAAGC
Primer set 2 F GGAAAGGGGAAAAGAGTATTGGTGG
Primer set 2 R AATGTGTCATAGTTTGCTACTCCTTGC
Primer set 3 F TTCATGGAAGGGCAAGGAGTAGC
Primer set 3 R GGACATCAACTGCACAACGA
Primer set 4 F CTGACAATCGTTGTGCAGTTG
Primer set 4 R TGTCTTCCACTTTGTCCCACA
Primer set 5 F ATATGTGGGACAAAGTGGAAGACAC
Primer set 5 R GGGCTATTGGCCCTTCATTGTAC
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3ʹ RACE
RNA was extracted from 2.5x105 THP-1 monocytes using the Direct-zol RNA 
Miniprep Kit (Zymo) (Appendix A2.1). 500 ng of RNA was converted to cDNA 
using the SuperScript IV First-Strand Synthesis System (Thermo Fisher 
Scientific) as per the manufacturer’s instructions (Appendix A2.2), with the 
exception of using the bespoke 3ʹ RACE polydT_adapter R primer instead of 
the provided primers in the kit. This produced a 3ʹ adapter-tagged cDNA 
library. A nested PCR approach was used to amplify the 3ʹ end of AMANZI. In 
the first round of amplification, PCR1 was set up to contain 10 μl 5x Q5 Buffer 
(NEB), 0.2 mM deoxyribonucleotide triphosphate (dNTP) mix, 0.5 μM 3ʹ RACE 
F1, 0.25 μM 3ʹ RACE adapter R (binds to the adapter sequence on the 3ʹ end 
of the cDNA), 1 μl cDNA template, 0.25 μl Q5 Polymerase (NEB) and water to 
make up the reaction to a final volume of 50 μl. PCR1 was subject to the 
following conditions: an initial cycle of 98˚C for 30 seconds, 98˚C for 10 
seconds, 65˚C for 10 seconds, 72˚C for 10 minutes followed by 35 cycles of 
98˚C for 10 seconds, 65˚C for 10 seconds, 72˚C for 1 minute and a final 
extension of 72˚C for 2 minutes. 5 μl of PCR1 was visualised on a 1% TAE 
(Appendix A3.8) agarose gel stained with 1 μg/ml ethidium bromide. PCR2 
contained 10 μl 5x Q5 Buffer (NEB), 0.2 mM dNTP deoxynucleotide 
triphosphate (dNTP) mix, 0.5 μM 3ʹ RACE F2, 0.5 μM 3ʹ RACE adapter R, 1 μl 
of PCR1 (1:300), 0.25 μl Q5 Polymerase (NEB) and was made up to a final 
volume of 50 μl with water. Cycling conditions were as follows for PCRs: 98˚C 
Primer set 6 F CCTCCCTGTCTGTATTGA
Primer set 6 R GCATACCGTATGTTCTCTG
Primer set 7 F ATACGGTATGCAGGGTTCAGGC
Primer set 7 R GCAGAGCTCATCTGGCATTGATC
Primer set 8 F AACCAGATCAATGCCAGATGAGC
Primer set 8 R ACTTTGCTGGTGTCTCGGTTAAAG
Primer set 9 F TTTAACCGAGACACCAGCAAAGTGC
Primer set 9 R AGGCAAAGGAGGGTGTTCCTAC
63
for 30 seconds, followed by 30 cycles of 98˚C for 10 seconds, 65˚C for 10 
seconds, 72˚C for 30 seconds and a final extension of 72˚C for 2 minutes. 
The entire volume of PCR2 was visualised on a 1% TAE (Appendix A3.8) 
agarose gel stained with 1 μg/ml ethidium bromide. Bands of interest were gel 
extracted using to the GeneJet Gel Extraction Kit (Thermo Fisher Scientific) 
according to the manufacturer’s protocol (Appendix A2.5). PCR amplicons 
were ligated into pUC19 according to a 6:1 molar ratio, after KpnI and EcoRI 
digestion. Plasmid clones were transformed (Appendix A2.7) into chemically 
competent Stbl3 E.coli and 5 colonies representing each band on the gel were 
sent for Sanger Sequencing at Inqaba Biotec. Returned sequences were 
analysed using the sequence alignment tool from Snapgene. Primer 
sequences are presented in Table 2.2.
Table 2.2: List of primer sequences for 3ʹ RACE
Locked nucleic acid (LNA) delivery in THP-1 monocytes
LNA GapmeRs (Exiqon) were electroporated into THP-1 monocytes using the 
Neon Transfection System. 2.5x105 THP-1 monocytes were harvested and 
prepared according to the Neon Transfection System protocol (Appendix 
A2.3). 200 nM LNA GapmeR was introduced into these cells by using 3 
pulses at 1 600 V and 10 ms in a 10 μl tip. LNA sequences are provided in 
Table 2.3. After 24 hours, the cells were then stimulated with 10 ng/ml LPS for 
24 hours prior to RNA extraction and transcriptional analysis by RT-qPCR (as 
described in HUVEC stimulation with TNF and RT-qPCR in Chapter 2) (see 
Table 2.4 for primer sequences). For 3C and ChIP, the same protocol was 
Primer Name Sequence (5ʹ - 3ʹ)
3ʹ RACE F1 ATACGGTATGCAGGGTTCAGGC
3ʹ RACE F2 AACCAGATCAATGCCAGATGAGC
3ʹ RACE polydT_adapter R GACTCGAGTCGACATCGAGGTACCTTTTT
TTTTTTTTTTTT
3ʹ RACE adapter R GACTCGAGTCGACATCG
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carried out, with the exception of using the 100 μl tip to accommodate the 
larger cell numbers and the appropriate upscaled volume of reagents. 
Table 2.3: List of LNA GapmeR sequences
 
Table 2.4: List of RT-qPCR primers for IL-1β TAD genes 
CRISPR guide RNA (gRNA) design and cloning
gRNAs were designed using the online CRISPOR tool (http://
www.crispor.tefor.net). Three gRNA candidates targeting each end of the 
AMANZI “safe” deletion region were chosen based on predicted cleavage 
efficiency and off-target activity. Complementary oligonucleotides (oligos) 
encoding the target regions (see Table 2.5) were annealed in a 10 μl reaction 
containing 10 μM oligo F, 10 μM oligo R, 1 μl 10X T4 ligation buffer (Thermo 
LNA Name Sequence (5ʹ - 3ʹ)
AMANZI LNA CCAAGAAAGGTCAATT
IPL-IL-1β LNA AGGTAAAGAGAGTCAG









IL-1β eRNA F GTGAGGTCCAAGGTTAGGGC




Fisher Scientific), 0.5 μL T4 polynucleotide kinase and made up to the final 
volume with water. The reaction was incubated in a thermocylcer at 37˚C for 
30 minutes and then heated to 95˚C for 5 minutes followed by a slow ramp 
down to 25˚C at 0.1˚C/second. The pX330 (Addgene #42230) CRISPR/Cas9 
expression plasmid was digested as follows: 1 μg of plasmid, 1 μl FastDigest 
BbsI (10 U/μl) (Thermo Fisher Scientific), 2 μl 10X FastDigest Buffer and 
water to make up a final volume of 20 μl. The reaction was incubated for 1 
hour at 37˚C and resolved on a 1% TAE (Appendix A3.8) agarose gel stained 
with 1 μg/ml ethidium bromide. Successfully linearised plasmid was gel 
extracted using the GeneJet Gel Extraction Kit (Appendix A2.5). The annealed 
oligos were then ligated into the linearised pX330 backbone in a 10 μl reaction 
containing 50 ng of digested BbsI, 1 μl of the annealed oligos diluted 1:300, 1 
μl of T4 ligation buffer (Thermo Fisher Scientific), 10 U of T4 ligase and water. 
The ligation reaction was incubated at 22.5˚C for 60 minutes before 4 μl was 
transformed into Stbl3 E. coli (Appendix A2.7). Two clonal colonies for each 
construct were then picked for plasmid extraction using the QIAprep Spin 
Miniprep Kit (Appendix A2.8) (Qiagen). 
Table 2.4: List of CRISPR gRNA oligonucleotides
Primer Name Sequence (5ʹ - 3ʹ)
sgRNA 1 F GACCCTCAATACAGACAGGGA
sgRNA 1 R TCCCTGTCTGTATTGAGGGTC
sgRNA 2 F GCCACACCCTCAATACAGACA
sgRNA 2 R TGTCTGTATTGAGGGTGTGGC
sgRNA 3 F GCACCCTCAATACAGACAGGG
sgRNA 3 R CCCTGTCTGTATTGAGGGTGC
sgRNA 4 F GTGTGATTACAAGCTGAACGA
sgRNA 4 R TCGTTCAGCTTGTAATCACAC
sgRNA 5 F GTTGCCGCATAAAGACTCTG
sgRNA 5 R CAGAGTCTTTATGCGGCAAC
sgRNA 6 F GATTACAAGCTGAACGAAGG
sgRNA 6 R CCTTCGTTCAGCTTGTAATC
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T7 endonuclease 1 (T7E1) assay
To validate the DNA cleavage activity of the CRISPR clones, the T7E1 assay 
was carried out using HeLa cells. 24 hours prior to transfection, 7.5x104 HeLa 
cells per well were seeded in a 24-well plate. On the day of transfection, the 
cell culture medium was replaced with 0.5 ml fresh medium. 500 ng of 
plasmid DNA was mixed with 2 μl Lipofectamine 2000 (Thermo Fisher 
Scientific) and made up to 50 μl with DMEM. The reaction was incubated for 5 
minutes at room temperature and added drop-wise to a well of cells. 48 hours 
post-transfection, gDNA was extracted using QuickExtract (Lucigen). To do 
this, the cells were dissociated as described in the Cell culture section of 
Chapter 2. Cells were collected by centrifugation at 300 g for 3 minutes. The 
supernatant was discarded and 200 μl QuickExtract (Lucigen) was used to 
resuspend the cell pellet. The cell suspension was then incubated at 65˚C for 
6 minutes, mixed by vortexing for 15 seconds and incubated at 98˚C for 2 
minutes. The gDNA was then used as a template to amplify the gRNA target 
regions using a PCR containing 10 μl 5x Q5 Buffer (NEB), 0.2 mM dNTP 
deoxynucleotide triphosphate (dNTP) mix, 0.5 μM Primer F, 0.5 μM Primer R, 
50 ng gDNA, 0.5 μl Q5 Polymerase (NEB) and water to make up a final 
volume of 50 μl. PCR cycling conditions were as follows: 98˚C for 30 seconds, 
followed by 30 cycles of 98˚C for 10 seconds, 65˚C for 10 seconds, 72˚C for 
30 seconds and a final extension of 72˚C for 2 minutes. Amplicons were then 
column purified using the GeneJet PCR Purification Kit (Thermo Fisher 
Scientific) (Appendix A2.6). Heteroduplexes were formed by melting and 
reannealing (95˚C for 5 minutes and ramp down to 25 ˚C at 0.1˚C per second) 
600 ng DNA in 2 μl 10X DreamTaq Buffer (Thermo Fisher Scientific) and 
water to make a final reaction volume of 20 μl. The heteroduplexes were then 
digested with T7E1 in a reaction containing 10 μl of the heteroduplex reaction, 
0.6 μl of T7E1 (NEB), 2 μl of 10X T7E1 buffer and water to make up a final 
volume of 20 μl. The entire reaction was resolved on an 8% polyacrylamide 
gel stained with 1 μg/ml ethidium bromide. Band density was analysed using 
Fiji (ImageJ) and cleavage efficiency was calculated as described by (Ran et 
al., 2013). T7E1 primer sequences are presented in Table 2.5.
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Table 2.5: List of primer sequences for T7E1 PCR
Construction of TRISPR vectors
The reagents for the TRISPR system were developed and kindly donated by 
the D. Grimm laboratory. The system allows for three gRNAs to be expressed 
from independent RNA Pol III promoters (U6, H1 and 7SK) from a single AAV 
particle. Two TRISPR constructs were generated, with each containing three 
guides to target the 5 ́  and 3 ́  regions of AMANZI to induce a deletion. 
Individual gRNAs were first ligated downstream of either a U6, H1 or 7SK 
expression plasmid using Golden Gate Assembly by setting up the following 
reaction: 40 fmol expression plasmid, 1μl of annealed oligos from the CRISPR 
guide RNA (gRNA) design and cloning section above diluted 1:200, 1 μl 
FastDigest BsmBI (10 U/μl) (Thermo Fisher Scientific), 1 μl 10X FastDigest 
Buffer (Thermo Fisher Scientific), 30 U T4 ligase (Thermo Fisher Scientific), 1 
mM adenosine triphosphate (ATP), 1 mM dithiothreitol (DTT) and water to 
make up a final volume of 10 μl. The reaction was incubated for 20 cycles of 
digestion and ligation at 37˚C for 3 minutes and 20˚C for 5 minutes followed 
by 80˚C for 20 minutes. 3 μl of the assembled DNA was transformed into 
chemically competent Stbl3 E. coli (Appendix A2.7). Colonies were picked and 
cultured at 30˚C for 24 hours for plasmid extraction using the QIAprep Spin 
Miniprep Kit (Appendix A2.8). To assemble the CRISPR multiplex vectors, a 
subsequent Golden Gate Assembly reaction containing 20 fmol triplex 
expression plasmid, 20 fmol U6 gRNA expression plasmid, 20 fmol, H1 gRNA 
expression plasmid, 20 fmol 7SK gRNA expression plasmid, 0.5 μl FastDigest 
BbsI (10 U/μl) (Thermo Fisher Scientific), 1 μl 10X FastDigest Buffer (Thermo 
Fisher Scientific), 15 U T4 ligase (Thermo Fisher Scientific), 1 mM adenosine 
Primer Name Sequence (5ʹ - 3ʹ)
5ʹ cut F CTGACAATCGTTGTGCAGTTG
5ʹ cut R GCATACCGTATGTTCTCTG
3ʹ cut F CTCTCTCCTAGACAGGATCTACCTTTATC
3ʹ cut R GAAGCTCAAGGTTTCTGACCTGTATC
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triphosphate (ATP), 1 mM dithiotheitol (DTT) and water to make up a final 
volume of 10 μl was set up. Reaction conditions were the same as the first 
Golden Gate Assembly reaction. 8 μl of the reaction was used to transform 
chemically competent Stl3 E.coli. Colonies were screened by Sanger 
Sequencing using the AAV triplex expression plasmid sequencing primer: 
GTATGTTGTGTGGAATTGTGAG. Positive clones were bulk cultured and 
plasmid DNA was extracted using the NucleoBond Xtra Maxi Kit (Macherey-
Nagel) according to the provided instructions (Appendix A2.9).
AAV packaging
Crude AAV stocks were produced by performing a triple transfection in 
HEK293T cells in 6-well plates. 3.5x105 cells in 4 ml of medium per well were 
seeded 24 hours prior to transfection. Transfection was carried out using 
Lipofectamine 2000 according to the manufacturer’s protocol. A triple plasmid 
mixture consisting of 1.3 μg of each plasmid (the AAV helper plasmid 
(encoding rep and cap), the adenovirus helper plasmid and the triplex gRNA 
or SpCas9 expression plasmid) was used for each transfection. The cap 
variant used produced the AAV6 serotype. 72 hours post-transfection, the 
cells were harvested by centrifugation at 300 g for 10 minutes and 
resuspended in 300 μl PBS. These cells were then subjected to five freeze-
thaw cycles by incubating at 37˚C and then immersing in liquid nitrogen. The 
cell debris was then cleared by centrifugation at 3 000 g for 10 minutes and 
the supernatant containing the released AAV particles was stored at -80 ̊C 
until use.
THP-1 macrophage transduction with AAVs
48 hours prior to AAV transduction, 2x105 THP-1 monocytes per well were 
seeded in a 24-well plate and differentiated with 100 ng/ml of PMA. 24 hours 
after PMA differentiation, the PMA medium was removed and the cells were 
allowed to recover in normal culture medium for 24 hours. On the day of AAV 
transduction, the medium on the THP-1 macrophages was removed and 
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replaced with 13.3 μl of AAV6-5ʹ cut, 13.3 μl of AAV6-3ʹ cut, 13.3 μl of AAV6-
Cas9 and 160 μl of complete culture medium. The cells were incubated for 24 
hours after which 0.5 ml of complete culture medium was added to each well 
of cells. Fresh culture medium was added every 3 days and after 7 days, the 
cells were harvested for analysis. 
3C
3C was carried out using THP-1 monocytes as described in the 3C section of 
Chapter 2. Primer sequences are presented in Table 2.6 and the RP11-68O13 
BAC clone was used (Thermo Fisher Scientific). Primer testing data are 
presented in Appendix A1.2
 Table 2.6: List of primer sequences for 3C-qPCR




















ChIP-qPCR was performed using THP-1 monocytes as described in the 
section ChIP-qPCR  of Chapter 2. Primer sequences are presented in Table 
2.7.






GAPDH control F1 TGCCAATCTCCTTGTTTTCTAATG
GAPDH control F3 TATTCCCCCAGGTTTACATGTTC
Primer Name Sequence (5ʹ - 3ʹ)
IL-37 promoter F CCCGTGTGTTAGCACTGTGA
IL-37 promoter R GCAACCAGAAAGGCACCAAG
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Results
A novel lncRNA called AMANZI emanates from the IL-1β promoter region
The rs16944 polymorphism is equally distributed across the global population 
by allelic frequency and is strongly associated with numerous inflammatory 
conditions (Figure 3.1A and B). Strikingly, alternate homozygous genotypes 
are correlated with highly divergent phenotypes, with rs16944 GG individuals 
being at risk for hyper-inflammation and rs16944 AA individuals being at risk 
for immunosuppressive conditions. The rs16944 SNP is located 511 bp 
upstream of the TSS of IL-1β, in the putative promoter region (Figure 3.3). In 
order to gain deeper insights to the role of this SNP in modulating 
inflammation, ChIP-Seq data from ENCODE was examined (Figure 3.3). 
We hypothesised that the SNP could be altering transcription factor binding 
motifs in the IL-1β promoter to alter its activity and modulate the inflammatory 
response. Surprisingly, transcription factor ChIP-Seq analysis revealed that 
there was no transcription factor enrichment at the location of the SNP (Figure 
3.3A). Instead, a transcription factor rich region was identified upstream of the 
rs16944 polymorphism. Importantly, PU.1 and CEBPB, which are transcription 
factors that were previously shown to be essential for IL-1β activation, did not 
coincide with the position of the SNP (Toda et al., 2002). This suggested that 
the rs16944 SNP did not interfere with transcription factor binding at the 
promoter to alter IL-1β transcription. 
ChIP-Seq for epigenetic histone modifications showed that the position of the 
SNP coincided with signals for H3K4me1 and H3K27Ac in CD14+ monocytes 
(Figure 3.3B). This particular epigenetic histone signature is characteristic of 
active enhancer regions in the genome (see section entitled Enhancers), 
suggesting that the region surrounding the rs16944 polymorphism may be 
transcribed into a regulatory lncRNA that functions as an eRNA. Indeed, 
FANTOM CAGE data showed that the region was being transcribed, from 
approximately 100 bp upstream of the SNP, to produce a previously 
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unannotated lncRNA which we named AMANZI (Figure 3.3C). Interestingly, 
transcription of AMANZI occurred in the forward (sense) direction, which was 
opposite to the direction of IL-1β transcription, revealing a bidirectional 
transcription pattern at the IL-1β promoter. Furthermore, active transcription of 
this region selectively occurred in activated CD14+ monocytes, which are a 
major source of IL-1β. Taken together, this data showed that rs16944 was 
unlikely to modulate transcription factor recruitment to the promoter of IL-1β. 
However, a novel transcript (AMANZI), resembling an eRNA, does emanate 
from this region and could potentially be involved in the transcriptional 
regulation of IL-1β.
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Figure 3.3: The promoter region surrounding the rs16944 SNP is actively transcribed in 
monocytes to produce a novel lncRNA called AMANZI
(A) The rs16944 SNP falls within the promoter region of IL-1β but does not coincide with any 
ChIP-Seq validated transcription factor binding sites that are relevant for the regulation of 
IL-1β transcription. 
(B) ChIP-Seq of epigenetic histone modifications showed that the SNP was located in an 
active enhancer region (enriched for H3K4me1 and H3K27Ac). 
(C) Analysis of CAGE data revealed that this enhancer was transcribed, predominantly in 
activated monocytes, to produce a novel eRNA (AMANZI). AMANZI was transcribed in the 
forward direction, opposite to the direction of IL-1β transcription (reverse), revealing a 





AMANZI can be detected by RT-qPCR and 3ʹ RACE
In order to isolate primer pairs that could recover the non-coding transcript 
that emerged from this region by RT-qPCR, an array of primers were 
designed to tile along the genomic locus downstream of the CAGE annotated 
TSS (Figure 3.4A). This encompassed the entire enhancer region as 
demarcated by H3K4me1 and H3K27Ac ChIP-Seq peaks. cDNA libraries 
were prepared from RNA harvested from the monocytic-like cell line, THP-1. 
Primer sets designed downstream of the AMANZI TSS (primer set 4-9) 
showed high levels of AMANZI expression (1.5 - 10 fold increase) after 60 
minutes of stimulation with bacterial LPS, with the exception of primer set 5 
(Figure 3.4B). Signal from primer set 5 after LPS stimulation resembled the 
poor signal from primers that targeted upstream of the TSS (primer sets 1-3), 
which represented an untranscribed region (Figure 3.4B). The low signal of 
primer set 5 could be the result of poor primer efficiency or the loss of the 
corresponding primer target region as a result of AMANZI being spliced. From 
these experiments, primer set 6 was chosen for the detection and 
quantification of AMANZI in subsequent experiments. 
CAGE data provided the coordinates of the TSS, allowing for the 5ʹ end of 
AMANZI to be mapped. However, the 3ʹ end of AMANZI remained unknown. 
3ʹ rapid amplification of cDNA ends (RACE) is a commonly used technique to 
discriminate the terminal end of a transcript. This requires capturing the 
transcript by the 3ʹ polyA tail found on mRNAs. In order to determine whether 
the non-coding AMANZI transcript was polyadenlyated, primer set 6 was used 
to detect AMANZI from a cDNA library constructed using a polydT primer 
(Figure 3.4C). AMANZI could be retrieved from this polyA captured cDNA 
library, albeit less frequently compared to using a random hexamer cDNA 
library. This indicated that AMANZI was indeed polyadenylated and amenable 
for interrogation by 3ʹ RACE. 
3ʹ RACE was performed in LPS stimulated and unstimulated conditions, using 
a nested PCR approach. In the first round of PCR (PCR1), gene specific 
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primer 1 (GSP1) and  the polydT primer were used to amplify a larger region 
of the transcript. This yielded multiple products, ranging from 200 - 800 bp in 
length, as observed by agarose gel electrophoresis (Figure 3.4D). Controls for 
this PCR included a library that did not contain any reverse transcriptase (-
RT) and a water control. These control reactions were devoid of any 
amplification products, indicating that there was no residual gDNA or 
exogenous contaminants in the reactions. As only a single GSP was used in 
PCR1, it was expected that the specificity of the reaction would be poor. 
Therefore, a second round of PCR (PCR2) with GSP2 and the polydT primer 
was used to amplify a smaller region of AMANZI from within the products of 
PCR1. Observation of the resulting amplicons showed a significantly 
improved PCR specificity (Figure 3.4D). Despite this, there were still multiple 
products being amplified. However, these were considered as possible on-
target products that could be describing variants of AMANZI length. Therefore, 
each of these bands were cloned and sent for Sanger sequencing. The result 
of this revealed that the DNA fragments that were around the 500 bp mark on 
the agarose gel of PCR2, mapped back to the AMANZI region, while the 
fragments that were 100 bp or 1 000 bp in length were non-specific. Taking 
into consideration the CAGE annotated TSS, AMANZI was found to be 
approximately 1 kb in length irrespective of LPS stimulation (Figure 3.4E).
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Figure 3.4: AMANZI is detectable by RT-qPCR and 3ʹ RACE in THP-1 monocytes
(A) A schematic showing the position of overlapping primer sets that were designed to tile the 
entire enhancer region as demarcated by H3K4me1 and H3K27Ac ChIP-Seq peaks.
(B) RT-qPCR was performed on unstimulated and LPS stimulated THP-1 monocytes to 
isolate primer sets that could detect AMANZI. Primer sets 4-9 bound downstream of the 
CAGE peak, whereas primer sets 1-3 bound upstream of the CAGE peak. Primer set 6 





(C) RT-qPCR using primer set 6 was performed on cDNA libraries made using a polydT 
primer or random hexamer. Recovery of AMANZI from the polydT library indicated that 
AMANZI was polyadenylated and conducive for 3ʹ RACE.
(D) A nested PCR approach was used to amplify and map the 3ʹ end of AMANZI (3ʹ RACE). 
PCR products were visualised by gel electrophoresis and showed that the nested PCR 
approach significantly improved the specificity of AMANZI recovery. Amplicons from PCR2 
were cloned and identified by Sanger sequencing. 
(E) A summary of the 3ʹ ends recovered by 3ʹ RACE after Sanger sequencing. These results 
revealed that AMANZI was approximately 1 kb in length.
AMANZI is a negative regulator of IL-1β transcription
The close proximity of AMANZI to IL-1β suggested that the two genes (coding 
and non-coding) would be co-transcribed when the shared IL-1β promoter 
was activated. To confirm this, RT-qPCR was used to measure the 
transcriptional response of AMANZI and IL-1β in THP-1 monocytes and PMA 
differentiated macrophages stimulated with LPS for 24 hours (Figure 3.5A). In 
both cell types, it was observed that the increase in IL-1β transcription in 
response to LPS stimulation, was accompanied by the significant increase in 
AMANZI transcription. This confirmed a co-transcriptional response between 
IL-1β and AMANZI. A similar response was also observed in the non-immune 
RPE1 cell line, however, the levels of IL-1β and AMANZI were much lower in 
these cells.
It was possible that the emergence of AMANZI from the promoter region of 
IL-1β may have been the result of transcriptional noise that accompanied 
IL-1β expression. In order to determine whether AMANZI was a bonafide 
functional lncRNA that regulates gene transcription, interfering LNAs were 
delivered into THP-1 monocytes 24 hours prior to LPS stimulation (Figure 
3.5B). IL-1β and AMANZI transcripts were then measured by RT-qPCR in 
cells that were LPS stimulated for 1 hour or 24 hours. At both time points, a 
modest, but significant, knockdown efficiency (~65%) was observed 
compared to a negative control LNA (Figure 3.5B). Surprisingly, this loss of 
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AMANZI resulted in the over expression of IL-1β by 2.5 and 4.5 fold after 1 
hour and 24 hours of LPS stimulation, respectively (Figure 3.5B). 
Figure 3.5: AMANZI is a negative regulator of IL-1β transcription
(A) RT-qPCR showed that IL-1β transcription was accompanied by the production of AMANZI 
in THP-1 monocytes and PMA differentiated macrophages, as well as the non-immune 
RPE1 cells, after 24 hours of LPS stimulation. (n=3)
(B) Modest depletion of AMANZI using interfering LNAs resulted in the over expression of 
IL-1β in THP-1 monocytes after 1 hour and 24 hours of LPS stimulation, compared to a 
negative control LNA. (n=3)
(C) Schematic of the negative feedback circuitry showing AMANZI functioning as a negative 





Data are represented as mean±SEM. n=number of independent experiments. p values were 
calculated using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
From the epigenetic histone modification signature of this region and the close 
proximity of AMANZI to IL-1β, it was originally hypothesised that AMANZI 
functioned as an eRNA that activated IL-1β transcription. In contrast to this, 
these data presented here shows that AMANZI functions as a negative 
regulator of IL-1β transcription, which when depleted results in IL-1β 
transcription progressing uninhibited (Figure 3.5C). For this reason, this 
transcript was named A MAster Non-coding RNA antagoniZing Inflammation 
(AMANZI).  
AMANZI and IL-1β co-occupy the same TAD as IL-37
TADs are regarded as the fundamental units of chromosomal organisation 
and gene regulation (see section entitle Nuclear architecture). In order to 
delineate the interaction network of IL-1β/AMANZI with other genes in 3D 
space, the IL-1β TAD was mapped using publicly available Hi-C data. This 
analysis revealed that other members of the IL-1 family, including IL-1α and 
IL-37, co-occupied this TAD with IL-1β and AMANZI (Figure 3.6A). 
Importantly, it was observed that the TAD was functionally bisected into two 
distinct sub-TADs (sub-TAD A and sub-TAD B), which segregated the pro-
inflammatory cytokines (IL-1α and IL-1β) from the anti-inflammatory cytokine, 
IL-37. A CTCF binding site, which generally marks TAD boundaries and 
facilitates chromosomal loop formation (see section entitle Nuclear 
architecture), was found to be positioned between sub-TAD A and sub-TAD B 
and presumably mediated the formation of the two sub-loops within the main 
TAD. In order to gain higher resolution of the physical interactions within this 
TAD,  publicly available Promoter Capture Hi-C data was examined. This data 
specifically enriches for genome-wide interactions between promoters, thus 
giving a more granular view of the interaction network between genes. This 
data revealed that there were several chromosomal contacts across the sub-
TAD boundary, between the IL-1β promoter (from which AMANZI emanates) 
and IL-37 (Figure 3.6B). Interestingly, these contacts were enriched in M1 
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(pro-inflammatory) macrophages. Taken together, these data suggested that 
these genes could be transcriptionally co-regulated through chromosomal 
looping events.
AMANZI is required for IL-37 transcription
To determine whether AMANZI regulated the transcription of the other genes 
in this genomic neighbourhood, AMANZI was depleted using LNAs delivered 
into THP-1 monocytes 24 hours prior to LPS stimulation (Figure 3.6C). RT-
qPCR was used to measure the transcription of the genes within the IL-1β 
TAD after 24 hours of LPS stimulation. CKAP2L, the only non-immune gene in 
this TAD, was unaffected by the loss of AMANZI when compared to the LNA 
control condition. However, a 2 fold over expression of IL-1α was observed as 
a result of AMANZI knockdown, producing a trend reminiscent of its pro-
inflammatory counterpart IL-1β (Figure 3.5B and 3.6C). A similar increase was 
observed for the previously characterised IL-1β eRNA, which was shown to 
activate IL-1β transcription in response to LPS treatment (Ilott et al., 2014). 
Strikingly, IL-37 transcription was abrogated (5 fold decrease) upon AMANZI 
depletion (Figure 3.6C). This revealed that AMANZI was necessary for the 
transcriptional activation of IL-37, suggesting that AMANZI potentially served 
as an eRNA for IL-37, rather than IL-1β as previously thought (Figure 3.6D). 
The over expression of the pro-inflammatory genes and their positive 
regulators (IL-1α, IL-1β and IL-1β eRNA) was likely to be an indirect effect of 
AMANZI depletion, as the resultant loss of the broad anti-inflammatory 
feedback of IL-37 allowed for their transcription to go unregulated. Thus, 
these data revealed a biphasic feedback circuit between IL-1β and IL-37 that 
regulates the pro- and anti-inflammatory response, respectively (Figure 3.6D). 
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Figure 3.6: IL-1β and IL-37 transcription is regulated by a biphasic circuit that is wired 
by AMANZI
(A) Hi-C analysis of the IL-1β TAD revealed that other members of the IL-1 family of cytokines 
(IL-1α and IL-37) co-occupied this TAD with IL-1β and AMANZI. The TAD was functionally 
bisected such that the pro-inflammatory cytokines (IL-1α and IL-1β) were segregated from 





(B) Promoter Capture Hi-C analysis of the IL-1β TAD showed specific chromatin contacts 
between IL-1β and IL-37 in naïve macrophages. These contacts were enriched in M1 
polarised macrophages. 
(C) Knockdown of AMANZI affected the transcription of the immune genes in the IL-1β TAD, 
compared to the negative LNA control (n=3).
(D) A schematic of the biphasic genetic circuit derived from these knockdown experiments. 
LPS activation of the IL-1β promoter results in the activation of IL-1β transcription. 
Accompanying this is the transcription of AMANZI, which is required for the transcriptional 
activation of IL-37. Functionally, the anti-inflammatory IL-37 introduces negative feedback 
into the system by inhibiting pro-inflammatory gene transcription. The depletion of 
AMANZI results in loss of IL-37 and its anti-inflammatory effects, thus resulting in pro-
inflammatory gene expression to progress uninhibited. 
Data are represented as mean±SEM. n=number of independent experiments. p values were 
calculated using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
The IL-1β/AMANZI/IL-37 circuitry is dependent on IL-1β eRNA
The IL-1β eRNA had been previously described by Ilott et al. 2014, to regulate 
the activation of the IL-1β promoter in response to LPS in human monocytes 
(Figure 3.7A). The LNA knockdown experiments presented here show that 
IL-1β eRNA was over expressed in response to AMANZI knockdown (Figure 
3.6C), implicating a feedback mechanism between the two lncRNAs. In order 
to understand the role of the IL-1β eRNA in the regulation of the genes within 
this TAD, (in particular the IL-1β/AMANZI/IL-37 circuitry) previously published 
LNAs were used to deplete IL-1β eRNA in THP-1 monocytes, 24 hours prior 
to LPS stimulation. RT-qPCR measurements showed that the LNA was highly 
effective at reducing the levels of IL-1β eRNA (82% knockdown efficiency) 
compared to the LNA control (Figure 3.7A). CKAP2L remained unaffected by 
this reduction of IL-1β eRNA, however, IL-1α was observed to be over 
expressed by 3.5 fold. Remarkably, IL-1β eRNA knockdown abrogated IL-1β 
transcription (as previously shown by Ilott et al. 2014), but also AMANZI and 
IL-37. This indicated that the activity of IL-1β eRNA was directed towards the 
activation of the IL-1β/AMANZI promoter unit and indirectly of IL-37 (through 
AMANZI), while IL-1α was activated independently. 
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Figure 3.7: IL-1β eRNA is the master regulator of the IL-1β/AMANZI/IL-37 biphasic 
circuit
(A) Depletion of IL-1β eRNA strongly abrogated the transcription of IL-1β, AMANZI and IL37 
compared to the negative control.  IL-1α was over expressed, indicating that its activation 
was independent of IL-1β eRNA. (n=3)
(B) A schematic showing a two-tiered lncRNA regulatory system controlling IL-1β and IL-37 
transcription. IL-1β eRNA (activator 1) is sensitive to LPS and serves as an upstream 
regulator that activates the IL-1β/AMANZI promoter for transcription. Activation of IL-1β 
results in the co-transcription of AMANZI (activator 2), on which the transcription of IL-37 
relies. Expression of IL-37 inhibits IL-1β transcription in a negative feedback loop.
Data are represented as mean±SEM. n=number of independent experiments. p values were 




In summary, these data revealed a two-tiered lncRNA regulatory system. At 
the apex of the regulatory hierarchy, IL-1β eRNA (activator 1) is sensitive to 
LPS stimulation and serves to activate the IL-1β/AMANZI promoter. This 
triggers the transcription of IL-1β, which marks the beginning of pro-
inflammation. Accompany IL-1β is the co-transcription of AMANZI (activator 
2), which is essential for the transcriptional activation of IL-37. Due to the 
broad anti-inflammatory function of IL-37, it is able to negatively feed back in 
the system to reduce the expression of the pro-inflammatory genes. Thus 
IL-1β eRNA serves as the master activator of this biphasic circuit, while 
AMANZI acts as the central toggle switch between the pro- and anti-
inflammatory states mediated by the functionally opposed IL-1β and IL-37, 
respectively (Figure 3.7B). 
CRISPR/Cas9 can be directed to genomic regions that safely delete 
AMANZI
In order to validate the observations made by LNA-mediated knockdown of 
AMANZI, CRISPR gRNAs were designed to delete the AMANZI genomic 
locus. Previous analysis of transcription factor ChIP-Seq revealed that the 5ʹ 
terminal end of AMANZI was enriched for transcription factor binding sites 
(Figure 3.8A). In particular, this region contained SPI1 and CEBPB binding 
sites, which are essential for the transcriptional activation of IL-1β (Toda et al., 
2002). Therefore, CRISPR gRNAs were designed to delete a “safe” region of 
AMANZI that would preserve the transcriptional activity of IL-1β but remove a 
significant portion of the AMANZI genomic sequence. Six gRNA candidates 
were chosen to target this region, of which 3 produced cuts in the 5ʹ end (5ʹ 
cuts) and 3 produced cuts in the 3ʹ end (3ʹ cuts). The cutting efficiency of each 
guide was tested in HeLa cells using the T7E1 assay (Figure 3.8B). Cutting 
efficiency ranged from approximately 11-20%. Mock control conditions made 
use of an empty gRNA expression cassette, which resulted in no observable 
cuts in the genomic regions of interest. Functional clones for each gRNA 
candidate were obtained and used in subsequent experiments. 
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Figure 3.8: Design and validation of CRISPR gRNAs to delete the AMANZI locus
(A) Transcription factor ChIP-Seq analysis of the AMANZI region. CRISPR gRNAs were 
designed to delete most of the AMANZI sequence and preserve an area rich in 
transcription factor binding sites, some of which have been shown to be essential for 




(B) T7EI assay of the 5′ and 3′ targeting gRNAs. gRNA candidates were cloned into pX330 
and assessed for cutting efficiency (indel %) in HeLas. Two clones of each guide were 
screened for cleavage activity. 
Deletion of the AMANZI genomic locus recapitulates the gene 
expression trends observed from AMANZI knockdown
Adeno-associated viral (AAV) vectors (AAV6 serotype) were constructed to 
effectively deliver the CRISPR/Cas9 payloads into PMA differentiated THP-1 
macrophages (Figure 3.9A). In order to improve the efficiency of AMANZI 
deletion, all the validated gRNAs (6 in total) targeting the 5ʹ and 3ʹ ends were 
delivered in triplex via two sets of viral vectors. Within each viral expression 
cassette, three gRNAs were expressed in cis from independent Pol III 
promoters. Accompany the two gRNA expression vectors, a third viral vector 
encoding Cas9 was included. An equimolar ratio of these three AAVs were 
used to transduce PMA differentiated THP-1 macrophages. A GFP expressing 
AAV was used to monitor the progression of infection. 
14 days post-transduction, PCR was performed on the gDNA extracted from 
an unselected heterogeneous population of cells (Figure 3.9B). Using primers 
that flanked the outside of the cut sites (deletion primer F and R), the deletion 
of AMANZI gDNA (1 927 bp) could be detected as a smaller amplicon (328 
bp) compared to the larger wild type amplicon (2 255 bp). Banding patterns 
were compared to a Cas9 only and water control, which showed wild type 
amplicons only or no amplicons, respectively. Using primers that bound to the 
deleted region of AMANZI (internal deletion primer F and R), qPCR was used 
to quantify the relative loss of AMANZI gDNA relative to an unaffected region 
nearby (Figure 3.9C). A modest, but significant, 28% reduction in AMANZI 
gDNA was detected compared to the Cas9 only control. These measurements 
confirmed that the AMANZI genomic region was deleted by AAV-delivered 
CRISPR/Cas9 in a proportion of the cell population. 
In order to study the effects of this genomic deletion on gene expression, RT-
qPCR was performed on this heterogenous population (Figure 3.9D). AMANZI 
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deletion resulted in the insignificant loss of AMANZI transcripts, but this was 
sufficient to cause the significant 2 fold over expression of IL-1β compared to 
the Cas9 only control. Further following the trend of the previous knock down 
experiments, IL-1α and IL-1β eRNA seemed to be over expressed, while 
IL-37 expression was observed to be lower. These changes were however 
statistically insignificant. Despite this, the results from this mixed population of 
cells closely recapitulated the gene expression trends observed with the 
knockdown of AMANZI. 
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Figure 3.9: Deletion of the AMANZI genomic locus by AAV delivery of triplex gRNA 
CRISPR/Cas9
(A) AMANZI deletion strategy using AAV vectors to deliver CRISPR/Cas9 payloads into 
THP-1 macrophages. Validated gRNAs were packaged in AAVs and expressed in triplex 
by independent Pol III promoters (TRISPR). gRNA expression AAVs were accompanied 
by a Cas9 expressing AAV vector. 
(B) AMANZI deletion was detected by PCR in a heterogenous cell population using primers 
that bound to regions outside of the cut sites (deletion primer F and R). The detection of 
the smaller amplicon, compared to the larger wild-type amplicon, was indicative of 





(C) The loss of AMANZI gDNA was quantified using qPCR and primers that targeted the 
deleted region of AMANZI (internal deletion F and R). (n=2)
(D) RT-qPCR was used to measure the expression of the genes in the IL-1β TAD in a 
heterogenous population of edited cells. The observed trends were concordant with the 
results of the AMANZI knockdown experiments, but were generally statistically 
insignificant. (n=2)
Data are represented as mean±SEM. n=number of independent experiments. p values were 
calculated using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
AMANZI mediates a long-range chromatin loop with IL-37 to activate its 
transcription
Our analysis indicated that IL-37 occupied a distinct sub-TAD that was 
segregated from the IL-1β/AMANZI hub by an intervening CTCF boundary 
(Figure 3.6A). Furthermore, IL-37 was also located 76 kb downstream of 
AMANZI. In order for AMANZI to regulate IL-37, AMANZI would need to either 
traverse or collapse this linear distance. It was hypothesised that IL-37 was 
being recruited into the active sub-TAD A, containing IL-1β, through the 
formation of a dynamic chromatin loop during LPS stimulation. To map the 
specific chromosomal interactions within this region, 3C was performed 
across the boundary of these two sub-TADs in THP-1 monocytes before and 
after LPS stimulation. The IL-1β/AMANZI promoter region was set as the 
anchor point for this assay. In unstimulated cells, there was no observable 
chromosomal contact between the IL-1β and IL-37 promoter regions (Figure 
3.10A). Remarkably, the formation of dynamic chromosomal contact between 
the promoters of IL-1β and IL-37 was observed after 60 minutes of  LPS 
stimulation, and this was further consolidated after 12 hours (Figure 3.10A). 
This indicated that IL-37 was able to traverse the sub-TAD boundary and 
enter the transcriptionally active IL-1β/AMANZI genomic neighbourhood after 
LPS stimulation. LNA depletion of AMANZI, prior to stimulation with LPS, 
resulted in the loss of this contact compared to the LNA control, even after 12 
hours of LPS stimulation (Figure 3.10B). This revealed that AMANZI was 
essential for the formation of this dynamic contact. 
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(A) 3C across the sub-TAD boundary revealed that a dynamic contact between the promoter 
of IL-1β and IL-37 forms after LPS stimulation. The promoter region of IL-1β (red primer) 
was used as an anchor point. (n=2)
(B) Depletion of AMANZI prior to LPS stimulation resulted in the loss of this dynamic contact. 
(n=2)
(C) Time course measurements by RT-qPCR showed that IL-37 transcription was delayed by 
1 hour, following IL-1β and AMANZI transcription. The timing of this transcriptional 
activation coincided with the timing of the formation of the chromosomal contact between 
IL-1β and IL-37. (n=3)
Data are represented as mean±SEM. n=number of independent experiments.
Time course RT-qPCR was used to correlate the transcription kinetics of 
IL-1β, AMANZI and IL-37 to the timing of this chromosomal reorganisation. 
This revealed that the establishment of the chromosomal contact between 
IL-1β and IL-37 coincided with the transcriptional activation of IL-37. It was 
observed that IL-37 transcription was delayed by an hour after IL-1β and 
AMANZI transcription had initiated (Figure 3.10C). This provided correlative 
evidence linking the timing of IL-37 repositioning to its transcriptional 
activation. 
Intuitively, such dynamic chromosomal looping events introduce a temporal 
delay in the transcriptional activation of genes. In this case, this may be 
responsible for coordinating IL-37 expression to ensure that its anti-
inflammatory effects always follow IL-1β pro-inflammation. This suggests that 
dynamic chromosomal looping may be coordinating the progression of 
inflammation. 
AMANZI is essential for the recruitment of MED12, Pol II and H3K4me3 
deposition at the IL-37 promoter
eRNAs are known to mediate long-range chromosomal loops in order to 
facilitate precise stimulus-dependent spatio-temporal regulation of 
transcription (see section entitled Enhancer RNAs). From the previously 
presented data, it was shown that the AMANZI locus had the epigenetic 
histone signature of an active enhancer region and produced a transcript that 
92
was essential for the genomic repositioning of IL-37 and its transcriptional 
activation. It was hypothesised that AMANZI functioned as an eRNA that 
regulated IL-37 transcription and would facilitate the recruitment of 
transcription factors to the IL-37 promoter. For example, the Mediator complex 
has been shown to collaborate with eRNAs to mediate chromosomal looping 
events which bring the enhancer regions into close spatial proximity to their 
cognate promoters (Lai et al., 2013). As a result, these promoters can then 
gain access to enhancer-associated transcription factors and transcriptional 
machinery, such as Pol II, which are causal to active transcription. 
In order to determine whether AMANZI was associated with the recruitment of 
Mediator and other transcriptional activators, ChIP-qPCR was performed on 
THP-1 monocytes after AMANZI was depleted. The promoter region of IL-37 
was interrogated for MED12 (a subunit of Mediator), active Pol II (Ser5) and 
H3K4me3 occupancy after 24 hours of LPS stimulation (Figure 3.11A). An 
IgG antibody was used to create libraries that controlled for the random 
recovery of gDNA. When examining the results of the LNA control condition, it 
was observed that LPS stimulation resulted in the accumulation of MED12, 
Pol II Ser5 and H3K4me3 at the promoter of IL-37. Strikingly, the knockdown 
of AMANZI resulted in the significant loss of the accumulation these 
transcriptional activators. This indicated that AMANZI was mediating the 
establishment of chromosomal contact between IL-1β and IL-37 via the 
recruitment of the Mediator complex (Figure 3.11B). Furthermore, AMANZI 
was needed for the accumulation of Pol II and H3K4me3 at the IL-37 
promoter, which are both essential for transcription. 
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Figure 3.11: AMANZI is required for the recruitment of MED12, Pol II and H3K4me3 at 
the IL-37 promoter
(A) ChIP-qPCR in THP-1 monocytes showed that LPS stimulation induced the recruitment of 
MED12, Pol II and H3K4me3 to the promoter of IL-37. Depletion of AMANZI resulted in 
the loss of these factors, which was likely to be causal to the loss of IL-37 chromosomal 
contacts and transcription (n=3) 
(B) Schematic showing the dependency on AMANZI for the recruitment of MED12, Pol II and 
H3K4me3 to the promoter of IL-37.
Data are represented as mean±SEM. n=number of independent experiments. p values were 
calculated using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
Discussion
The biphasic nature of inflammation is regulated by the coordinated 
transcription of pro- and anti-inflammatory cytokines (Figure 1.1) (Medzhitov, 
2008, Rogatsky and Adelman, 2014). This coordination ensures that pro-
inflammation and anti-inflammation are temporally out of phase, such that the 
former always precedes the latter. This allows for an effective yet controlled 




In this chapter, the data presented reveals that the two functionally opposed 
states of the innate immune system, pro- and anti-inflammation, are 
coordinated by a biphasic circuit housed within a single TAD (Figure 3.11). 
Through a series of knockdown experiments, a two-step lncRNA activation 
system that regulated the transcription of IL-1β and IL-37 was observed. At 
the apex of the inflammatory response, IL-1β was transcriptionally activated 
by the previously characterised LPS-sensitive IL-1β eRNA, marking the 
initiation of the pro-inflammatory phase (Ilott et al., 2014). Accompanying this 
activation was the co-production of a novel unannotated lncRNA, called 
AMANZI, which emerged from the IL-1β promoter in the opposite (forward) 
direction to IL-1β transcription. The concomitant production of AMANZI led to 
the transcriptional activation of the broadly anti-inflammatory IL-37, which 
negatively fed back into the system to attenuate pro-inflammatory processes 
and suppress the function of IL-1β (Nold et al., 2010). Indeed, depletion of 
AMANZI led to the loss of IL-37 transcription, which caused the over 
expression of the pro-inflammatory IL-1α and IL-1β. The over expression of 
these pro-inflammatory cytokines was the indirect result of the loss of IL-37. 
This was concordant with observations made by previous studies that 
attenuated the anti-inflammatory response by direct siRNA knockdown of 
IL-37 (Nold et al., 2010). The work presented here essentially revealed that 
the functionally opposed IL-1β and IL-37 are co-regulated by a biphasic circuit 
that is wired by AMANZI and triggered by IL-1β eRNA (Figure 3.12).
Central to the biphasic function of this genetic circuit is the ability of AMANZI 
to serve as a toggle switch that controls the two states of inflammation. This 
highlighted the importance of non-coding elements hidden in the genome that 
regulate complex biological processes. Currently, there are no reliable 
methods to identify regulatory elements genome-wide experimentally or 
computationally. However, phenotypic variations associated with SNPs 
occurring in the non-coding genome can direct investigators to regions that 
may encode for important regulatory function. 
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In this work, the discovery of AMANZI, and the biphasic genetic circuit that it 
regulates, was guided by the pathology-associated rs16944 SNP. The position 
of this polymorphism led to the finding of an underlying regulatory feature that 
encoded for AMANZI, which functionally coupled IL-1β and IL-37 transcription. 
Importantly, homozygous rs16944 genotypes are associated with divergent 
inflammatory phenotypes, each of which can be associated with the function 
of IL-1β (pro-inflammation) and IL-37 (anti-inflammation) (Figure 3.1B). While 
the precise mechanism of the SNP currently remains unknown, it is possible 
that rs16944 alters the function of AMANZI to perturb the natural balance of 
this biphasic circuit, causing shifts that tilt the circuit to favour one state over 
the other. Future work that includes measurements of the transcriptional state 
of the genetic circuit in genotyped individuals may prove to be very insightful 
in this matter (see Chapter 4).  
Functional characterisation of AMANZI showed that it mediates a dynamic 
chromosomal looping event across a CTCF sub-TAD boundary, to bring IL-37 
into close proximity to the active IL-1β/AMANZI transcriptional hub. Previous 
studies have corroborated this dynamic long-range contact between IL-37 and 
IL-1β in LPS stimulated human monocytes (Sharaf et al., 2014). Coinciding 
with the establishment of this contact was the transcriptional activation of 
IL-37, suggesting that this chromatin reorganisation was linked to IL-37 
activation. Indeed, the loss of AMANZI resulted in the loss of transcriptional 
activators (Mediator, Pol II and H3K4me3) accumulating at the IL-37 promoter. 
These data evoke a model whereby AMANZI functions like an eRNA to 
reposition the transcriptionally inactive IL-37 to the active IL-1β/AMANZI 
transcriptional hub. At this position, IL-37 can access transcription factors and 
histone modifiers (such as the IL-1β IPL) that can help activate its 
transcription. However, it remains unclear how IL-37 physically traverses a 
clearly demarcated CTCF sub-TAD boundary to facilitate contact with IL-1β. 
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Figure 3.12: A schematic of the biphasic circuit regulating IL-1β and IL-37 transcription
Inflammatory stimulation activates the LPS-sensitive IL-1β eRNA, which in turn can induce 
transcriptional activity at the IL-1β/AMANZI promoter unit. The transcription of IL-1β initiates 
the pro-inflammatory phase of inflammation. Accompanying IL-1β transcription is the 
production of AMANZI, which mediates long-range chromosomal rearrangements that are 
essential to the activation of IL-37 transcription. The expression of the anti-inflammatory IL-37 
negatively feeds back into the system to broadly inhibit pro-inflammation. 
Chromosomal loops are formed by the extrusion of chromatin (see section 
entitled Nuclear architecture). It is possible that dynamic changes in CTCF 
boundary demarcation and cohesin recruitment at this locus, results in the 
extrusion of IL-37 from sub-TAD B into the IL-1β/AMANZI sub-TAD A during 
inflammation. This dynamic physical remodelling of the sub-TAD structures 
could be causal to the distinct functional states of inflammation. Future 
experiments using sophisticated genetic manipulations, such as the deletion 
of the intervening CTCF site or the forced looping of chromosomal loci, will be 
useful in validating this model. 
Chromosomal contacts can also be mediated by homotypic chromatin 
interactions across compartments (Monahan et al., 2019). Recent analyses of 
Hi-C data have suggested that nuclear A/B compartments are significantly 
smaller than previously thought (Rowley and Corces, 2018). Classically, 
compartments were defined to comprise multiple TADs that associated 
according to their chromatin state. The new model indicates that 
compartments are smaller than the size of TADs. This suggests that within the 
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boundaries of a single TAD, regions of the chromatin fibre as small as an 
individual active or inactive locus can be assigned to the A or B compartment, 
respectively (Rowley and Corces, 2018). As compartments are defined by 
their chromatin state, loci with homotypic chromatin are likely to engage in 
LLPS-mediated interactions. These can direct the formation of chromosomal 
contacts and be causal to transcription (see section entitled Nuclear 
architecture). 
Perhaps one of the most exquisite examples of this type of regulation is how a 
singular olfactory receptor gene is expressed in individual olfactory sensory 
neurons. Over a thousand olfactory receptors genes are confined within a 
transcriptionally heterochromatic phase separated compartment. Their 
regulatory enhancers and transcriptional activators are located in an adjacent 
euchromatic compartment (Monahan et al., 2019). While the two adjacent 
regions are incompatible, changes in the chromatin state by transcription 
factors and histone modifiers to a single olfactory receptor gene, allows it to 
switch compartments and penetrate into its active neighbour. This 
compartment switching allows for the stable transcription of a single olfactory 
receptor in each olfactory sensory neuron (Rodriguez, 2013, Monahan et al., 
2019). Such discrete compartment switching provides extremely fine control 
of chromosomal interactions and transcription. In the IL-37 sub-TAD, such 
locus specific compartment switching could be the driving mechanism of the 
chromosomal interactions between the active IL-1β and the inactive IL-37, 
providing highly precise regulation of the pro- and anti-inflammatory response. 
Despite certain aspects of the IL-1β/AMANZI/IL-37 genetic circuit being 
incompletely described, our current understanding is sufficient to realise that 
the architecture of this genetic circuit can provide features that are 
fundamental for the regulation and coordination of the inflammatory response. 
Firstly, IL-1β and IL-37 transcription are coupled by the function of AMANZI in 
this biphasic circuit. The production of AMANZI is hardwired into the 
transcription of IL-1β, as they both emerge from a common promoter. 
Therefore, the activation of IL-37 is essentially dependent on the activity of the 
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IL-1β/AMANZI promoter unit. This coupling of IL-1β and IL-37 transcription 
ensures that the IL-37 anti-inflammatory response is always calibrated to the 
amplitude of the IL-1β pro-inflammatory response, in a dose-dependent 
manner. This suggests that the primary function of IL-37 is to regulate the 
IL-1β pro-inflammatory response by serving as a direct counterbalance.
Secondly, dynamic spatial reorganisation of the genome inherently introduces 
a temporal delay in the transcriptional activation of the genes that are 
dependent on the formation of de novo chromosomal contacts. Indeed, the 
contact between IL-1β and IL-37 only emerges after an hour of LPS 
stimulation and this timing coincides with the transcriptional activation of 
IL-37. While IL-1β is transcribed immediately after stimulation to initiate pro-
inflammation, IL-37 transcription is dependent on the production of AMANZI 
and the reorganisation of chromosomal loops, introducing a temporal delay 
that ensures anti-inflammation always follows pro-inflammation. Thus, by 
serving as a kinetic barrier to IL-37 transcription, this dynamic reorganisation 
of the locus allows for IL-1β (pro-inflammatory) and IL-37 (anti-inflammatory) 
processes to be temporally coordinated during inflammation. 
Thirdly, characterisation of this circuit revealed that its behaviour is 
reminiscent of bistable switches that oscillate between different transcriptional 
states, such as the synthetic mammalian oscillator and the repressilator 
(Elowitz and Leibler, 2000, Tigges et al., 2009). This is unsurprising as cyclical 
expression patterns of immune genes, characterised by successive waves of 
immune gene activation and attenuation, have been previously reported (Amit 
et al., 2009). mRNA stability plays an integral role in shaping the kinetics of 
these oscillatory gene expression patterns (Hao and Baltimore, 2009). Fast 
mRNA turnover ensures that the dynamics of the transcriptional control 
elements are not overridden by long-lived mRNA species (Hao and Baltimore, 
2009). In this body of work, time course measurements exhibit out of phase 
oscillations between IL-1β and IL-37, with approximately 12 hour periods 
(Figure 3.10C). Previous studies have shown that IL-1β and IL-37 mRNAs are 
unstable and exhibit a faster turnover rate, which can be as short as 4 hours 
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(Bufler et al., 2004, Hadadi et al., 2016). This discrepancy can be explained 
by the 6 hour measurement intervals made in this study, which would mask 
any oscillations occurring at smaller timescales. Importantly, faster turnover 
rates of IL-1β and IL-37 would allow for higher frequency oscillations in their 
cellular mRNA abundance under stimulation (Bufler et al., 2004, Adelman et 
al., 2009). Intuitively, more dynamic levels of IL-1β and IL-37 afford greater 
regulatory resolution, allowing for the more precise and fine tuned control of 
pro- and anti-inflammation, compared to oscillations with larger periods 
(Figure 3.13). By encoding these different inflammatory states within a single 
bistable control unit, IL-1β and IL-37 transcription can be dynamically 
regulated to produce a coordinated and well calibrated immune response to a 
constantly changing environment during infection. 
Figure 3.13: A schematic showing high frequency and low frequency oscillations in 
IL-1β  and IL-37 mRNA concentration
The fast turnover rate of IL-1β and IL-37 mRNA along with the bistable nature of this genetic 
circuit allows for high frequency oscillations in the cellular mRNA abundance of IL-1β and 
IL-37. Compared to low frequency oscillations, this provides for more precise and highly 
dynamic regulation of inflammation.
In summary, the elucidation of this biphasic circuit reveals an exquisite 
mechanism that balances the two states of inflammation. The chromatin-
regulated coordination of IL-1β and IL-37 transcription from a single TAD, 
through the function of the lncRNA AMANZI, introduces a novel paradigm for 
immune gene regulation and inflammation. Furthermore, considering that this 
genetic circuit coordinates and regulates the expression of two integral 
mediators of inflammation, this study has potentially uncovered the workings 
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of a “master TAD” of inflammation. This has important implications in health 
and disease, as many aspects of cellular homeostasis and inflammatory 
function rely on IL-1β and IL-37 expression. Manipulation of this genetic circuit 
could possibly yield favourable outcomes in the modulation of inflammatory 
conditions, infection and vaccination. It is also possible that such biphasic 
circuits exist to regulate other immune genes or functionally opposed genes 
elsewhere. Essentially, this work illuminates a framework that involves 
numerous layers of transcriptional regulation, which function together to direct 
the progression of contradictory cellular processes.
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Chapter 4
THE IL-1β/AMANZI/IL-37 BIPHASIC CIRCUIT 
REGULATES TRAINED IMMUNITY
Introduction
Immunological memory refers to the ability of the immune system to recognise 
pathogens from prior exposures in order to elicit a more rapid and effective 
secondary immune response upon re-exposure. The ability to form these 
memories have traditionally been ascribed to the adaptive arms of the 
immune system. Here, adaptive immunological memory is preserved as a 
collection of epitopes in T- and B cells. Re-exposure to the pathogen will lead 
to the activation and expansion of these memory cell reservoirs to potentiate a 
subsequent immune response and the production of antigen-specific 
antibodies (O'Leary et al., 2006, Ratajczak et al., 2018). However, many 
plants and invertebrates lacking adaptive immune systems have displayed 
long-term protection against secondary infections, suggesting that the innate 
immune system is also capable of forming immunological memories. (Kurtz 
and Franz, 2003, Kurtz, 2005, Gourbal et al., 2018, Ramirez-Prado et al., 
2018). Indeed, recent studies have demonstrated that human innate immune 
cells, particularly those of the myeloid lineage, such as monocytes and 
macrophages, are able to elicit immune responses that are shaped by past 
engagements with pathogens and vaccines (Quintin et al., 2012, Sun et al., 
2012, Saeed et al., 2014).
The earliest observations of innate immune memory in mammals came from 
athymic mice which were vaccinated with the attenuated yeast strain Candida 
albicans (C. albicans). Subsequent infection of these immunocompromised 
mice with a virulent strain of C. albicans or the pathogenic bacteria 
Staphylococcus aureus (S. aureus) showed improved immunological 
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protection as a result of the vaccination independently of T-cells (Bistoni et al., 
1986, Bistoni et al., 1988). Importantly, the acquisition of this protection was 
associated with the activation of macrophages and the strong induction of pro-
inflammatory cytokines, which are both components of the innate immune 
system (Bistoni et al., 1986, Vecchiarelli et al., 1989). In humans, vaccination 
with BCG (Bacille Calmette-Guérin) improved non-specific immunological 
protection and survival against infection in West African children (Garly et al., 
2003). This broad immunological protection was attributed to the enhanced 
production of cytokines in myeloid cells and persisted for over a month (Arts 
et al., 2018b). This revealed a long-lived form of innate immune memory 
associated with vaccination that is now called trained immunity. 
Trained immunity can be induced in myeloid cells by a variety of stimuli, 
including cytokines, fungal, bacterial and metazoan antigens (Rizzetto et al., 
2016, Arts et al., 2018b, Rusek et al., 2018, Schrum et al., 2018). However, 
the standard model used to induce and study trained immunity in the 
laboratory setting is through the pre-exposure of monocytes to β-glucan (BG), 
which is a major component of the cell wall from C. albicans (Quintin et al., 
2012). Irrespective of the induction method, trained immunity culminates in 
the significantly increased transcription of pro-inflammatory cytokines upon re-
stimulation, providing enhanced broad immunological protection in response 
to heterologous infections (Figure 4.1A) (Quintin et al., 2012, Saeed et al., 
2014).
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Figure 4.1: A schematic showing the transcriptional basis of trained immunity
(A) Trained immunity is induced through the pre-exposure of innate immune cells (such as 
monocytes) to training stimuli, which include BG or BCG vaccination. This training 
exposure is embedded as a long-lived immunological memory. Re-exposure of these 
trained cells to heterologous stimuli induces a significantly more power inflammatory 
response, compared to naive cells. Underlying this enhanced inflammatory response is 
the increased transcriptional output of inflammatory genes. As a result, trained immunity 
provides enhanced broad orthologous immunological protection. 
(B) The immunological memory of trained immunity is embedded as epigenetic changes on 
the promoters of innate immune genes. After the induction of trained immunity (i.e the 
exposure to the training stimulus), increased H3K4me3 accumulation is observed at the 
promoters of the pro-inflammatory genes. This allows for the more rapid and robust 
transcription of these genes, allowing for the enhanced inflammatory response provided 
by trained immunity. 
Hallmark characteristics of trained immunity include the metabolic 
reprogramming of cells towards aerobic glycolysis (Warburg effect) and 
genome-wide changes in epigenetic histone modifications, both of which are 
causal to trained immunity (Quintin et al., 2012, Cheng et al., 2014, Saeed et 
al., 2014, Arts et al., 2016). In particular, trained immunity is encoded as the 
discrete accumulation of H3K4me3 on the promoters of the immune genes, 
allowing for their transcriptional priming and rapid and robust activation upon 
re-stimulation (Figure 4.1B) (Quintin et al., 2012, Saeed et al., 2014). Recent 
work has implicated the IPLs in facilitating the discrete deposition of 
H3K4me3 at specific immune gene promoters during training, firmly 
establishing the role of lncRNAs and nuclear architecture in trained immunity 
(Fanucchi et al., 2019). Importantly, this epigenetic storage of innate 
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immunological memory is supported by the cellular switch towards glycolytic 
metabolism, which redistributes energy and metabolite stores to support this 
phenotype (Arts et al., 2016, Fok et al., 2018). The metabolic reprogramming 
during trained immunity is driven by hypoxia inducible factor-1α (HIF-1α) 
signalling (Cheng et al., 2014). Changes in cellular metabolism during trained 
immunity allow for the accumulation of key metabolites, such as succinate 
and fumarate, which serve as substrates and cofactors for chromatin writers 
and erasers (Cheng et al., 2014, Arts et al., 2016, Fok et al., 2018). These 
consolidate H3K4me3 deposition during training, highlighting a strong link 
between cellular metabolism and the epigenetic regulation of transcription.
IL-1β is an important endogenous mediator of trained immunity that can 
induce trained immunity itself (Arts et al., 2018b). Metabolically, IL-1β can up 
regulate HIF-1α expression to reinforce the essential glycolytic metabolism of 
trained immunity (Jung et al., 2003, Cheng et al., 2014). Furthermore, the 
elevated levels of IL-1β during trained immunity, drive the pro-inflammatory 
responses that are associated with improved immunological protection. This 
has been observed in cases of BCG vaccination, in which the resultant broad 
orthogonal immune protection is directed by elevated levels of IL-1β 
production (Garly et al., 2003, Kleinnijenhuis et al., 2012, Arts et al., 2018b). 
When IL-1β signalling was blocked, the loss of these functions hindered 
trained immunity (Kaufmann et al., 2018, Mitroulis et al., 2018). Thus, IL-1β is 
causal to the establishment and consolidation of trained immunity and 
provides the immunological protection associated with enhanced pro-
inflammation. It is therefore evident that IL-1β plays a central role in trained 
immunity, suggesting that its regulation shapes the phenotype. 
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Figure 4.2: Trained immunity is directed by IL-1β
Pre-exposure of monocytes to BG or BCG results in the induction of trained immunity. This 
response is primarily mediated by the increased expression of IL-1β. Functionally, IL-1β is 
able to mediate the progression of pro-inflammation by inducing the expression of other pro-
inflammatory immune genes such as IL-6 and TNF-α. This enhanced pro-inflammatory 
response provides the enhanced immunological protection associated with trained immunity. 
IL-1β is also able to help establish and consolidate trained immunity by metabolically 
reprogramming the cells towards glycolytic metabolism. This shift in cellular metabolism 
redistributes energy and metabolites which are essential for the establishment and 
maintenance of the epigenetic changes that underly trained immunity.
The previously described rs16944 polymorphism, occurring in the promoter 
region of IL-1β (see Chapter 3), has been shown to modulate trained 
immunity (Arts et al., 2018b). BCG vaccination consistently elicited a more 
powerful pro-inflammatory (protective) response in rs16944 GG individuals 
compared to rs16944 AA individuals (Arts et al., 2018b). This observation has 
particular importance for vaccinations that rely on trained immunity (such as 
BCG), as it implies that the efficacy of trained immunity (and vaccination) 
depends on modulators of IL-1β transcription. Furthermore, while it is clear 
that the regulation of IL-1β plays an important role in driving the pro-
inflammatory components of trained immunity, compensatory molecules which 
are able to modulate and promote anti-inflammatory responses that 
antagonise IL-1β during trained immunity, have remained unidentified. 
The elucidation of the IL-1β/AMANZI/IL-37 biphasic circuit (see Chapter 3) 
revealed how IL-1β was transcriptionally regulated. Importantly, through the 
function of AMANZI, the genetic circuit coupled IL-1β transcription to IL-37. 
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Functionally, IL-37 has broad anti-inflammatory capabilities that include the 
inhibition of IL-1β expression in peripheral blood mononuclear cells (PBMCs) 
(Nold et al., 2010). Furthermore, IL-37 can activate AMPK to reverse glycolytic 
metabolism (Cavalli et al., 2017). These functions of IL-37 diametrically 
oppose those of IL-1β and are able to modulate many of the processes which 
are essential for trained immunity. This suggests that IL-37 could function as a 
key modulator of this cellular response. As the previous work in this thesis 
demonstrated the genetic circuitry that regulates IL-1β and IL-37 transcription, 
it was hypothesised that the IL-1β/AMANZI/IL-37 biphasic circuit plays an 
important role in regulating the establishment of innate immunological 
memory. 
In this chapter, trained immunity was induced in rs16944 genotyped human-
derived monocytes. The state of the genetic circuit was measured in these 
samples to reveal a divergent tilt between rs16944 GG and AA individuals, 
who either favoured elevated IL-1β or AMANZI/IL-37 transcription, 
respectively. These reciprocal transcription patterns suggested that changes 
in the balance of the IL-1β/AMANZI/IL-37 genetic circuit modulated the 
efficacy of trained immunity between individuals of different rs16944 
genotypes. In order to prove causality, suppression of AMANZI (and IL-37) in 
the THP-1 cell line recapitulated the transcription pattern as well as the 
enhanced trained immunity observed in rs16944 GG individuals. These 




200 Functional Genomics (200FG) cohort and ethics statement
Individuals in this study were healthy volunteers from the 200FG cohort. 
Volunteers were between 23 and 73 years of age, and consisted of 23% 
females and 77% males. Venous blood was drawn after healthy volunteers 
had given informed consent. The study was approved by the Ethical 
Committee of Radboud University Nijmegen, the Netherlands (2011/399). 
Experiments were conducted according to the principles expressed in the 
Declaration of Helsinki. All experiments on these human samples was 
performed by Simone Moorlag from Radboud University Nijmegen, 
Netherlands.
Human-derived monocyte isolation and culture
V e n o u s b l o o d w a s d r a w n f r o m v o l u n t e e r s i n t o 1 0 m l 
ethylenediaminetetraacetic acid (EDTA) tubes (Monoject). PBMCs were 
isolated by density centrifugation of 1:1 diluted blood in PBS over Ficoll-
Paque (GE Healthcare). Recovered cells were washed twice in PBS and 
cultured in RPMI (Invitrogen) supplemented with 50 μg/ml gentamicin 
(Centrafarm), 2 mM GlutaMAX (Gibco) and 1 mM pyruvate (Gibco). 
Training of human-derived monocytes
5x105 PBMCs were seeded in 96-well flat bottom plates in 100 μl of culture 
medium and were allowed to adhere at 37˚C for 1 hour. Non-adherent cells 
were washed off with PBS. Adherent cells were treated with 2 μg/ml of BG for 
24 hours in the presence of 10% pooled human serum. Cells were then 
washed with 200 μl of PBS and incubated for 5 days in culture medium 
containing 10% human pooled serum. Medium was changed on day 3. On 
day 6, the cells were re-stimulated with 10 ng/ml of LPS for 24 hours before 
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analysis by ELISA or RT-qPCR (as described previously). Primer sequences 
are presented in Table 2.4.
Cytokine ELISA
Excreted cytokines in the supernatant were quantified using ELISA kits for 
human IL-6 (Sanquin) and TNF-α (R&D Systems) according to the 
manufacturer’s instructions.
AMANZI knockdown and training of THP-1 monocytes
24 hours prior to BG training, LNA gapmeRs were electroporated into THP-1 
monocytes as described in the section Locked nucleic acid (LNA) delivery in 
THP-1 monocytes from Chapter 3. LNA sequences are provided in Table 2.3. 
10 μg/ml of BG was then used to train these electroplated cells for 24 hours, 
after which the BG was washed off by collecting the cells via centrifugation at 
300 g for 3 mins and resuspending the pellet in 5 ml of PBS. This was 
repeated twice. Washed cell pellets were then resuspended in 0.5 ml THP-1 
culture medium and allowed to rest for 5 days. The culture medium was 
replaced after 3 days. On day 7, the cells were stimulated with 10 ng/ml LPS 
for 24 hours prior to RNA extraction and RT-qPCR using the primers 
presented in Table 2.4 as described previously.
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Results
rs16944 SNP alters the induction of trained immunity in vitro
Trained immunity can be recapitulated in the laboratory by pre-exposing 
human-derived monocytes to BG (Figure 4.3A). After 24 hours of exposure to 
this training stimulus, BG is washed off and the cells are allowed to rest for 5 
days. LPS is then administered to challenge the cells for 24 hours, after which 
the immune response is assayed for the enhanced expression of pro-
inflammatory cytokines (commonly IL-6 and TNF-α) associated with 
successful training. To validate this in vitro model, trained immunity was 
induced in monocytes derived from 36 healthy individuals from the 200FG 
cohort (Li et al., 2016). Using enzyme-linked immunosorbent assay (ELISA) to 
measure secreted IL-6 and TNF-α, significantly elevated levels of these 
cytokines were detected in the supernatant of BG trained monocytes, 
compared to the untrained (RPMI) controls (Figure 4.3B). Unfortunately, IL-1β 
production from these cells could not be measured due to the inability of 
monocytes to secrete this cytokine after a week in ex vivo culture. These 
results indicated that the primary monocytes from this cohort could be 
successfully trained in vitro.
A previous study by Arts et al. demonstrated that the rs16944 polymorphism 
affected the efficacy of trained immunity provided by BCG vaccination (Arts et 
al., 2018b). In order to determine whether this polymorphism had similar 
affects on BG induced trained immunity, the ELISA measurements for IL-6 
and TNF-α were stratified according to the rs16944 genotype of the 
individuals in this study group (Figure 4.3C). Although this analysis did not 
yield statistically significant differences, the trend of the data was concordant 
with observations made in previous studies using BCG, where rs16944 GG 
individuals were consistently better trained than rs16944 AA individuals. This 
was evident by the enhanced production of IL-6 and TNF-α by the rs16944 
GG individuals compared to the rs16944 AA individuals, after training. 
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Figure 4.3: rs16944 SNP alters trained immunity in vitro
(A) A schematic showing the in vitro protocol for BG training of human-derived monocytes.
(B) BG training of human-derived monocytes harvested from healthy individuals of the 200FG 
cohort. Immune responses were assessed by measuring secreted IL-6 and TNF-α by 
ELISA (n=36).
(C) Trained immune responses (as determined by IL-6 and TNF-α ELISA) were stratified 
according to the rs16944 polymorphism. rs16944 GG individuals (n=22) showed patterns 
of enhanced trained immunity compared to rs16944 AA individuals (n=14)
Data are represented as mean±SEM. n=number of independent experiments. p values were 
calculated using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
rs16944 SNP alters the expression of IL-1β, AMANZI and IL-37 in 
response to BG
The enhanced inflammatory capacity associated with trained immunity is 
heavily reliant on IL-1β, suggesting that its regulation is paramount in shaping 
the trained immune response. With the elucidation of the IL-1β/AMANZI/IL-37 
genetic circuit, it became apparent that the regulation of IL-1β was coupled to 
the transcription of AMANZI and IL-37. It was hypothesised that the rs16944 
SNP could potentially alter IL-1β or AMANZI (and indirectly IL-37) 
transcription due to its genomic position. This could potentially tilt the genetic 




trained immunity. In order to test this, the transcriptional state of the genetic 
circuit was measured by RT-qPCR and the results were stratified according to 
the rs16944 genotype of the volunteers in this study group. Previously, it was 
demonstrated that BG treatment induced trained immunity within 24 hours of 
exposure (Saeed et al., 2014). Thus IL-1β, AMANZI and IL-37 levels were 
measured immediately after this 24 hour training period (Figure 4.4A).  
Figure 4.4: Transcriptional analysis of the IL-1β/AMANZI/IL-37 genetic circuit according 
to the rs16944 genotype
(A) RT-qPCR of IL-1β, AMANZI and IL-37 in human derived monocytes stratified by the 
rs16944 genotype after 24 hours of BG training. (n=36)
(B) Schematic showing that rs16944 GG individuals who are associated with enhanced 
trained immunity express higher levels of IL-1β and lower levels of AMANZI and IL-37, 
compared to rs16944 AA individuals who show the reciprocal transcription pattern and are 
more poorly trained. 
Data are represented as mean±SEM. n=number of independent experiments. p values were 




RT-qPCR measurements revealed that rs16944 GG individuals transcribed 
more of the pro-inflammatory IL-1β compared to AA individuals, whereas 
rs16944 AA individuals expressed higher levels the anti-inflammatory AMANZI 
and IL-37. While these differences were statistically insignificant, the trends 
suggested that the rs16944 SNP was associated with differences in the 
transcriptional response of IL-1β, AMANZI and IL-37. Furthermore, these 
transcription patterns were correlated with the differences in trained immunity 
that were previously observed amongst rs16944 individuals (Figure 4.4B). 
More specifically, rs16944 GG individuals expressed lower levels of AMANZI 
and IL-37, which would allow for the unencumbered expression of IL-1β and 
enhanced trained immunity. rs16944 AA individuals exhibited the reciprocal 
profile, expressing higher levels of AMANZI and IL-37. This stunted IL-1β 
transcription, resulting in poorer trained responses.  This data suggested that 
the rs16944 SNP could be altering trained immunity by tilting the biphasic 
genetic circuit to affect the relative levels of IL-1β and AMANZI (and IL-37) to 
predispose individuals for enhanced or attenuated trained immunity. 
AMANZI modulates trained immunity by regulating IL-37 transcription
rs16944 GG individuals showed skewed transcription favouring elevated IL-1β 
levels during the 24 hour BG training period (Figure 4.4A). In order to 
determine if this was causal to enhanced trained immunity, AMANZI was 
depleted in THP-1 monocytes, prior to BG training, to recapitulate the relative 
levels of high IL-1β and low IL-37 observed in these individuals (see Results 
section of Chapter 3). It was hypothesised that the role of IL-37 featured 
prominently to regulate IL-1β and the induction of trained immunity.
Using the same LNAs that were previously validated in Chapter 3, AMANZI 
was depleted in THP-1 monocytes prior to BG training (Figure 4.5A). 5 days 
after the removal of the BG, the cells were challenged with LPS for 24 hours 
and IL-1β and IL-37 transcript levels were measured by RT-qPCR (Figure 
4.5B). When examining IL-1β transcript levels between untrained and BG 
trained cells in the negative control LNA condition, a 2.5 fold increase in IL-1β 
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transcription was observed as a result of BG training. This indicated that 
trained immunity was successfully induced in THP-1 monocytes. Strikingly, a 
significant 4.5 fold increase in IL-1β transcription was observed in trained 
THP-1 monocytes that had AMANZI depleted prior to BG training. This 
indicated that trained immunity was significantly enhanced as a result of 
AMANZI depletion, compared to the negative control LNA. This suggested 
that AMANZI is capable of modulating trained immunity by regulating the 
transcriptional activation of IL-37 during the initial BG exposure time period.
When comparing the levels of IL-37 between the AMANZI LNA and negative 
control LNA conditions, it would appear that IL-37 transcript levels had 
returned to normal at the time of measurement. This suggested that the 
inhibitory effects of the AMANZI LNA was no longer active 8 days after the 
introduction of the LNAs. This indicated that the modulatory effects of IL-37 on 
trained immunity occurred within the 24 hours of BG exposure, when trained 
immunity was being established.
In summary, these data revealed that AMANZI is a modulator of trained 
immunity by regulating IL-37 transcription. They also prove that shifts in the 
IL-1β/AMANZI/IL-37 circuit can induce different outcomes of trained immunity. 
Specifically, rs16944 can seemingly tilt this circuit to enhance or reduce 
trained immunity. Indeed, by mimicking the shifts observed in rs16944 GG 
individuals through the depletion of AMANZI, significantly enhanced trained 
immunity was acquired via the indirect loss of IL-37 and the gain of IL-1β 
transcription. This suggests that the balance of this biphasic circuit is central 
in the regulation of trained immunity, with AMANZI and IL-37 being important 
modulators of this response. 
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Figure 4.5: Depletion of AMANZI enhances trained immunity
(A) A schematic showing the protocol for the knock down of AMANZI prior to the induction of 
BG trained immunity.
(B) RT-qPCR of IL-1β and IL-37 in cells that had AMANZI depleted prior to BG training. An 
enhanced trained response, detected as elevated IL-1β transcription, was elicited when 
AMANZI was depleted during BG training (Day 1) in THP-1 monocytes. The low 
concentrations of AMANZI and IL-37 during this period (Day 1) mimicked the state of the 
genetic circuit in rs16944 GG individuals, resulting in an enhanced trained phenotype 
when re-stimulated with LPS 7 days later. (n=3)
Data are represented as mean±SEM. n=number of independent experiments. p values were 
calculated using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
Discussion
Trained immunity is a fundamental feature of the innate immune system which 
provides enhanced pro-inflammatory responses and improved immunological 
protection against reoccurring pathogenic attacks (Garly et al., 2003, 
Kleinnijenhuis et al., 2012, Quintin et al., 2012, Saeed et al., 2014, Arts et al., 
2018b). Due to the central role of IL-1β in pro-inflammatory processes, the 
regulation of IL-1β plays an important part in the induction of trained immunity 




al., 2018, Mitroulis et al., 2018). Indeed, the data presented here corroborates 
previous observations which showed that the rs16944 polymorphism, located 
in the promoter of IL-1β, can modulate the inflammatory capacity of trained 
immunity (Arts et al., 2018b). Furthermore, SNPs in the downstream 
participants of IL-1β signalling have also been shown to affect the induction of 
trained immunity (Arts et al., 2018b). Together, this highlights the importance 
of IL-1β signalling in trained immunity and implicates the newly discovered 
IL-1β/AMANZI/IL-37 genetic circuit in the regulation of trained immunity, 
where IL-37 could play a counter-modulatory role in the process. 
In order to contextualise the identity of the rs16944 SNP with the function of 
the biphasic genetic circuit, transcriptional measurements revealed that the 
polymorphism affected the relative levels of IL-1β, AMANZI and IL-37. More 
specifically, rs16944 GG individuals produced more pro-inflammatory IL-1β, 
while rs16944 AA individuals transcribed more anti-inflammatory IL-37. 
Elevated levels of IL-1β are likely to underly the enhanced trained immunity 
observed in the rs16944 GG individuals. Conversely, the higher levels of 
IL-37, through its broad anti-inflammatory capabilities, can counter IL-1β and 
lead to the attenuation of trained immunity in rs16944 AA individuals. Such 
differences would explain why homozygous rs16944 individuals are so 
divergent in their inflammatory capabilities, with GG individuals being at risk of 
hyper-inflammatory conditions and AA individuals predisposed to 
immunosuppression (see Chapter 3). 
The data presented here suggests that the rs16944 SNP is able to shift the 
balance of the IL-1β/AMANZI/IL-37 biphasic circuit to favour pro- or anti-
inflammation and enhance or attenuate trained immunity, respectively. Indeed, 
when the genetic circuit was forcefully shifted to favour IL-1β transcription 
(through the knockdown of AMANZI and the loss of IL-37), the enhanced 
trained immunity observed in rs16944 GG individuals was recapitulated. This 
proved that the IL-1β/AMANZI/IL-37 circuit was important for regulating 
trained immunity, by controlling the relative levels of IL-1β, AMANZI and IL-37. 
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In addition to the inflammatory processes regulated by this biphasic circuit, it 
is also involved in regulating cellular metabolism. Studies have shown that a 
shift towards aerobic glycolysis is imperative for the induction of trained 
immunity (Cheng et al., 2014). This is mediated by HIF-1α signalling, which is 
consolidated by IL-1β (Jung et al., 2003, Cheng et al., 2014). Intriguingly, 
IL-37 can reverse glycolysis and promote oxidative phosphorylation via the 
activation of AMPK  (Hardie et al., 2012, Cavalli et al., 2017). Thus, in addition 
to the pro- and anti-inflammatory function of this genetic circuit, it is likely to 
regulate the cellular metabolic state during trained immunity (Figure 4.6).
Figure 4.6: Metabolic modulation by IL-1β and IL-37
During BG training, activation of the Dectin-1 receptor induces trained immunity, resulting in 
the increased expression of IL-1β. Accompanying this is a shift towards glycolytic metabolism 
that is mediated by HIF-1α signalling. IL-1β is able to upregulate HIF-1α expression, 
consolidating the glycolytic metabolism that is essential for trained immunity. IL-37 signalling 
functionally opposes this through the activation of AMPK. This results in the reversal of 
glycolysis and the restoration of oxidative phosphorylation.
While the clinical data presented in this chapter revealed trends that fitted well 
with a model where rs16944 skews the genetic circuit to favour IL-1β pro-
inflammation or IL-37 anti-inflammation, the comparisons between the 
genotypes were mostly statistically insignificant. This was the result of large 
variations in the inflammatory response between individuals. Such variations 
have previously been well documented, highlighting the pervasive and 
compounding roles of SNPs in shaping inflammation and immunity (Li et al., 
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2016). Furthermore, the majority of these variations occur in the non-coding 
genome, suggesting that they affect the function of transcriptional regulatory 
elements (Nishizaki and Boyle, 2017). Phenotypic variations associated with 
these polymorphisms can be used to pinpoint genomic regions that encode 
for regulatory function. However, how these variations exactly affect the 
function of these regulatory elements to shape biological responses, such as 
inflammation, remains a long standing question. 
Intriguingly, the rs16944 SNP was seemingly able regulate IL-1β and AMANZI 
in a divergent manner (i.e high IL-1β and low AMANZI versus low IL-1β and 
high AMANZI), even though they both emanate from a common promoter 
region. Usually, SNPs in the promoter region of genes modify transcription 
factor binding sites to alter their transcriptional activity. However, transcription 
factor ChIP-Seq analysis (see Chapter 3) has shown that the SNP does not 
fall within any transcription factor binding sites. Specifically, it has been 
demonstrated that IL-1β transcription is highly dependent on the PU.1 and 
CEBPB transcription factors, both of which were mapped to bind upstream of 
the SNP. However, changes in the 3D DNA shape proximal to transcription 
factor binding sites have been shown to affect DNA accessibility and alter 
transcription factor binding (Zhou et al., 2013, Abe et al., 2015). Predictive 
analysis of the local 3D DNA shape revealed that rs16944 variants did in fact 
alter key characteristics of the DNA structure, particularly the minor groove 
width, propeller twist and the helix twist of the DNA (Figure 4.7). Such 
changes in the DNA shape may alter the nearby chromatin accessibility and 
divergently affect IL-1β and AMANZI transcription. Alternatively, since the 
position of the SNP falls within the AMANZI sequence, variants of the SNP 
could be affecting the function of the AMANZI transcript, by altering its stability 
or its interactions with other biomolecules. It is possible that in rs16944 AA, 
AMANZI is stabilised to induce higher levels of IL-37, whereas in rs16944 GG, 
AMANZI is more readily degraded, allowing for the higher levels of IL-1β. 
Such a hypothesis will have to be experimentally tested in future work and is 
outside the scope of this current thesis. 
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Figure 4.7: DNA shape analysis of the genomic region around the rs16944 SNP (A/G)
Predictive analysis showed significant changes in the minor grove width, propeller twist and 
the helix twist of the DNA shape between the rs16944 genotypes. These changes could affect 
the local DNA accessibility and proximal transcription factor binding to alter gene expression. 
Changes to the DNA roll were insignificant.
While the precise mechanism by which this SNP coordinates this divergent 
bidirectional transcription currently remains unclear, its role in the regulation of 
trained immunity has important implications. For example, the BCG vaccine 
relies heavily on the induction on trained immunity for protection against the 
pervasive and lethal Mycobacterium tuberculosis. However its efficacy is 
highly variable (0-80%) amongst vaccinated individuals (Andersen and 
Doherty, 2005). The rs16944 SNP could serve as a predictive marker to 
gauge trained immunity and BCG vaccination efficacy, allowing for adjuvant 
measures to be implemented to enhance trained immunity in rs16944 AA 
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individuals. This could include the use of more virulent BCG strains, which 
have been shown to provide more effective protection (Zhang et al., 2016). 
Alternatively, modulation of the IL-1β/AMANZI/IL-37 circuit could also be 
helpful. Depletion of AMANZI prior to vaccination would augment the IL-1β/
AMANZI/IL-37 genetic circuit to favour pro-inflammation and yield improved 
trained immunity and vaccination efficacy. 
Trained immunity clearly provides immunological protection, but it is also 
thought to be the basis of many diseases brought about by excessive 
inflammation (Arts et al., 2018a). In many of these diseases, the hallmarks of 
trained immunity, including epigenetic changes, cellular metabolic shifts and 
excessive pro-inflammatory gene expression have been observed (Arts et al., 
2018a). Conversely, conditions afflicted by severe immunosuppression may 
benefit from the enhanced pro-inflammation associated with trained immunity. 
Indeed, the use of BG to reverse the immunosuppressive state of tumour-
associated macrophages in cancer has already demonstrated success in a 
few studies (Tian et al., 2013, Liu et al., 2015). Thus, the ability to curb or 
enhance the effects of trained immunity could be highly effective in treating 
disease. By implicating the IL-1β/AMANZI/IL-37 circuit in the regulation of 
trained immunity, it has provided novel ways to modulate this heightened pro-
inflammatory response. Therapeutic augmentation of this genetic circuit could 
alter trained immunity to favour enhanced or attenuated inflammation and 
reverse or mitigate pathological inflammatory states. 
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Chapter 5
GENERAL DISCUSSION AND CONCLUSION
In the eukaryotic nucleus, functional complexity is embedded within the non-
coding portion of the genome. Here, numerous layers of transcriptional 
regulation serve to control the expression of the protein-coding genome in 
space and time. Each of these layers function at different size scales within 
the nucleus, allowing for the increasingly finer control of transcription. Many of 
these regulatory mechanisms function cooperatively and combinatorially to 
give rise to higher-order biological processes.
Inflammation is an important and complex cellular response that is required 
for immunological protection against pathogens (Rogatsky and Adelman, 
2014). During the initial acute pro-inflammatory phase of this response, 
cytokine transcription needs to be rapid and robust in order to effectively 
initiate host defence mechanisms. The subsequent anti-inflammatory phase 
needs to be temporally delayed to follow pro-inflammation. This requires the 
precise coordination of pro- and anti-inflammatory cytokine expression. 
Dysregulation of these key processes during inflammation is a major cause of 
many diseases (Netea et al., 2017). 
The studies presented in this thesis illuminate some of the mechanisms that 
regulate these phases of the inflammatory response and have been shown 
here, and elsewhere (Fanucchi et al., 2019), to regulate trained immunity. In 
particular, the work highlights the role of two novel lncRNAs which provide 
highly discrete, locus specific regulation of immune gene transcription. 
UMLILO was shown to exploit the local 3D topology and epigenetically prime 
the ELR+ CXCL chemokines for their signal-dependent transcription. AMANZI 
was found to function as a central toggle switch in a biphasic genetic circuit 
that coordinated pro- and anti-inflammation by dynamically reorganising key 
121
chromosomal contacts. Due to the central role of these lncRNAs in regulating 
inflammation, they provide novel potential targets for the therapeutic 
modulation of inflammation. In this chapter, prospects of targeting lncRNAs to 
therapeutically treat pathological inflammation will be discussed. 
Drugging lncRNAs: A novel paradigm for modern medicine
Inflammatory diseases are generally characterised by the deregulated 
production of cytokines, which contribute to excessive states of pro- or anti-
inflammation. In order to restore homeostasis, strategies to block aberrant 
cytokine signalling or initiate counteracting signalling pathways have been 
pursued.
Cytokine therapy makes use of exogenous recombinant cytokines to activate 
or inhibit endogenous signalling pathways that counteract pathological states 
of inflammation. This has been particularly effective in treating certain 
cancers, where pro-inflammatory cytokines, such as IL-2 and interferon-α 
(INF-α) have been approved by the Food and Drug Administration (FDA) for 
their use in inducing anti-tumour immunity (Lee and Margolin, 2011). Other 
studies have demonstrated the benefits of using exogenous interferon-ɣ (INF-
ɣ) and IL-10 for treating infections and autoimmune diseases, respectively 
(Delsing et al., 2014, Saxena et al., 2015). However, due to the broad effects 
of cytokine signalling, the systemic delivery of recombinant cytokines has 
many adverse side-effects, making this treatment less than ideal (Weber et 
al., 2015).
In contrast, anti-cytokine therapies block excessive cytokine signalling through 
the use of monoclonal antibodies or mimetic peptides to ameliorate their 
inflammatory effects. IL-1β has emerged as a key therapeutic target for many 
diseases due to its central role as the gatekeeper of pro-inflammation. Three 
IL-1β targeting modalities, including a receptor antagonist, a decoy receptor 
and a monoclonal antibody, have already been successfully developed to 
block IL-1β signalling. These have been shown to effectively reduce the 
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severity of inflammation associated with many diseases such as rheumatoid 
arthritis, gout, diabetes and myocardial infarction (Dinarello, 2011, Dinarello et 
al., 2012). While anti-cytokines for IL-37 have not been therapeutically 
explored yet, blocking of IL-10, a similarly powerful anti-inflammatory cytokine, 
has been effective in enhancing the efficacy of certain vaccines and 
promoting the anti-tumour effects of immunotherapies (Sato et al., 2011, Ni et 
al., 2015). However, anti-cytokine therapies function at the protein level and 
serve to titrate cytokines away from their inflammatory action. This is 
intrinsically an inefficient way of controlling inflammation as the therapeutic 
effects will be transient and dosages will have to persistently compensate for 
the continued expression of these cytokines. 
With a deeper understanding of the mechanisms that govern cytokine 
expression, especially at the transcriptional level, new strategies that 
circumvent some of the shortfalls of conventional protein-based cytokine 
therapies can be developed. The newly described lncRNAs in this body of 
work, as well as those described elsewhere (Chen et al., 2017), are potential 
targets for the modulation of cytokine transcription. This provides a novel 
modality for regulating cytokine levels during pathological inflammation. 
Importantly, transcription is at the apex of the gene expression process, 
placing these lncRNAs in a prime position for modulating cytokines at the 
source of their expression. Thus, the therapeutic depletion of these lncRNAs 
may prove to be a highly effective and efficient alternative or adjuvant to 
protein-based anti-cytokine therapies. Furthermore, due to the cell-type 
specific transcription of many lncRNAs and their unique nucleotide sequence, 
lncRNAs can be targeted in a much more precise and discrete manner, 
potentially mitigating side-effects and therapeutic toxicity associated with 
broad, systemically delivered cytokine therapies. 
The IPLs (such as UMLILO) epigenetically prime the promoters of innate 
immune genes for transcriptional activity. The loss of the IPLs would render 
pro-inflammatory gene transcription impotent and effectively ameliorate 
conditions of hyper-inflammation. Conversely, therapeutically targeting 
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AMANZI would completely abrogate the IL-37 anti-inflammatory response, 
allowing for enhanced IL-1β signalling and pro-inflammation. This has been 
demonstrated in this work to enhance trained immunity, which may be 
beneficial for vaccination or the reversal of immunosuppression. In both these 
examples, the loss of the IPLs or AMANZI present significant barriers to the 
transcriptional activation of their respective innate immune genes, providing 
novel targets that can essentially shut off pro- or anti-inflammation. 
LncRNAs can be modulated transcriptionally, functionally and post-
transcriptionally. Drugging lncRNAs at the transcriptional level is probably the 
most effective method to control lncRNA activity. However, this requires in 
depth knowledge of the upstream regulatory mechanisms that govern lncRNA 
transcription. Recently, UMLILO and the IPLs were found to be regulated by 
calcium-dependent nuclear factor of activated T-cells (NFAT) signalling 
(Fanucchi et al., 2019). Calcium influx in response to certain stimuli results in 
the activation of calcineurin and the dephosphorylation of NFAT, which allows 
for its passage into the nucleus to activate transcription (Goodridge et al., 
2007). Inhibition of calcineurin activation using the small molecule inhibitor 
tacrolimus, blocked IPL transcription and resulted in the loss of immune gene 
expression (Fanucchi et al., 2019). Clinically, tacrolimus is widely 
administered to blunt pro-inflammatory responses and prevent organ rejection 
and treat autoimmune diseases (Larsen et al., 2007, Ge et al., 2015, Hannah 
et al., 2016, Yu et al., 2017). The effectiveness of this drug is now partly 
attributed to its role in regulating IPL transcription, highlighting the potency 
and long track record of drugging lncRNAs (although inadvertently) at the 
transcriptional level. However, calcineurin signalling is not exclusive to IPL 
regulation and plays an important role in numerous biological functions, 
particularly in excitatory cells such as neurons and cardiomyoctes (Parra and 
Rothermel, 2017). Thus, the use of tacrolimus to manage inflammation is 
often associated with cellular toxicity and adverse side-effects that results 
from broad disruptions in calcium signalling (Hoorn et al., 2011, Sikma et al., 
2015).
124
Small molecules that disrupt the assembly of ribonucleoprotein complexes on 
the lncRNA, can also be effective in modulating lncRNA function. These can 
include inhibitors that occlude or distort lncRNA structures that are essential 
for functional interactions with other biomolecules. Such modalities require in 
depth characterisation of the lncRNA candidates, including the mechanism of 
lncRNA function and potentially RNA shape. For example, the IPLs are known 
to interact with the WDR5/MLL1 complex in order to execute their function. 
The small molecule inhibitor MM102 blocks the WDR5/MLL1 interaction, 
thereby interfering with the assembly of the complete protein complex on the 
IPL. As a result, treatment of cells with MM102 causes the decreased 
expression of pro-inflammatory chemokines (Fanucchi et al., 2019). However, 
WDR5/MLL1 activity is ubiquitous in the cell and is also important for the 
function of other lncRNAs (Wang et al., 2011). Thus, broad inhibition of 
WDR5/MLL1 can have detrimental side-effects. Furthermore, small molecules 
(such as MM102 and tacrolimus) act indiscriminately on all cell types, 
disrupting biological functions within the entire organism. In order to 
implement these small molecules effectively, conjugated molecules or drug 
carriers that can specify cell targets will greatly mitigate potential adverse 
side-effects and enhance efficacy. 
At the post-transcriptional level, the classical RNA-targeting modalities of 
RNAi, such as siRNAs or short hairpin RNAs (shRNAs) can be used to 
deplete cellular concentrations of the lncRNA in a sequence-specific manner 
(Rinn et al., 2007, Lai et al., 2013, Yang et al., 2013, Fanucchi et al., 2019). 
Despite numerous examples showing the success of RNAi in targeting 
lncRNAs, there has been controversy around the activity of RNAi in the 
nucleus (Zeng and Cullen, 2002). Thus, for the knockdown of nuclear-resident 
lncRNAs, it may be more prudent to use antisense oligonucleotides (ASOs), 
such as LNAs, as their mechanism of RNAseH-mediated degradation is 
specific to the nuclear compartment (Lennox and Behlke, 2016). While the 
knockdown of lncRNAs is the most discrete and specific method of targeting 
lncRNA function, the delivery of RNAi or ASOs has remained the biggest 
challenge for their therapeutic use. It has been particularly difficult to deliver 
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effective and safe dosages that balance between the poor stability of naked 
nucleic acids and their associated immunotoxicity. Cationic liposomes have 
shown great success in the delivery of nucleic acid-based drugs (NABDs) in 
experimental cell cultures and animal models for quite some time. Only 
recently have these lipid-based carriers been approved for human use (Barba 
et al., 2019). Furthermore, significant improvements in NABDs involving the 
use of functionalised nanoparticles, chemical modifications and cell-type 
specific ligand conjugates have increased their stability and specificity while 
reducing immunogenicity (Juliano, 2016, Kaczmarek et al., 2017). In contrast, 
shRNAs can be delivered much more readily with therapeutic viral expression 
vectors, such as AAVs. These can be engineered to have particular tropisms 
for cell-type specific delivery of the shRNA expression payload (Muik et al., 
2017, Naso et al., 2017, Hartmann et al., 2018).
The implementation of many of these post-transcriptional strategies have 
already progressed to clinical trials for the depletion of disease-causing 
mRNAs, suggesting that their use is transferable to drugging lncRNAs. With 
the development of novel methods to target lncRNAs and deliver these 
modulators in a tissue and cell-specific manner, the highly discrete, 
efficacious and durable therapeutic transcriptional regulation of cytokine 
expression will be the basis of the next generation of immunotherapies.
Beyond cytokines
Receptors and signalling cascades
While the main focus of the work presented here is around the regulation of 
cytokines, there are other key components that contribute to shaping the 
inflammatory response. Cytokines function as integral signalling effectors for 
inflammation, but their encoded signals must be received by cognate 
receptors in order for specific functions to be elicited. This suggests that the 
regulation of receptor expression is equally important as the regulation of 
cytokine expression in order for a successful inflammatory response to be 
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mounted. Furthermore, this is not limited to just the receptors, but also the 
downstream partners that constitute signalling cascades. In a study that 
examined the variation of BCG-induced trained immunity, strong associations 
with SNPs occurring in the components of the IL-1 signalling pathway were 
discovered (Arts et al., 2018b). It was found that polymorphisms occurring in 
the IL-1 and IL-18 receptors as well as in components of the inflammasome, 
significantly modulated BCG-induced trained immunity. Importantly, the IL-1 
receptor and inflammasome are integral for IL-1β function, which has been 
implicated as a key driver of trained immunity (Moorlag et al., 2018). 
Furthermore, the IL-18 receptor is important for IL-37 signalling, which has 
been shown in this present study to be involved in the modulation of trained 
immunity (Moorlag et al., 2018). This highlights the importance of receptors 
and components of signalling cascades for the successful execution of 
cytokine signalling. 
Similar to how the transcription of cytokine genes are locally regulated by 
lncRNAs, cytokine receptor genes and their signalling partners are likely to be 
subjected to the same rigorous transcriptional control. This would provide the 
additional layer of regulation that allows certain subsets of cells to either be 
responsive or refractory to cytokine signalling at different timepoints of the 
inflammatory process (Gupta et al., 1998, Belay et al., 2002). However, the 
lncRNA regulation of cytokine receptors and their signalling partners has 
mostly been overlooked, with only a few examples of cytokine and chemokine 
receptors being shown to be regulated by lncRNAs (Hu et al., 2013, Wang 
and Zheng, 2018). Efforts to discover these lncRNA regulators could reveal 
additional targets for lncRNA-based therapies that modulate cytokine receptor 
and signalling pathways to control pathological inflammation. 
Cellular metabolism
Conventionally, changes in cellular metabolism are associated with the growth 
and survival of the cell. However, in the recent years, it has become clear that 
cellular metabolism is deeply connected to the immune response (O'Neill et 
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al., 2016). Perhaps the best example that illustrates this is during macrophage 
polarisation. M1 pro-inflammatory macrophages become highly glycolytic 
compared to their M2 anti-inflammatory counterparts which predominantly 
make use of oxidative phosphorylation (O'Neill et al., 2016). A similar 
glycolytic shift in metabolism has been observed in macrophages during 
trained immunity (Cheng et al., 2014). These metabolic changes redirect 
energy sources to power pro-inflammatory activities as well as allow for the 
accumulation of key metabolites, which serve as substrates and cofactors for 
the epigenetic regulation of pro-inflammatory gene transcription (Fok et al., 
2018).  Central to the glycolytic state is the mammalian target of rapamycin 
(mTOR)-HIF-1α signalling axis, with inhibition of mTOR signalling reducing 
pro-inflammation and blocking the induction of trained immunity (Cheng et al., 
2014, Jiang et al., 2014). This suggests that the metabolic state of the cell is 
highly important during inflammation, revealing a prime target for modulating 
inflammation during disease. 
During trained immunity, it was observed that the accumulation of H3K4me3 
was not exclusive to the immune genes, but also occurred on the metabolic 
genes (Saeed et al., 2014). This suggests that these metabolic genes are 
primed for transcriptional activation during training and may make use of a 
family of lncRNAs with a similar function to the IPLs. By applying the 
bioinformatic pipeline developed by Fanucchi et al., it may be possible to 
identify such lncRNA candidates (Fanucchi et al., 2019). These metabolic 
gene priming lncRNAs (MPLs) could prove to be highly desirable drug targets 
for manipulating cellular metabolism during inflammation as well as during 
other metabolic diseases. 
Conclusion
In this thesis, the regulatory mechanisms and genetic circuitry underlying the 
transcription patterns during inflammation were dissected. These include the 
epigenetic priming of pro-inflammatory genes for their rapid and robust 
transcription during acute pro-inflammation and the elucidation of a biphasic 
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genetic circuit that coordinates the functionally opposed phases of 
inflammation. Importantly, this work implicates a central role of lncRNAs in 
mediating these processes. By characterising the function of these lncRNAs, 
this work contributes to (1) the functional annotation of the human genome, 
(2) deepening our understanding of the molecular mechanisms that regulate 
inflammation and (3) potentially providing novel targets for therapies that 
modulate its response.
As the role of the non-coding genome is becoming apparent in almost every 
cellular process, it is now more important than ever to understand biological 
function in the context of genome regulation. This perspective provides a 
more granular understanding of the molecular basis of these processes, 
allowing them to be manipulated with greater precision. Currently, one of the 
greatest challenges in this post-genomics era is to decipher the hidden 
functions within the non-coding genome and uncover the regulatory network 
that underlies higher-order biological processes. This remains difficult 
because there are no reliable ways to identify and predict the regulatory 
function of a genomic region. Our efforts so far, have completely relied on the 
laborious experimental testing of individual genomic regions. However, these 
efforts have been greatly aided by genome-wide datasets which can help 
investigators navigate to the location of potentially functional genomic regions 
and assist in the development of hypotheses about their activity. With the 
continuous development of powerful high-throughput assays and 
technologies, the functional annotation of the genome can only become easier 
and progress more rapidly. As we continue to decode the genome and 
catalogue functional regulatory elements, the underlying genetic basis of the 




Appendix 1: Supplemental data
A1.1 UMLILO 3C primer testing
Supplementary Figure 1: UMLILO 3C primers tested by PCR
Primers designed for UMLILO 3C were tested in combination with the anchor 
primer on a BAC library by PCR. Amplicons were visualised on a 1% TAE 
agarose gel stained with 1 μg/ml ethidium bromide. Primers that showed the 





Supplementary Figure 2: UMLILO 3C primers tested by qPCR
Primers designed for UMLILO 3C were tested in combination with the anchor 
primer on a BAC library by qPCR. A serial dilution of the template BAC library 
was made and qPCR was performed to ensure that all primers used in the 3C 
assay were similarly efficient.
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A1.2 AMANZI 3C primer testing
Supplementary Figure 3: AMANZI 3C primers tested by PCR
Primers designed for AMANZI 3C were tested in combination with the anchor 
primer on a BAC library by PCR. Amplicons were visualised on a 1% TAE 
agarose gel stained with 1 μg/ml ethidium bromide. Primers that showed the 




Supplementary Figure 4: AMANZI 3C primers tested by qPCR
Primers designed for UMLILO 3C were tested in combination with the anchor 
primer on a BAC library by qPCR. A serial dilution of the template BAC library 
was made and qPCR was performed to ensure that all primers used in the 3C 
assay were similarly efficient.
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Appendix 2: Standard laboratory protocols
A2.1 Direct-zol RNA Miniprep
300 μl TRIzol (Ambion) was added directly into the plate after the culture 
medium was discarded (for adherent cells) or used to resuspend cell pellets 
collected by centrifugation  (for suspension cells). 300 μl of 98% ethanol was 
added to the lysed sample and thoroughly mixed. The mixture was then 
transferred to a Zymo-Spin Column and centrifuged at 10 000 g for 30 
seconds. The column was placed in a new collection tube and 400 μl of RNA 
Wash Buffer was added and passed through the column by centrifugation at 
10 000 g for 30 seconds. In the meanwhile, a mixture containing 5 μl DNaseI 
and 75 μl DNA Digestion Buffer was prepared. This was then added to the 
column and incubated at room temperature for 30 minutes. 400 μl of Direct-
zol RNA PreWash was then added to the column and centrifuged at 10 000 g 
for 30 seconds. The flow through was discarded and the previous step was 
repeated. 700 μl of RNA Wash Buffer was then added and centrifuged at 10 
000 g for 2 minutes. The column was then carefully transferred into a RNAse-
free tube, where the RNA was eluted in 50 μl of DNAse/RNase-Free Water by 
centrifugation for 1 minute at 10 000 g. The collected RNA was quantified 
using a Nanodrop ND-1000 spectrophotometer and used immediately or 
stored at -80˚C. 
A2.2 SuperScript IV First-Strand Synthesis System
Primer annealing:
A 13 μl reaction containing the following was set up: 1 μl Oligo d(T)20 (50 μM) 
or 1 μl random hexamers (50 μM), 1 μl dNTP mix (10 mM), 500 - 1 000 ng 
RNA and water to make up the final volume. The reaction was gently mixed 
and incubated at 65˚C for 5 minutes and chilled at 4˚C for 5 minutes.
Reverse transcription:
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To the primer annealing reaction, the following were then added: 4 μl 5X SSIV 
Buffer, 1 μl mM DTT (100 mM), 1 μl RNaseOUT and 1 μl Superscript IV 
reverse transcriptase (200 U/μl). The reaction was gently mixed and 
incubated as follows: (1) For Oligo d(T)20 libraries the reaction was incubated 
at 55˚C for 10 minutes then 80˚C for 10 minutes (2) For random hexameter 
libraries, the reaction was first incubated at 23˚C for 10 minutes then 55˚C for 
10 minutes and finally 80˚C for 10 minutes.
RNA digestion:
The RNA was the digested by adding 1 μl of RNaseH to the reaction and 
incubating at 37˚C for 20 minutes. The cDNA was then immediately used of 
stored at -20˚C. 
A2.3 Preparing cells for the Neon Transfection System
Cells were harvested by centrifugation at 300 g for 3 minutes. The 
supernatant was discarded and the cells were washed in 10 ml calcium and 
magnesium-free PBS by resuspending the cell pellet and recollecting the cells 
by centrifugation at 300 g for 3 minutes. The PBS was completely removed 
and the cell pellet was resuspended into a single cell suspension by repeat 
pipetting in 12 μl of Buffer R. This was then mixed with the appropriate volume 
of siRNA or LNA and loaded into a 10 μl gold-plated electroporation tip. This 
was then inserted into the Neon tube containing 2 ml of Buffer E. The correct 
parameters were set on the system and the electroporation was then carried 
out.
A2.4 RNAiMAX transfection
24 hours prior to transfection, 6x106 cells (HeLa) were seeded in a T75 flask 
with 10 ml of complete culture medium. The following day, the siRNA was 
prepared by diluting the appropriate volume in DMEM to make a final volume 
of 750 μl. The RNAiMAX solution was prepared by diluting 59 μl in DMEM to 
make a final volume of 750 μl. The two mixtures were then combined, mixed 
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and incubated at room temperature for 5 minutes. This was then added to the 
HeLa cell culture and mixed by tilting the flask back and forth. The cells were 
then analysed 48 hours later. 
A2.5 GeneJet Gel Extraction Kit
The DNA band of interest was excised from the agarose gel using a clean 
scalpel. The gel slice was weighed and a 1:1 (mass:volume) amount of 
Binding Buffer was added to the gel slice. The gel slice was then melted by 
incubating the mixture at 55˚C for 10 minutes, with periodic agitation. The 
melted gel mixture was then transferred to a GeneJect purification column 
and centrifuged at 10 000 g for 1 minute. The flow though was discarded and 
700 μl of Wash Buffer was added. The column was centrifuged again at 10 
000 g for 1 minute. The flow through was discarded and any residual buffer 
was removed by repeating the previous centrifugation step. The captured 
DNA was eluted using 50 μl of pre-warmed Elution Buffer and incubating at 
the column for 1 minute at room temperature. The DNA was recovered by 
centrifugation at 10 000 g for 1 minute. 
A2.6 GeneJet PCR Extraction Kit
This was carried out as described in section A2.5, with the exception of using 
a 1:1 ratio of PCR volume to Binding Buffer. 
A2.7 Bacterial transformation
Preparing chemically competent Stbl3 E. coli:
8 ml of Luria Bertani (LB) broth (Oxoid) was inoculated with a scraping of a 
Stbl3 E. coli glycerol stock. The culture was grown overnight at 37˚C in a 
shaking incubator. The next day, 2 ml of the culture was used as a starter 
culture to inoculate 48 ml of fresh LB broth. This was incubated at 37˚C in a 
shaking incubator and periodically monitored for the exponential phase of 
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growth using the Nanodrop ND-1000 spectrophotometer (OD600 = 0.4). When 
in this phase of growth, the progression of the culture was immediate 
suspended by immersing the flask in an ice water bath for 15 minutes, with 
vigorous agitation. The bacterial cells were then collected by centrifugation at 
500 g for 15 mins at 4 ˚C. The supernatant was poured off and the bacterial 
cell pellet was gently resuspended in 1 ml of Transformation Buffer (Appendix 
A3.9) and topped up with a further 4 ml of Transformation Buffer. The cell 
suspension was then incubated on ice for 30 minutes. The cells were then 
collected again by centrifugation at 136 g for 10 minutes at 4˚C. The 
supernatant was discarded and the pellet was gently resuspended in 1 ml of 
Transformation Buffer. This was then distributed into 50 μl aliquots and stored 
at -80˚C.
Transformation:
Aliquots of the chemically competent Stbl3 E. coli  were thawed on ice. 2-10 μl 
of plasmid DNA was then added to the bacterial suspension and incubated on 
ice for 30 minutes. The cells were then heat shocked at 42˚C for 90 seconds 
and were allowed to recover on ice for 5 minutes. 1 ml of LB broth was then 
added to the cells and incubated at 37˚C for 1 hour. The cells were then 
collected by centrifugation at 800 g for 3 min. 800 μl of the supernatant was 
removed and the pellet was resuspended in the remaining liquid. The 
transformed bacteria were then plated on antibiotic LB agar plates (Oxoid) 
and grown overnight. 
A2.8 QIAprep Spin Miniprep Kit
10 ml of LB broth (containing the appropriate selection antibiotic) was 
inoculated with the bacterial clone of interest and allowed to grow for 14 hours 
at 30/37˚C in a shaking incubator. The bacterial cells were then harvested by 
centrifugation at 2750 g for 10 minutes at 4˚C. The bacterial pellet was then 
resuspended in 250 μl Buffer P1. The cells were lysed by adding 250 μl Buffer 
P2 and inverting the mixture 24 times and incubating at room temperature for 
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5 minutes. The lysis process was then stopped using 350 μl Buffer N3 and 
mixing by inversion. The cell debris was separated from the plasmid DNA by 
centrifugation at 13 000 g for 10 minutes. The supernatant was then 
transferred to a QIAprep spin column and passed through by centrifugation at 
13 000 g for 1 minute. The column was washed with 500 μl Buffer PB and 
centrifuged at 13 000 g for 1 minute. 750 μl Buffer PE was then added to the 
column and centrifuged at 13 000 g for 1 minute. Residual wash buffer was 
removed by centrifugation at 13 000 g for an additional minute. The plasmid 
DNA was then eluted by adding 60 μl of Buffer EB, incubated at room 
temperature for 1 minute and then centrifuged at 13 000 g for 1 minute. 
Recovered DNA was stored at -20˚C.
A2.9 NucleoBond Xtra Maxi Kit
An overnight culture of 300 ml LB broth, with the appropriate selection 
antibiotic, was inoculated with the bacterial clone of interest. This was cultured 
overnight at 30/37˚C for 14 hours in a shaking incubator. The bacterial cells 
were harvested by centrifugation at 5 000 g for 10 minutes at 4˚C. The 
bacterial pellet was resuspended in 12 ml of Resuspension Buffer RES. Cells 
were lysed by adding 12 ml of Buffer LYS and inverting the mixture 5 times 
and incubating at room temperature for 5 minutes. The lysis was then 
neutralised by adding 12 ml of Buffer NEU and gently inverting the lysate. A 
NucleoBond Xtra Column was then equilibrated by applying 25 ml of Buffer 
EQU around the rim of the column filter. The column was allowed to drain by 
gravity. The lysate was then applied to the column by pouring it through the 
filter and allowing it to pass by gravity. The column filter was then washed with 
15 ml of Buffer EQU, after which the filter was then discarded from the 
column. The column was washed with 25 ml of Buffer WASH. The captured 
plasmid DNA was then eluted with 15 ml Buffer ELU and precipitated by 
adding 10.5 ml room temperature isopropanol, mixing vigorously and 
centrifuging at 2 750 g for 2 hours at 4˚C. The DNA pellet was washed with 14 
ml of 70 % ethanol and recollected by centrifugation at 2 750 g for 15 minutes 
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at room temperature. The DNA pellet was then allowed to dry at room 
temperature for and then resuspended in 100 μl of TE buffer (Appendix A3.2). 
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Appendix 3: Recipes
A3.1 3C Lysis Buffer




1X complete protease inhibitor (Roche)
A3.2 10X TE Buffer
100 ml 1 M Tris-HCl (pH 7.5 for RNA and pH 8.0 for DNA)
20 ml 0.5M EDTA (pH 8.0)
Water to make up 1l.
Autoclave and filter sterilise.
Store at room temperature. 
A3.3 FA Lysis Buffer
50 mM HEPES-KOH (pH 7.5)
140 mM NaCl




1X complete protease inhibitor (Roche)
A3.4 RIPA Buffer
50 mM Tris-HCl (pH 8.0) 
150 mM NaCl









2 mM EDTA (pH 8.0) 
150 mM NaCl
20 mM Tris-HCl (pH 8.0) 
A3.6 Final Wash Buffer
0.1% SDS
1% Triton X-100
2 mM EDTA (pH 8.0) 
500 mM NaCl





242 g Tris-base (Sigma-Aldrich)
57.1 ml of 100% acetic acid (Merck)
100 ml of 0.5 M sodium EDTA (pH 8.0)
Water to make up 1l final volume.
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A3.9 Transformation Buffer
15 ml Glycerol (Sigma-Aldrich)
1.47 g CaCl2.2H2O (Sigma-Aldrich)
302.4 mg PIPES.HCl (Sigma-Aldrich) 
NaOH (Sigma-Aldrich)
Water to make up a final volume of 100 ml. 
The glycerol, CaCl2.2H2O and PIPES.HCl were mixed together with 80 ml of 
water. The pH of the solution was then adjusted with NaOH until exactly 7.0. 
The final volume of 100 ml was then made up with water. The buffer was then 
autoclaved and stored at -20˚C. 
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